Anthrapyrazole cysteinyl peptides as inhibitors of AP-1 transcription factor binding. by Tran, Phuong My
"Anthrapyrazole Cysteinyl Peptides 
as Inhibitors of AP-l 
Transcription Factor Binding" 
By Phuong My Tran 
Thesis submitted to De Montfort University for 
the degree of Doctor of Philosophy, October 1998. 
Contents 





Chapter 1. Introduction 























General biology of transcription factors. 
Recognition of DNA by proteins. 
DNA conformational changes upon binding and in recognition. 
Protein conformation changes upon binding and in recognition. 
Whole proteins and recognition of DNA. 
Multimerisation of DNA binding proteins and DNA binding. 
sequence-specific DNA binding by pseudopeptides. 
Bzip proteins. 
Binding sites of bzip proteins. 
Subfamilies ofbzip proteins. 
The role ofbzip proteins. 
Structure-function relationships in bzip proteins - the basic 
regIOn. 
Dimerisation is required for DNA binding. 
The lzip is required for dimerisation. 
The basic and lzip regions are functionally independent. 
Homo- and heterodimerisation ofbzip proteins. 
The lzip determines which dimers are present. 
Activation of the AP-l protein by redox mechanism. 
Ref-l a ubiquitous nuclear protein. 
3D model(s) for DNA binding bzip proteins. 





























l.7 DNA recognition by hybrid molecules - naturally occurring hybrid 
molecules. 27 
1.8 Aims. 30 
Chapter 2. Synthesis of the Anthrapyrazole Derivatives. 
2.1 Lerman model for intercalation. 32 
2.1.1 Anthrapyrazole as intercalators. 34 
2.2 Synthesis of the anthrapyrazole derivatives. 35 
2.3 Discussion and Mechanisms. 35 
2.3.1 Synthesis of 2-[(2-hydrazino ethy1) amino ] ethanol (4) (step 1). 40 
2.3.2 Synthesis of 2-{2-[N-(-2-hydroxyethyl)amino]ethyl}anthra[I,9-
c,dJ pyrazol-6(2H)-one (5) (step2). 41 
2.3.2.1 Synthesis of 2-{ 2-[N-(2-Hydroxyethyl)-N-methylamino ] ethyl } 
anthra[I,9-c,dJpyrazol-6(2H)-one (6) (step 3). 43 
2.3.2.2 Synthesis of 2-{ 2-[N-(2-Chloroethy1)-N-methylamino ] ethyl } 
anthra[I,9-c,dJ pyrazol-6(2H)-one (7) (step 4). 45 
2.3.3 Synthesis of 7 -Chloro-2-{ 2-[N-(2-hydroxyethyl)amino ] ethyl } 
anthra[I,9-c,dJ pyrazol-6(2H)-one (9) (step 5). 46 
2.3.3.1 Synthesis of 7-Chloro-2-{2-[N-(2-hydroxyethyl)-N-
methylamino] ethyl} anthra[ 1, 9-c, dJpyrazol-6( 2H)-one (10) 
(step 6). 46 
2.3.3.2 Synthesis of 7-(2-Aminoethyl)amino-2-{2-[N-(2-hydroxyethyl)-
N-methyl amino] ethyl }anthra[I,9-c,dJpyrazol-6(2H)-one (11) 
(step 7). 47 
2.3.3.4a Synthesis of 7-{2-[(methoxycarbonylmethyl)amino]ethylamino}-
2-{2-[N-(2-hydroxyethyl)-N-methylamino]ethyl}anthra[I,9-
c,dJpyrazol-6(2H)-one (13) (step 9). 48 
2.3.3.5 Conversion of ester to acid. 48 
2.33.4b Synthesis of 7-(2-Succinamidoethy1)amino-2-{2-[N-(2-
hydroxyethyl)-N-methylamino ] ethyl } anthra[I,9-c,dJpyrazol-
6(2H)-one (12) (step 8). 49 
2.3.4a Synthesis of 1, 4-dichloroanthraquinone (15) via Friedel Craft' s 
























Synthesis of 1, 4-dichloroanthraquinone (15) via leucoquinizarin 
(step 12). 
Synthesis of 5 -Chloro-2-{ 2-[N -(2-hydroxyethyl ) amino ] ethyl } 
anthra[I,9-c,dJpyrazol-6(2H)-one (16) (step 13). 
Synthesis of 5-Chloro-2-{2-[N-(2-hydroxyethyl)-N-
methylamino] ethyl} anthra[I,9-c,dJpyrazol-6(2H)-one (17) 
(step 14). 
7.6.3 Synthesis of 5-(2-Aminoethyl)amino-2-{2-[N-(2-
hydroxyethyl)-N-methyl amino] ethyl} anthra[ 1, 9-c, dJpyrazol-
6(2H)-one (18) (step 15). 
The Synthesis, Isolation and Characterisation of Short 
Oligopeptides. 
The synthesis ofKCR containing peptide using the solid phase 
peptide synthesizer. 
Solid phase peptide synthesis (SPPS). 
The Fmoc strategy. 
Coupling reagent. 
Amino acid derivatives: problem species. 
Spectrometric monitoring in continuous-flow synthesis. 
Qualitative colour test using ninhydrin. 
TF A cleavage and deprotection. 
Isolation and characterisation of the synthesised peptide. 
Isolation of the synthesised oligopeptide using rp-HPLC. 
Mass analysis of the peptide using MALDI-MS. 
2D NMR of the synthesised peptide. 
Nuclear Overhauser effect (n.O.e). 
Synthesis of Intercalator-linked peptide complexes. 
Synthesis of inter cal at or-linked peptide ligands. 
Coupling via formation of a reactive aziridinium ion. 























Chapter 5. Cell free Biological Evaluation and DNA binding 
Studies. 
5.1 Introduction. 84 
5.2 Binding of inter cal at or-peptide to AP-1 DNA consensus 
sequence as determined by PAGE. 84 
5.3 The affinity and mode of binding to DNA as determined by UV/vis 
spectrophotometry and fluorimetry. 85 
5.3.1 Effect of inter cal at or-peptide on thermal denaturation properties of 
DNA. 85 
5.3.2 Effect of inter cal at or-peptide on the binding of ethidium to DNA. 86 
Results 
5.4 Specificity and redox sensitivity of c-jun homodimer protein for 
AP-1 DNA consensus sequence. 87 
5.5 The effect of Anthrapyrazole and Anthraqionone derivatives on the 
binding of AP-1 protein to AP-1 DNA consensus sequence. 89 
5.5.1 The effect of peptide units on the binding of AP-1 protein to AP-1 
DNA consensus sequence. 90 
5.5.2 The effect of intercalator-peptide conjugates on the binding of AP-1 
protein to AP-1 DNA consensus sequence. 90 
5.6 The specificity of inter cal at or-peptide for AP-1 DNA consensus 
sequence. 90 
5.7 The effect of intercalator-peptide conjugates on thermal denaturation 
of DNA. 90 
5.7.1 The effect of intercalator -peptide conjuagtes on fluorescence 
enhancement of ethidium bromide due to binding to DNA. 91 
5.8 Discussion 
5.8 Discussion: DNA binding studies. 118 
5.8.1 Effect of inter cal at or-peptide conjugates on thermal denaturation 
of DNA. 118 
5.8.2 Effect of intercalator-peptide on fluorescence enhancement of ethidium 
bromide due to binding to DNA. 119 
5.9 Biological evaluation: Establishing the specificity and redox sensitivtiy 
IV 
of c-jun homodimer protein for AP-1 DNA consensus sequence. 119 
5.10 Effect of Anthrapyrazole and Anthraquinone derivatives on AP-1 
protein binding to AP-1 DNA consensus sequnce. 122 
5.11 Effect of oligopeptide functionality on AP-1 protein binding to AP-1 
DNA consensus sequnce. 126 
5.12 Effect of intercalator -peptide conjugates on AP -1 protein binding to 
AP-1 DNA consensus sequence. 127 
5.13 Specficity of inter cal at or-peptide conjugates for AP-1 DNA consensus 
sequence. 130 
5.14 Molecular modelling of the AP-1leucine zipper: Oligopeptide-DNA 
interaction. 132 
5.14.1 Molecular modelling of peptide containing the AP-1 leucine zipper. 132 
5.15 Discussion 134 
5.16 Summary 137 
Chapter 6. Experimental. 
6.1 Synthesis of the Anthrapyrazole derivatives. 138 
6.2 Synthesis of 2-[(2-hydrazinoethyl)amino ] ethanol (4). 138 
6.3 Synthesis of 2-{ 2- [N-( -2-hydroxyethyl )amino ] ethyl} anthra[ 1 ,9-
c,d] pyrazol-6(2H)-one (5). 138 
6.3.1 Synthesis of 2-{2-[ N-(2-Hydroxyethyl)-N-methylamino ] ethyl } 
anthra[ 1, 9-c, d]pyrazol-6(2H)-one (6). 139 
6.3.2 Synthesis of 2-{ 2-[N-(2-Chloroethyl)-N-methylamino ] ethyl } 
anthra[1,9-c,d] pyrazol-6(2H)-one (7). 139 
6.4 Synthesis of 7 -Chloro-2-{2-[ N-(2-hydroxyethyl)amino ] ethyl} 
anthra[1,9-c,d] pyrazol-6(2H)-one (9). 140 
6.4.1 Synthesis of 7-Chloro-2-{2-[N-(2-hydroxyethyl)-N-
methylamino] ethyl} anthra[1,9-c,d]pyrazol-6(2H)-one (10). 141 
6.4.2 Synthesis of 7 -(2-Aminoethyl)amino-2-{ 2-[ N-(2-hydroxyethyl)-
N-methyl amino] ethyl}anthra[1,9-c,dJpyrazol-6(2H)-one (11). 141 
v 
6.4.3a Synthesis of 7-{2-[ (methoxycarbonylmethyl )amino J ethylamino }-
2-{2-[N-(2-hydroxyethyl)-N-methylamino Jethyl }anthra[I,9-
c,dJpyrazol-6(2H)-one (13). 142 
6.4.4 Synthesis of 7 -{2-( carboxymethylamino )ethylamino } -2-{2-{N -(2-
hydroxyethyl)-N-methylamino Jethyl} anthra[ 1, 9-c, d]pyrazol-
6(2H)-one (14). 142 
6.4.3b Synthesis of 7 -(2-Succinamidoethyl)amino-2-{2-[ N-(2-
hydroxyethyl)-N-methylamino Jethyl} anthra[ 1, 9-c,d]pyrazol-
6(2H)-one (12). 143 
6.5a 1,4-Dichloroanthraquinone (15) via Friedel Craft's acylation -
synthesis of2,5-dichloro-2-benzylbenoic acid. 143 
6.5b Synthesis of 1, 4-dichloroanthraquinone (15). 144 
6.6 Synthesis of 1, 4-dichloroanthraquinone (15) from leucoquinizarin. 144 
6.6.1 Synthesis of 5 -Chloro-2-{2-[N-(2-hydroxyethyl)amino J ethyl} 
anthra[ 1, 9-c, d]pyrazol-6( 2H)-one (16). 145 
6.6.2 Synthesis of 5-Chloro-2-{2-[N-(2-hydroxyethyl)-N-
methyl amino J ethyl} anthra[ 1, 9-c, d]pyrazol-6( 2H)-one (17). 145 
6.6.3 Synthesis of 5-(2-Aminoethyl)amino-2-{2-[N-(2-
hydroxyethyl)-N-methyl amino J ethyl} anthra[ 1, 9-c, d]pyrazol-
6(2H)-one (18). 146 
6.7 Solid phase peptide synthesis. 147 
6.8 Preparing the resin. 148 
6.8.1 Assembling the peptide. 148 
6.8.1 Ninhydrin (Kaiser) colour test. 148 
6.8.1 Coupling of the peptide to intercalator - removal ofN-terminal Fmoc-
group. 149 
6.8.4 Attaching the intercalator to peptide. 149 
6.8.5 Cleavage from the resin. 149 
6.9 Biological evaluation - preparation of polyacrylamide gels. 151 
6.10 DNA "end-labelling" using y_[
32pJATP - phosphorylation 
reaction. 152 
























Determination of percentage incorporation. 
Ethanol precipitation. 
Gel shift retardation assays - effect of dithiothreitol (DTT). 
Effect of TP A on AP-l protein. 
Determination of AP-l binding to wild-type and mutant AP-l 
DNA consensus sequence. 
Specificity of c-jun for AP-l DNA consensus sequence as 
demonstrated by competition assay. 
Supershift assay for AP-l in HeLa nuclear extract. 
Effect of oxygenation on the binding of AP-l protein to AP-l DNA 
consensus sequence. 
Effect of the intercalators on the binding of AP-l protein to AP-l 
DNA consensus sequence. 
Effect of pep tides on the binding of AP-l protein to AP-l DNA 
consensus sequence. 
Effect of inter cal at or-peptide conjugates on the binding of AP-l 
protein to AP-l DNA consensus sequence. 
Specificity of the intercalator-peptide for the AP-l DNA consensus 
sequence. 
Protein estimation using the Bradford method. 
Quantitating the [fos] and [jun] proteins in celllysates using 
SDS-Page - preparing the gel. 
Preparing the protein molecular weight markers. 
Running the SD S gel. 
DNA binding assays: Materials 
Effect of inter cal at or-peptide conjugates on thermal denaturation 
properties of DNA. 
Effect of inter cal at or-peptide conjugates on the fluorescence 






















List of Figures and Tables. 
Chapter 1. Introduction 
Table 1 Leucine zipper proteins know to date. 9 
Table 2 Some leucine zipper protein DNA sites. 11 
Figure 1 Helical wheel diagram of GCN4 leucine zipper. 14 
Table 3 Referring to positions in the leucine zipper. 14 
Figure 2 The Y -shaped scissors grip model for the GCN4 bound 
to the GTGACATCAC. 25 
Figure 3 Schematic diagram and nomenclature of protein domains. 26 
Aims 
Figure 4 Fos-Jun region-intercalator hybrid peptide construct. 30 
Chapter 2. Synthesis of the Anthrapyrazole derivatives. 
Figure 5 The Lerman intercalation model, in schematic form. 33 
Figure 6 Structures of various A-ring modified anthrapyrazoles. 34 
Figure 7 General synthetic route to 2-substituted APZ derivative. 36 
Figure 8 General synthetic route to 2,7 -disubstituted APZ derivative. 37 
Figure 9 General synthetic route to 2,5-disubstituted APZ derivative. 39 
Figure 10 Synthesis of the side chain 2-[ (2-hydrazinoethyl)amino Jethanol. 40 
Figure 11 Mechanism of reaction of l-chloroanthraquinone with side 
chain. 41 
Figure 12 Mechanism of imine formation by reaction of ketone 
with primary amine. 42 
Figure 13 Mechanism for methylation of side-chain nitrogen. 44 
Figure 14 Conversion of hydroxyl to chloride group. 45 
Figure 15 Two possible products. 46 
Figure 16 Ring closure. 47 
Figure 17 Freidel Crafts acylation. 51 
Figure 18 Cyclisation of benzophenone to 1, 4-dichloroanthraqionone. 52 




















General synthetic routes for the anthraquinone derivatives. 
The Synthesis, Isolation and Characterisation 
of Short Oligopeptides. 
Two peptides synthesised on the solid phase peptide 
synthesizer. 
The strategy of solid phase peptide synthesis. 
The cleavage of the Fmoc protecting group by piperidine. 
A complete cycle for the acylation of a single amino acid 
residue. 
Carbonium ions. 
HPLC chromatograph of peptide acid after cleavage 
from resin using TF A. 
HPLC chromatograph of peptide acid after storage 
at O°C in CH3NIH20 for three days. 
HPLC chromatograph of peptide acid after cleavage 
from resin using TF A. 
Retention times, eluent and purity for both peptide acid 
and amide. 
Positive-ion MALDI mass spectrum of peptide acid. 
Molecular ion is seen as rnJz 550. 
Positive-ion MALDI mass spectrum of intercalator 
(D)-linked peptide (1). Molecular ion is seen as 
rnJz 903. 
F AB mass spectrum of peptide amide. Molecular 
ion seen as rnJz 565. 
Chemical shifts for the four amino acid residues. 
Partial IH_IH COSY spectrum ofNH2-A-R-C-K-A-NH2 
in dimethylsulfoxide. 


































Synthesis of intercalator-linked peptide complxes. 
Model system for coupling. 
Coupling via a reactive aziridinium ion. 




Shows two anthraquinone derivative-linked peptide complexes. 83 
Cell free Biological Evaluation and DNA Binding 
Studies. 
Gel electrophoresis to show the effect of increasing 
concentration of unlabelled AP-I DNA consensus sequence on 
the binding of c-Jun homodimer protein to labelled 
AP-I DNA consensus sequence. 92 
Gel electrophoresis to show the effect of increasing 
concentration of unlabelled SP-I DNA consensus sequence on 
the binding of c-Jun homodimer protein to labelled 
AP-I DNA consensus sequence. 93 
Five different cell extracts were incubated with the labelled 
AP-I DNA consensus sequence and analysed in duplicate. 94 
EMSA of c-Jun homodimer protein with wild-type 
(lanes 1, 3, 5 & 7) and mutant (lanes 2, 4, 6 & 8) AP-I 
oligonucleotide. 95 
EMSA of c-Jun homodimer protein in the presence and 
absence of dithiothreitol (DTT). 96 
EMSA to show the effect of oxygenation on the binding 
of AP-I protein to AP-I DNA consensus sequence. 97 
EMSA ofFos-Jun (AP-I) heterodimer protein binding 
to the AP-l DNA consensus sequence in the presence 
of AP-l antibody. 98 
EMSA to show the effect on the binding of AP-I protein 
to AP-I DNA consensus sequence in the presence of a 
range of concentrations of ethidium (10 to 40: 1 ; 
ethidium:DNA). 99 
x 
Figure 46 EMSA of AP-1 protein binding to AP-1 DNA 
consensus sequence in the presence of intercalator A. 100 
Figure 47 EMSA of AP-1 protein binding to AP-1 DNA 
consensus sequence in the presence of intercalator D. 101 
Figure 48 EMSA of AP-1 protein binding to AP-1 DNA 
consensus sequence in the presence of peptide 1. 102 
Figure 49 EMSA of AP-1 protein binding to AP-1 DNA 
consensus sequence in the presence of peptide 7. 103 
Figure 50 EMSA of AP-1 protein binding to AP-1 DNA 
consensus sequence in the presence of a range of 
concentrations of conjugate 4D. 104 
Figure 51 EMSA of AP-1 protein binding to AP-1 
consensus sequence in the presence of a range of 
concentrations of conjugate 7D. 105 
Figure 52 EMSA to show the effect of conjugate 7D on the binding 
of SP-1 protein to SP-1 DNA consensus sequence. 106 
Figure 53 EMSA to show the effect of conjugate 7D on the binding 
of AP-1 protein to AP-1 DNA consensus sequence. 107 
Table 6 The effect of intercalators on the binding of AP-1 protein 
to AP-1 DNA consensus sequence. 108 
Table 7 The effect of peptide units on the binding of AP-1 protein 
to AP-1 DNA consensus sequence. 109 
Table 8 The effect of intercalator -peptide conjugates on the binding 
of AP-1 protein to AP-1 DNA consensus sequence. 110 
Figure 54 The effect of increasing concentration of pep tides 1, 2, 4, 5 
and 7 on the binding of AP-1 protein to AP-1 DNA consensus 
sequence as measured by densitometry. III 
Figure 55 The effect of increasing concentration of intercalators A, D 
and E on the binding of AP-1 protein to AP-1 DNA consensus 
sequence as measured by densitometry. 112 
Figure 56 The effect of increasing concentration of conjugates 1D, ID, 
7J and 8D on the binding of AP-1 protein to AP-1 DNA 
Xl 
consensus sequence as measured by densitometry. 113 
Table 9 ~Tm values for calf thymus DNA incubated with intercalator-
peptide conjugates. 114 
Figure 57 Melting curves ofDN~ DNA + 5J and DNA + ID, 
in the temperature range 58-94°C. 115 
Figure 58 The effect of 4D, 4G, 4J and 4L on the fluorescence 
enhancement of ethidium binding to DNA. 116 
Figure 59 The effect ofID, 7G, 7J and 7L on the fluorescence 
enhancement of ethidium binding to DNA. 117 
Figure 60 Donor and acceptor groups in the grooves of A. T and G. C 
base pairs. 133 
Table 10 Binding energies upon interaction of peptides 1 to 8 with 
the AP-1 DNA binding site. 134 
Figure 61 Peptide 6 bound to AP-1 DNA consensus sequence. 135 
Figure 62 Intercalator D-linked peptide 7 bound to AP-1 DNA consensus 
Sequence. 136 
XlI 
The work reported in this thesis is original 
except where due reference is made and has 
not been submitted in whole or in part for 
any other degree at De Montfort University 
or other institute of higher education. 
~(
'~~ , \ 
/ ~) 
, , - ------- ........ 




The abbreviations used for ammo acids and peptides are those recommended by 
the IUP AC-IUB Commission on Biochemical Nomenclature (J. BioI. Chem., 










































Activator protein - 1 
Anthrapyrazole 
Activating transcription factor 
Avian sarcoma virus 
tert-Butoxycarbonyl 
EB V immediate early protein 
Basic region leucine zipper 
Celsius 
Cyclic adenosine monophosphate 
CAAT/enhancer binding protein 
cAMP responsive element 
CRE-binding protein 
Correlation spectroscopy 





Epstein barr virus 
1,2-Ethanedithiol 
Electrophoretic mobility shift assay 
Fast atom bombardment 
9-Fluorenylmethoxycarbonyl 
General control protein 4 (yeast) 
Histone DNA-binding protein 










Nicotinamide adenine dinucleotide phosphate 
Nanometer 
Nuclear magnetic resonance 



























Solid phase peptide synthesis 
Trifluoroacetic acid 
TGACG-sequence specific binding proteins 
Triisopropylsilane 
Melting point of DNA 
12-0-Tetradecanoyl-phorbol-13 -acetate 
TP A responsive element 
Trityl 
Volume for volume 
Weight for volume 
Yeast AP-1 binding factor 
xv 
Nomenclature for Amino Acids 
The protein codes used in this thesis are those from the IUP AC definitions. 
These are summarised below. 'X' is frequently used in a consensus or the 
definition of a motif and refers to any amino acids. 
Codes for amino acids. 
A Ala Alanine 
C Cys Cystine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K L~s Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q GIn Glutamine 
R Arg_ Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W T~ Tryptophan 
y Tyr Tyrosine 
X Any amino acid 
XVI 
Anthrapyrazole Cysteinly Peptides as Inhibitor of AP-l 
Transcription Factor Binding. 
Phuong Tran. 
Abstract 
Synthesis of peptides anchored to DNA by intercalating chromophores can 
incorporate the design principle of the naturally occurring peptide based 
antibiotics. This work is concerned with the synthesis of DNA anchored cysteinyl 
peptides designed to be potentially nucleotide sequence specific with possible 
affinity for the AP-l transcription site. Previous work has shown that 
anthraquinones and anthrapyrazoles (APZs) substituted with cationic side groups 
are excellent DNA intercalating agents. In this work a series of APZ analogues 
has been synthesised which are coupled onto the amino terminus of varying 
peptide sequences. Three derivatives of APZs were prepared namely 2-, 2,5- and 
2,7-substituted. Eight short polypeptides (see below), all varying slightly in 
sequence but all containing the KCR motif (with one exception where a Cys 
was replaced with Ser) were combined with the APZ chromophore to give a 
series of intercalator-peptide molecules. Peptides were synthesised using the Fmoc 
strategy on a solid phase peptide synthesizer (SPPS). The peptides were then 
isolated by reversed-phase HPLC using a water: acetonitrile gradient. 
Characterisation of the peptides was carried out by matrix assisted laser 
desorption ionisation (MALDI) mass spectrometry and two dimensional nmr (i.e. 
COSY and NOESy). Anthraquinone linked peptide ligands were also synthesised 
using similar synthetic routes, and tested for their activity. Coupling of the two 
components was achieved via activation of the carboxylic acid group using 
PyBOP or via formation of a reactive aziridinium ion. All intercalator-peptides 
prepared were examined for their DNA binding properties. The methods included 
the effect of intercalator-peptides on the thermal denaturation of DNA and the 
competitive displacement of ethidium by fluorimetry. It was shown that the APZ 
binds to DNA by intercalation. Peptides prepared were: H2N-A-K-C-R-A-C02H; 
H2N-A-K-C-R-A-CONH2; H2N-A-K-S-R-A-CONH2; H2N-A-K-C-R-N-A-CONH2; 
H2N-A-K-C-R-K-A-CONH2; H2N-A-K-C-R-N-R-A-CONH2; H2N-A-K-C-R-K-R-A-
CONH2; H2N-A-A-K-C-R-A-A-CONH2. The biological activities of the intercalator-
peptides were then investigated using an electrophoretic mobility shift assay 
(EMSA), making use of cell nuclear extracts rich in AP-l and also c-Jun 
homodimer recombinant proteins. It was shown that most of the intercalator-
peptides were capable of inhibiting AP-l (fos/jun) heterodimer protein from 
binding to the AP-l DNA consensus sequence. Importantly, the intercalator-
peptides showed superior activity over the intercalator or peptide moieties alone. 
The order of binding affinity was intercalator-peptide> intercalator» peptide. 
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The principle goal of this investigation is the inhibition of 
transcription factor binding by intercalator-peptide complexes. The 
introduction to this thesis focuses on transcription factors mainly 
concentrating on the bZIP proteins, particularly the AP-I protein, 
and the mechanism by which they interact with DNA. A brief 
description of the transcription process is also provided, since this 
is the underlying process which we hope to selectively inhibit. 
1.1 DNA-Binding Proteins and the Process of Protein:DNA Recognition. 
Proteins are associated with many biological processes involving the recognition 
and manipulation of DNA. These processes include maintenance of the structure 
of chromatin (whether transcriptionally active or inactive), DNA replication, 
transcription, and the control of DNA replication and transcription. More 
specifically we can identify a variety of biological activities that DNA binding 
proteins are involved in. Classified by their biological activity, DNA binding 
proteins include; lsomerases, nucleases, ligases, primases, helicases, gyrases, 
integrases (for viral and transposon integration), DNA repaIr enzymes 
(glycosylases), polymerases, exo/endonucleases, DNA packing proteins (e.g. 
histones), chromosomal attachment proteins (e.g. membrane attachment, nuclear 
spindle attachment), recombinases and both positive and negative transcription 
factors. 
Consideration of all these classes is beyond the scope of this work, thus 
attention is restricted to transcription factors, especially fos/jun, which are 
required for the accurate and controlled expression of genes. 
Many transcription factors share common protein sequence motifs. As these are 
small motifs shared between otherwise different DNA binding factors, these 
motifs convey a role common to these proteins. They can be DNA recognition 
elements, multimerisation elements, transcriptional activation motifs or other 
protein:protein interaction motifs. The common ground for most DNA binding 
associated motifs is that they are involved in the association of nuclear factors 
(some motifs might be involved in binding co-factors or in protein modification 
(e.g. phosphorylation, glycosylation)). 
1.1.1 General Biology of Transcription Factors. 
The transcription process uses a variety of proteins besides the RNA polymerases 
itself, in particular the transcription factors. Broadly speaking we can divide 
transcription factors into activators (which "activate" or promote transcription) 
and repressors (which repress or inhibit transcription). Activators and repressors 
can respond to the changes in the cellular "state" (e.g. the concentration of 
1 
chemicals and proteins within and around the cell) in vanous ways, enabling the 
formation of feedback loops. Both positive (increased transcription in response to 
the stimulus) and negative (decreased transcription in response to the stimulus) 
control is possible. More complex competing schemes are also commonplace. 
Combinatorial control of gene expression is also present, as are "cascades" of 
transcriptional control (for example those used in dividing the cells into 
developmental categories). Activation of a transcription factor can result in 
"committing" the cell to a particular state. 
Transcription factors provide a means of converting a "signal" into a change in 
gene expression. The original signal (nutrients, toxins, other metabolic products) 
can be extracellular or intracellular. Extracellular signals include the steroid and 
thyroid hormones, which activate gene expression by binding to a membrane-
bound receptor, which in tum initiates a signal transduction pathway that 
ultimately results in altered gene expression. Intracellular signals include feedback 
from biosynthetic pathways and other cellular events. 
Autoregulation is commonly observed in transcription factors; some proteins bind 
to control regions in their own genes either activating or repressing their own 
synthesis (for a review see Serfiing, 1989). This can provide tight feedback on a 
gene's expression and allow a brief burst of expression following an initial 
stimulation (e.g. in the Jun/Fos family of proteins). Alternatively a basal level of 
expressIOn of a gene can be maintained by autorepression ( one way a higher 
level of expression could be invoked is by a protein binding onto the repressIOn 
site, derepressing the expression of the original transcription factor). 
The complexity of gene regulation can be appreciated when one thinks of a 
single gene being controlled by several (upstream) control elements which are the 
binding sites for various transcription factors. The several transcription factors 
can all, simultaneously, affect the gene, furthermore their actions on the gene are 
often not independent; they might act cooperatively or antagonistically. 
2 
1.1.2. Recognition of DNA by Proteins. 
There are two motifs associated with transcription factors, the leucine ZIpper 
(lzip) and CCIHH zinc finger motifs. The leucine zipper (lzip ), associated with 
the Jun and F os proteins, is a portion of the bZIP motif, which is composed of 
a 'basic region' immediately followed by the leucine zipper motif The basic 
region is the protein:DNA interaction motif; the leucine zipper is a dimerisation 
motif involved in the formation of homo- and heterodimers of this family of 
transcription factors. The monomers are unable to bind DNA. Different homo-
and heterodimers can form, possibly allowing complex gene regulation 
mechanisms to develop. The bZIP proteins are reviewed in more detail later in 
this chapter. Before this, an outline of DNA recognition by DNA binding 
proteins and resulting conformational rearrangements is presented. 
DNA binding motifs can be viewed from a variety of perspectives (reviewed in 
Steitz, 1990; Freemont et ai, 1991; von Hippel and Berg, 1989; Schlief, 1988). 
Thus binding can be considered at the level of motif recognition of DNA - both 
its target and non-target DNA. The reorganisation of both protein and DNA 
structure on forming the complex can be investigated, as well as the role of 
these alternations in recognition of the desired target site and the function of the 
complex. 
There are two mam components m site-specific recognition of DNA by proteins; 
(a) direct hydrogen bonding and van der Waals interactions with the edges of 
the bases and (b) the sequence-dependent conformation and flexibility of the 
DNA (Steitz, 1990). Proteins recognise DNA much in the way that they 
recognise other proteins; the basic principles are the same (e.g. Johnson and 
McKnight, 1989). 
1.1.2.1 DNA Conformational Changes upon Binding and in Recognition. 
The details of DNA conformations will not be discussed here, as there are 
numerous reVIews on this subject (e.g. Seanger, 1984). More pertinent to this 
work are the conformational changes in DNA as part of the recognition and 
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binding process. This has been well reviewed see: Travers 1988 1989 1990' , , , , 
Widom, 1985. 
An additional level of recognition is the sequence dependent conformation of the 
DNA, as well as deformations of the conformation of both the DNA and the 
protein from their uncomplexed structures in solution. Steitz (1990) notes that 
(a) proteins often bind DNA in a conformation that is different from the 
conformation observed in solution and (b) different DNA sequences have 
different free energies for distortions in the manner required for binding of a 
particular protein. Broadly speaking, the DNA conformation can be altered in 
two ways: 
-a locally-induced change caused by the "binding unit" (e.g. local twisting or 
kinking of the DNA). 
-a globally-induced change caused via the association of two (or more) 
different binding units. The protein complex need not be homomeric. 
(The term "binding unit" - is used to mean the smallest protein unit( s) that is 
able to form a stable DNA complex on its own). An example of a local induced 
change is the CAP repressor, which bends the DNA by about 90° upon binding. 
The Lac repressor system is an example of a globally induced change. 
One could postulate a two step scheme for recogrusmg an altered conformation 
of DNA where in the first step the protein binds loosely to the DNA, 
electrostatically trying to bend the DNA to roughly the conformation it desires. 
Most sequences will not be able to bind the protein appropriately within the 
energy limits of the positive interactions (e.g. hydrogen bonds) provided. For 
these sites the protein will then either falloff or "slide" to an adjacent site 
(note this step is a thermodynamic process). A second step occurs if the DNA 
is able to take up the appropriate conformation; a closer interaction forms which 
"tests" the exact sequence of the site. If the protein is capable of sliding, this 
interaction will arrest the sliding. If the protein has no particular specificity it 
can continue to slide. We could also consider alterations in protein conformation 
on DNA binding in the same manner, since protein conformation is also part of 
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the process. In this way protein-DNA binding IS a balance between 
conformational isomerisation and association energies. 
1.1.2.2 Protein Conformation Changes upon Binding and in Recognition. 
As indicated above, proteins can also be altered on DNA binding (see Freemont 
et aI, 1991). In particular, regions which are flexible in solution can become 
ordered in the DNA bound complex. This might be more true of proteins which 
are able to slide along the DNA, or otherwise non-specifically recognise DNA. 
Just as DNA distortions cost energy, so do protein alterations in conformation. 
So both DNA and protein "isomerisation" can contribute to DNA binding. 
More attention has been paid recently to ammo acids flanking the binding motif 
(see Freemont et aI, 1991). These are often flexible in solution, but become 
structured upon interaction with the DNA and can play an important part in 
recognition. This can increase the affinity for certain sites, which can have 
important biological effects. 
von Hippel and Berg (1989) suggest that DNA distortions can enhance 
specificity, whereas protein reorganisation/distortions will reduce specificity. Thus 
cooperative distortions from both the protein and DNA partners of the 
interaction are possible and could both contribute to the specificity of the 
interaction. 
Cofactors can also be used to regulate the binding affinity of a protein. They 
can alter either the protein's geometry (through an allosteric rearrangement of 
the protein structure upon ligand binding) or the electrostatic nature of the 
protein. 
1.1.2.3 Whole Proteins and Recognition of DNA. 
Generally protein recognition of DNA can be divided into specific and non-
specific. Proteins that recognise DNA non-specifically, recognise DNA in general, 
but do not favour any particular base sequence(s). This definition should be 
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viewed with some caution. Many so-called non-specific DNA-binding proteins 
that recognise structural features of the DNA can be indirectly sequence specific 
in that the conformation recognised can only be easily adopted by certain base 
sequences. In a sense this can be thought of as a shape complementary process. 
Non-specific single-stranded DNA binding proteins might be thought of as the 
most "pure" of non-specific DNA proteins in that they require neither global 
structure nor sequence. 
Site-specific DNA binding proteins only bind DNA containing a specified target 
sequence or "site", or close variations thereof Recognition of the sequence 
involves (usually direct) contact with the bases in their interaction with the 
DNA. These proteins go beyond recognising merely the shape of the DNA they 
interact with, and also recognise the character of the DNA surface. They still 
recognise the conformation of the DNA they bind, but additionally also recognise 
the base sequence. Many site specific DNA binding proteins are essentially 
unable to make stable interactions with non-target DNA (this is true of most of 
the transcription factors identified to date). Conversely, some site specific 
proteins are also able to recognise DNA non-specifically, in the process of 
"sliding" along DNA, scanning DNA for a binding site. All proteins that could 
be shown to "slide" along DNA must have some non-specific recognition 
component (Kim, 1983). EcoR! and EcoRV are good examples of this type of 
proteins. 
Although the energIes involved with specific recognition are small, the cost of an 
incorrect association is high. Inappropriate juxtaposition of atoms can result m an 
up to -5 kcallmole loss of energy in the association (see Tronrud et aI, 1987; 
Fersht, 1987). Thus poorly matching sites are efficiently distinguished from 
correct binding sites (note this assumes that the DNA and the protein are unable 
to alter their conformation to recover from the inappropriate positioning of the 
atoms). In this way, we can view specificity as a kind of negative selection 
procedure. Loss of too many specific interactions quickly excludes a binding site 
from consideration. 
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1.1.3 Multimerisation of DNA Binding Proteins and DNA binding. 
Many DNA binding proteins can associate with DNA only as dimers. This has 
the advantage that a smaller protein can recognise a large site (as in this case 
of homodimers) reducing the "genetic cost" of coding for proteins that can 
recogruse large binding sites. The dimerisation process can also provide an 
additional level of control of binding affinity and specificity. Common 
dimerisation interfaces can increase the combinatorial power of a given set of 
DNA binding proteins, bringing together monomers of different binding affinities, 
specificities and biological functions. Differential splicing can be (and is) used to 
create different functional isoforms of DNA binding proteins. 
The importance of dimerisation in generating a wider variety of transcriptional 
factors from common family of proteins has become clear from studies on the 
bZIP family of transcriptional activators (for a review see Jones, 1990). This 
family of proteins can form both homodimers and heterodimers within members 
of the family. In addition there are differentially spliced proteins with opposite 
roles; one product being an activator and the other a repressor. Interactions with 
the dimerisation region of these proteins have been observed with other families 
of DNA binding proteins. Clearly the combinatorial possibilities afforded by all 
these interactions is enormous (Ransone et aI, 1990). These interactions are 
strengthened by the fact that the monomers are unable to bind specifically and 
certain members of the family are unable to homodimerise (and hence cannot 
bind DNA alone) (Kouzarides and Ziff, 1989). One possible advantage is fast 
and efficient response to change in stimuli. 
Protein binding sites on DNA are frequently symmetrical, and this symmetry is 
reflected in the bound complex; the proteins from dimeric or tetrameric 
associations (Gentz et aI, 1989; Pu and Struhl, 1991). Most often these higher-
order protein units are homodimeric (Laughton, 1991), but, as indicated above, 
heteromeric units are also known (O'Shea et aI, 1989b). One advantage of this 
is to create a larger binding surface than found in a smaller protein. Dimers can 
bind better than the two monomers separately; part of this effect is probably due 
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to the favourable energy change upon dimerisation and on binding of the protein 
specifically to the DNA sequence (Weiss, 1990). 
Dimerisation can occur either in solution (Saudek et aI, 1991a) (usually in this 
case dimerisation is required for DNA binding) or once on the DNA (i.e. bound 
monomers associate once on the DNA) (Saudek et aI, 1991b). An example of 
the former are the bZIP proteins, typified by the Jun and F os proteins. The 
latter has been shown to be the case for the LexA repressor (Kim and Little, 
1992), for example. The second monomer can have enhanced binding, or 
"cooperativity" due to the presence of the first monomer bound to one half-site, 
as is the case for the LexA protein. 
1.1.4 Sequence-Specific DNA binding by Pseudopeptides. 
Talanian et al (1992) have reported efforts to minimise the size of the GCN4 (a 
member of the bZIP family) while retaining sequence-specific DNA binding 
activity. They used three criteria to evaluate the shorter peptides: DNase I 
footprinting, NMR analysis, and stability measurements using CD spectroscopy. 
Their study shows that DNA binding activity of GCN4, containing only 20 
residues from the basic region of the GCN4, is capable of binding DNA in a 
sequence-specific manner. Circular dichroism experiments suggest that specific 
binding involves only 15 residues in an oc-helical conformation. Thus it appears 
that most or all of the GCN4 residues that make specific DNA contact lie 
within the 15-residue region from GCN4 residues 231 to 245 (see below). 
Further reduction in the number of residues and its effect on DNA recognition 
still remains to be explored. 
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1.2 bZIP Proteins. 
Table 1 shows a list of some of the leucine ZIpper proteins known, the sub-
family they belong in, and the sequence reference. In the interests of brevity 
literature citations for these sequences are not given in the text below. 
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Table 1: Leucine zipper proteins known to date 
Family (if Reference FunctionIFeatures 
any) Name Species (putative) 
CIEBP rat Landschulz et ai, Binds either CAA'IT or enhancer 
(also 1988a core sites. CIEBP is knO'Ml to 
known promote growth arrest and terminal 
as EBP1) differentiation in adipocyctes. CIEBP 
has also been suggested to be 
involved in the control of 
polysaccharide and carbohydrate 
metabolism. 
Jun c-Jun human Bohmann et ai, phorbol ester inducible, probably via 
1987; Hattori et ai, the protein kinase C pathway; 
1988 (signal transduction). 
Jun v-Jun ASV17 Maki et ai, 1987 " 
Jun Jun-B mouse Ryder et ai, 1988 " 
Jun Jun-D mouse Ryder et ai, 1989 " 
Jun c-Jun mouse Ryseck et ai, 1988; " 
Lamph et ai, 1988 
Jun c-Jun chicken Nishimura and " 
Vogt, 1988 
Jun c-Jun rat " 
Fos c-Fos human Van Straaten et ai, serum responsive nuclear 
1983 phosphoproteins, probably via protein 
kinase C pathway. 
Fos c-Fos Van Beveren et ai, " mouse 
1983 
Fos c-Fos rat Curran et ai, 1987 " 
Fos-B Zerial et ai, 1989 " Fos mouse 
Fos c-Fos chicken Molders et ai, 1987 " 
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Table 1 continued. 
Family (if Name Species Reference Function (putative) 
any) 
Fos fra-l rat Cohen and Curran, serum responsive nuclear 
1988 phosphoproteins, probably via protein 
kinase C pathway. 
Fos v-Fos MuSV Van Beveren et ai, " 
1983 
BZLFI EBV Farrell, et ai, 1989 Required for the switch from latent 
to productive infection. 
GCN4 yeast Hinnebusch, 1986; general control of amino acid 
Thireos et ai, biosynthesis 
1984 
cpc-l N.crassa Paluh et ai, 1988 general control of amino acid 
biosynthesis 
cys-3 N.crassa Fu et ai, 1989 sulfur metabolism pathway control 
yAP 1 yeast Moye-Rowley et 
ai, 1989 
02 Zea Opaque-2 locus zein regulatory gene 
(Opaque mays 
2) (peas) 
HBP-l wheat transcriptional regulator 
OTF-2 mouse wide variety of promoters and 
enhancers may determine B-cell 
specificity. 
CREB CRE-BPI human Maekawa et ai, binds CRE; cAMP possible mediated 
1991 enhancer. 
CREB CREB human Hoefiler et ai, CRE binder, activated by cAMP, 
1988 prob. via protein kinase A; may 
have a role in signal transduction 
pathway. 
CREB TGAla tobacco Katagiri et ai, root gene expression control; 
1989 Possible transcriptional regulator 
CaMV 35S promoter. Possible 
analogue of HBPI 
CREB TGAlb tobacco Katagiri et ai, Potential transcriptional regulator; 
1989 CaMV 35S promoter. Possible 
analogue of HBPI 
CREB CREB Gonzalez et ai, " rat 
1989 
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1.2.1 Binding Sites of bZIP Proteins. 
In general these can be divided into two classes; the AP-l sites and CRE (ATF) 
sites, which differ by a single base in the centre of the dyad (see table 2). 
Some proteins (e.g. GCN4) are able to bind to both AP-l and CRE sites. The 
addition/loss of one base would cause a rotation of 34° and translation of about 
3 AA of the half-sites along the DNA principal axis. Studies suggest the protein, 
rather than the DNA, adapts to the different sites (Chothia, 1984; Chothia and 
Finkelstein, 1990). 
Table 2: Some leucine zipper protein DNA sites 
Site name Site family Binding site 
AP-l AP-l TGAC-TCA 
GCN4 AP-l GTGAC-TCAC 
CRE CRE/ATF TGACGTCA 
HBP-l CRE/ATF ACGTCA 
TGA-repeat CRE/ATF TGACGTGACG 
SV40 enhancer - TGTGGAAAG 
G-box G-box CCACGTGG 
1.2.2 Subfamilies of bZIP Proteins. 
This section has been used to elaborate on some of the biology of these 
proteins referred to in table 1 and some that have not been mentioned above. 
The Jun family. Jun, like Fos (see below), was originally identified as a viral 
oncogene (Maki et aI, 1987) and was one of the first oncogenes to be shown 
to be directly involved in transcription. 
The mammalian transcription complex AP-l has a consensus binding site (V ogt 
et aI, 1987; Lee, 1987; Piette and Yaniv, 1987) very similar to that of GCN4, 
which suggested that a Jun-like protein might be the mammalian AP-l complex. 
Several lines of evidence supported this theory. When anti-sera of two v-jun 
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peptides (Bos et aI, 1988) were immunoblotted against AP-1, both anti-sera 
recognised a single major polypeptide species; c-Iun (Bohmann et aI, 1987) and 
several tryptic peptides of the AP-1 complex were identical to the predicted 
sequence of v-jun. This was followed by the demonstration that Iun (expressed 
in E.coli) could bind to an AP-1 site (Bohmann et aI, 1987). 
Several cellular homologues to v-Iun have now been identified (see table 1) and 
more than one Iun-related protein has been identified in the AP-1 complex (e.g. 
Iun-B, Iun-D). 
The Fos family. The viral forms of Fos are found in the FBI and FBR munne 
sarcoma viruses (MSV or MuSV), where they are responsible for the induction 
of osteogenic sarcomas. Like v-Iun, v-Fos is rapidly and transiently stimulated by 
the presence of growth factors, including the tumour inducing phorbol esters 
(e.g. 12-0-tetradecanoyl-phorbol-13 acetate (TPA), for review see Iones, 1988). 
The cellular and viral forms of F os had long been suspected to be directly 
involved in transcription (Muller, 1986; Verma, 1986; Setoyama et aI, 1986a, b; 
Sambucetti and Curran, 1986; Renz et aI, 1987) and were later observed in a 
complex interacting with a fat-specific element of the promoter of the 
adipocyteprotein 2 (aP2) gene (Distel et aI, 1987). An AP-1 site was found to 
be present in the aP2 promoter element (see above), suggesting Fos might, too, 
be part of the AP-1 complex. Fos was shown to bind (in a complex) to AP-1 
sites (Rauscher et aI, 1988a, b; Franza et aI, 1988, Lucibello et aI, 1988; Chui 
et aI, 1988), trans-activate AP-1 dependent transcription (Schonthal et aI, 1988; 
Lucibello et aI, 1988; Sassone-Corsi et aI, 1988a; Chiu et aI, 1988) and also 
trans repress it's own (c-fos) promoter (Schonthal et aI, 1988; Sassone-Corsi et 
aI, 1988b). 
v-Fos and c-Fos were known to be associated with a nuclear phosphoprotein 
complex termed p39 (Curran and Teich 1982; Curran et aI, 1985; Franza et aI, 
1987), with a similar molecular mass to AP-l. This and F os transcriptional 
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regulation of AP-I transcription suggested that p39 and Jun/ AP-I were the same 
proteins, which was subsequently shown to be the case (Rauscher et aI, I988c; 
Sassone-Corsi et aI, I988a,b; Chiu et aI, 1988). 
GCN4. GCN4 regulates most of the ammo acid biosynthetic pathways in the 
yeast Saccharomyces cerevisae. Amino acid starvation of almost any amino acid 
results in the synthesis of GCN4 which binds upstream of many ammo acid 
biosynthesis genes, inducing their transcription (Hinnebusch, 1986). This is a 
'general control' mechanism; (negative) feedback from anyone of the pathways 
stimulates the whole collection of pathways via some common control mechanism 
(usually a transcription activator, as in this case). 
The CREB family. These binds the c-AMP responsIve element (CRE) whose 
consensus differs from the AP-I consensus in having one more base paIr in the 
centre of the dyad (see table 2). The first known member of this family was 
CIEBP. CRE-BPI, which shows strong similarity to other CREB proteins found, 
is unusual in that it contains a consensus CC/HH zinc finger at the ammo 
terminus. 
CREB proteins' function has been reviewed by Brindle and Montiminy (1992). 
The CREB family activate/repress gene expressIOn in response to extracellular 
stimuli. A common secondary messager is cAMP, which can in tum activate 
cAMP-dependent protein kinase A (PKA). In mammals the best studied response 
to cAMP is via the control of CREs by CREB. PKA activates CREB via 
phosphorylation of Ser 133. This does not alter DNA binding affinity. The 
CREB subfamily differs from the ATF family m having a conserved 
phosphorylation/activation domain and a kinase inducible domain (the latter 
consists of consensus sites for a variety of protein kinases). 
yAP 1. The transcriptional activator yAP 1 recogruses an AP-I site, but has an 
ammo acid sequence strikingly at odds with other members of the family. At 
650 amino acids long it is much longer than either Jun or GCN4 (figure 1 & 
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table 3), and the lzip is located at the N-terminal, rather than C-terminal end of 
the protein. In addition position 3d of the proposed lzip is held by Asn rather 
than Leu residue. yAP1 appears to be essential for yeast AP-1 element-dependent 
transcription. However, it should be noted that both GCN4 and yAP 1, among 
other proteins, are present in immunoblots of yeast AP-1 binding proteins. 
Figure 1: Helical wheel diagram of GNC4 leucine zipper (Hope and Struhl, 
1987), viewed down the helix axis. 
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CYS-3. The sulphur metabolic genes of Neurospora crassa (encoding for the 
enyzmes of the sulphur metabolism pathway) have two major regulatory genes; 
cys-3 and scan, which are, respectively, activators and repressors of this set of 
genes. Cys-3 has been shown to have some similiarity to Fos and GCN4 in the 
bZIP regions of these proteins. The 2d (table 3) position of the putative cys-3 
leucine zipper is a methionine. 
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CPC-l. Another N. crassa protein, CPC-l, has a regIOn with similarity to the 
DNA binding regIons of GCN4 and v-Jun, which suggested that this protein was 
analogous to GCN4. CPC-l is required for cross-pathway (i.e. general control) 
mediated regulation of amino acid biosynthesis, like GCN4, and is also 
transcriptionally regulated in response to amino acid starvation. However whereas 
yeast has a complex pathway leading to GCN4, so far in N. crassa only CPC-l 
has been identified. CPC-l has one of the most diverged of the lzips found thus 
far; only two of the d positions hold leucine. The 3d and 4d positions are Trp 
and His, respectively. The first heptad of the lzip is similar to GCN4's, but 
diverges after that. CPC 1 contains a region rich in GIn, Thr and Pro, like Jun, 
but unlike GCN4. CPCl cannot heterodimerise with GCN4, even though they 
are otherwise functionally equivalent. 
BZLFI. Biochemical studies indicated BZLFI had the functional characteristics of 
a bZIP protein, including dimerisation and binding an AP-l site as a dimer. The 
sequence of BZLFI was found to have a basic region, but (essentially) no 
leucine repeat. Only one of the d positions holds a Leu and two of the a 
positions have Leu. 
1.2.3 The Role of bZIP Proteins. 
Its has been considered that the bZIP proteins are the regulators of metabolic 
processes, but in a more general manner than envisaged by McKnight et al 
(1989). Most of the better characterised bZIP proteins are regulators of 
biosynthetic pathways (see table 1). Another common feature of these proteins is 
that they all act in response to extracellular stimuli. Those characterised are 
quick-acting, short-lived activators (or repressors). All these proteins share related 
target sites and general characteristics of activity. 
Schena and Davis (1992) have suggested that the common molecular role of the 
bZIP proteins may be to mediate the transfer of an external (or possibly also 
intracellular, but extranuclear) signal to the nucleus and thus alter gene 
expression. However, its possible that these proteins may also transfer the signals 
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required to control metabolism into the intranuclear signals (activation, repression) 
required to control the genes that govern metabolism. 
The Jun and Fos proteins are stimulated by growth factors implying that they 
are somehow involved in control of cell growth or differentiation. Recent work 
has illustrated the tissue and cell-cycle specifc expression of these proteins. F os 
IS activated in response to a very wide range of factors so Fos itself must have 
a very general function, such as activation of cellular growth, division or 
proliferation, etc. 
1.3 Structure-Function Relationships III bZIP Proteins-
The Basic Region. 
The basic region has been shown to be required for DNA binding by three lines 
of evidence: a. deletion mutagenesis, b. domain swops and c. point mutagenesis. 
Deletion mutagenesis has shown that of the 281 ammo acids In GCN4, the 60 
carboxyl terminal amino acids containing the bZIP region are required and 
sufficient for DNA binding (Hope and Struhl, 1986~ Vogt et ai, 1987). GCN4 
shows similarity to Jun, and this similarity is restricted to the carboxyl-terminal 
70 amino acids of GCN4, which show 44% identity. In addition, functional 
similarity has been shown by domain exchange with v-Jun (Struhl, 1987). Here a 
modified ( chimeric) GCN4 protein, with a Jun bZIP region was shown to bind 
the same site as GCN4, and be functionally similar in vivo. Likewise, a Lex A-
Jun fusion protein can replace GCN4 in an apparently fully functional manner. 
This work strongly suggests that the structure of this region is similar in Jun 
and GCN4. Furthermore, a fusion protein with the proposed GCN4 DNA 
binding region substituted with the corresponding region from Jun (a Lex A-
GCN4-Jun construct) functioned in vivo as a GCN4 analogue. More direct 
, domain swop' experiments have been done since, and convincingly show that 
the basic and lzip regions can functionally replace one another (Cohen and 
Curran, 1990~ Ransone et ai, 1990). 
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Mutations that alter the basic domain affect DNA binding (see Neuberg et ai, 
1989). A single basic to Glu substitution (Gentz et ai, 1989) abolished DNA 
binding. Gentz et al (1989) found deletions within the basic region affected 
DNA binding but not dimerisation. A single R~K substitution within the basic 
region of opaque-2 was able to abolish DNA binding (Aukerman et aI, 1991). 
Pu and Strohl ( 1991) have shown that a seven ammo acid insertion between the 
basic and lzip regions of GCN4 preserves function, whereas 2, 4 and 6 ammo 
acid insertions eliminate function. This shows that the phase of the basic regIOn 
with respect to the lzip region is important for DNA binding. 
1.3.1 Dimerisation is Required for DNA Binding. 
Hope and Strohl (1987) used the band-shift assay to show that GCN4 is bound 
to its target site as a dimer. This method has been taken up by other authors 
to illustrate some of the features of the bZlP proteins: That they all bind their 
target sites as dimers, that a functional lzip is required for this dimerisation, and 
that this leucine zipper mediated dimerisation in tum is required for DNA 
binding. Using the band-shift assay, Hill et al (1986) demonstrated that the 
carboxyl terminal 60 amino acids of GCN4 alone can both dimerize and bind to 
DNA; the last 37 amino acids can only dimerise (see also Kouzarides and Ziff, 
1989a), but not bind DNA, and that stable dimers form in the absence of DNA. 
The ability to form stable dimers in the absence of DNA is characteristic of 
these proteins, and strongly suggests they bind their target sites as a prefonned 
dimer as discussed in section 1. 1.3. This is consistent with the monomers being , 
unable to bind DNA. 
1.3.2 The Lzip is Required for Dimerisation. 
The lzip has been shown to be required for dimerisation by deletion and point 
mutagenesis. Several workers have found that only very short regtons 
corresponding to the lzip are needed for wild-type dimerisation. Kouzarides and 
Ziff (1989a) have demonstrated that about 37 amino acids are required for 
heterodimerisation of Jun and Fos. Turner and Tjian (1989) also demonstrated 
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this usmg a protein cross-linking band shift assay, as did Landschulz et al 
(1989), using glutaraldehyde cross-linking, both in solution and bound to the 
target site. A detailed mutagenesis study can be found in Ransone et al (1989). 
Gentz et al (1989) found replacement of individual Leu residue with Gly in Fos 
reduced, but did not block, dimerisation with Jun. Amino acid deletions within 
the lzip abolished dimerisation. Deletion within the basic region affected DNA 
binding but not dimerisation. Mutation of the three Ala's between the basic and 
lzip region reduced dimerisation and blocked DNA binding. One curious result 
was that the first 199 amino acids of Fos (which contains the complete lzip and 
5 amino acids after the fifth Leu) could not bind DNA efficiently, suggesting a 
requirement for the conserved histidine 7 amino acids after the last Leu for 
efficient dimerisation. 
1.3.3 The Basic and lzip Regions are Functionally Independent. 
The basic and lzip regions of different proteins can be functionally exchanged 
(Struhl, 1987; Kouzarides and ZitI, 1988; Agre et aI, 1989; O'Neil et aI, 1990; 
Cohen and Curran, 1990), suggesting they are independent structurally and 
functionally. Some workers do note that the basic regions can be affected by 
adjacent sequences (Cohen and Curran, 1990; Kerpolla and Curran, 1991). 
1.3.4 Homo- and Heterodimerisation of bZIP Proteins. 
There have been many reports that Jun and Fos bind their target site either as a 
Jun-Fos heterodimer or a Jun homodimer (but never as a Fos homodimer; see 
section 1.2.2 above). 
The lun-Fos heterodimer forms in preference to a Jun homodimer (Nakabeppu et 
aI, 1988; Turner and Tjian, 1989), and Fos is able to displace a Jun monomer 
from the homodimeric complex to form a Jun-Fos heterodimer (Nakabeppu et aI, 
1988). Likewise Fos can stabilise the JunJAP1 association (Rauscher et aI, 
1988a). Elsewhere it has been shown that the major species present in vivo IS 
the heterodimer. This raises the question of whether the Jun homodimer IS 
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actually present and/or functional in the in vivo situation, but it is at least clear 
that in the presence of equimolar or excess F os it is a minority species. 
The lun-Fos heterodimer has been shown to be very stable, capable of resisting 
high salt and detergent concentrations. This suggests that both hydrophilic and 
ionic interactions are crucial to the formation of dimers. 
Various authors report little or no DNA binding of the lun homodimer 
(Kouzarides and ZitI, 1988; Nakabeppu et ai, 1988; Sassone-Corsi et ai, 1988a, 
b) to the TP A-responsive element (TRE). This is likely to reflect the weaker 
and more stringent homodimerisation of lun rather than a lack of DNA binding, 
as the lun and Fos (and GCN4) basic regions have been shown to be 
functionally equivalent (it is known that the lun basic regions are capable of 
binding to DNA strongly in proteins with the lzip substituted with either a Fos 
or GCN4 lzip). On the other hand weaker association might be expected to be 
more sensitive to the conditions used. Since Jun-Jun has been shown to 
efficiently form homodimers in solution (e.g. Turner and Tjian, 1989) and the 
basic regions of Jun and Fos are functionally equivalent, it would be expected 
that Jun might be capable of binding DNA, albeit at lower efficiency due to its 
lower degree of dimerisation. 
The AP-1 and ATF/CREB families can form selective cross-family heterodimers 
(Rai and Curran, 1991). The DNA binding specificities of these heterodimers 
differ from the homodimers which they are derived from, and the different 
heterodimers show different DNA binding specificities. There seems to be an 
overall preference for the CRE, however. 
Brindle and Montiminy (1992) report that ATF2, ATF3 and ATF4 can 
heterodimerise with Fos, Jun or Fra-1 in vitro. ATF1 would not heterodimerise 
with these proteins (Hai and Curran, 1991). Similarity Hoefiler et al ( 1991 ) 
found ATF2 could heterodimerise with either Fos or Jun, whereas CREB or 
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ATF1 could not. ATF1, but not ATF2 has been shown to heterodimerise with 
CREB both in vitro and in vivo (Hurst et aI, 1990). 
1.3.5 The Lzip Determines which Dimers are present. 
Different lzips have differing affinities to associate as dimers with one-another. 
This raises the suggestion that the role of the lzip is to determine the dimer 
species available at anyone time. This could affect either the DNA binding 
specificity of these dimers (via the different DNA binding abilities of the DNA 
binding regions) or other functions associated with the proteins, or both. 
Kouzarides and Ziff (1988) analysed the relative contributions of the basic and 
lzip regIOns to DNA binding by domain exchange experiments, using Jun, Fos 
and GCN4. They constructed chimeric proteins with either the lzip or basic 
region domains swopped with those of one of the other two proteins used, and 
assayed the dimerisation and DNA activity of these chimeras. The Jun, Fos and 
GCN4 basic regions appear to be functionally equivalent; it is the differing 
dimerisation capacities of the different lzips that determine the relative affinities 
of the interactions with the TRE. They drew two conclusions: 
i) The dimerisation abilities of the chimeric proteins are a reflection of the 
dimerisation ability of the protein the lzip concerned came from. 
ii) An argument to explain the relative affinity of a lzip protein to its site IS 
that the strength of the dimerisation determines the concentration of available 
dimers in solution. By controlling the amount of complexes able to bind DNA, 
the lzip determines the amount of DNA binding activity. 
Other workers have found similar results. O'Shea et al (1989b) calculate that 
their Jun-Fos leucine zipper-based peptide heterodimer forms over 1000-fold 
preferentially to the Jun-based peptide homodimer. This parallels reasonably well 
with the >10-100 fold stronger binding of Jun-Fos to the same site as to Jun-
Jun (Halazonetis et aI, 1988; Kouzarides and ZitI, 1988; Nakabeppu et aI, 1988; 
Sassone-Corsi et aI, 1988a). Neuberg et al (1989) found that more than a one 
thousand-fold mcrease in the concentration of random oligonucleotide was 
required to abolish the band-shift of the Jun-Fos complex over that of Jun-Jun. 
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They observe that the ability of a dimer to bind to DNA correlates well with its 
ability to dimerise. 
There are several members of the Fos and Jun family from the same orgarusm, 
and it is known from experimental studies that several different related protein 
species are found in the AP-1 complex. The distinct dimerisation capacities of 
the different monomers may control the types of complexes that can associate, 
and hence bind DNA and thus control gene expression in some way. That is, 
while the general rules of what monomers could associate would remain the 
same (e.g. any Jun can dimerise with any Fos), the actual affinities of each 
monomer for the others would slightly vary, controlling the relative amounts of 
each complex available to bind DNA. 
1.4 Activation of the AP-l Protein by a Redox Mechanism. 
It has been demonstrated (Abate et aI, 1990a, b) that the in vitro DNA-binding 
activity of F os and Jun is regulated by a redox mechanism involving a cysteine 
residue located at the basic region of both protein monomers. The biochemical 
attributes of eys residues are often essential for functional and structural 
properties of proteins (Xanthoudakis and Curran, 1992a). Indeed, their presence 
and relative distribution are often used to define characteristic protein domains 
such as the zinc finger (Berg, 1990). For these reasons, Cys residues are often 
conserved across phylogenetic boundaries and among gene families. 
A highly conserved Cys residue, flanked by two invariant basic ammo acids, 
lysine-cysteine-arginine (KCR), is present in the DNA binding domain of the F os 
and Jun family members. As well as facilitating DNA base contact it is likely 
that the positively charged lysine and arginine residues increase the oxidisability 
of the cysteine making it more susceptible to redox control (Abate et aI, 1990a; 
Xanthoudakis et aI, 1992b ), hence, the oxidation constant (Kox) of a sulfhydryl 
group is influenced by its local environment and is subject to change caused by 
alterations in protein conformation. However, this residue does not participate in 
disulfide bond formation between Fos and Jun in vivo and it is not part of a 
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ZInC finger motif. In the proposed model of protein-DNA complexes involving 
basic region-leucine zipper proteins, the Cys is in close proximity to DNA, and 
as mentioned before this regulatory cysteine acts as a "sulfhydryl switch" that 
reversibly modulates binding of Fos and Jun to the AP-I site. The exact 
chemical nature of the redox change in F os and Jun has yet to be defined, but 
it is clear that oxidation of the Cys is not permissive for DNA binding, while 
reduction to a sulfhydryl state promotes the protein-DNA interaction. It is 
suggested that DNA binding of F os/Jun is prevented by conversion of the critical 
cysteine residue (Fos-CI54 and Jun-C272) of the KCR motif to the reversible 
oxidation products sulphenic (RSOH) or sulphonic (RS02H) acids, as in Oxy R 
proteins. 
Furthermore, DNA-binding activity of Fos and Jun can be enhanced or 
permanently activated by mutation of Cys to Ser (Fos-CI54S and Jun-C262S) or 
by treatment with high concentrations of reducing agents. This is indicative of 
the significant role of the cysteine residue in redox binding regulation. 
1.4.1 Ref-l a Ubiquitous Nuclear Protein. 
A cellular nuclear protein can activate the DNA-binding activity of Fos and Jun 
In the absence of high levels of reducing agents. This protein does not appear 
to participate in the DNA-protein complex, and it does not affect the specificity 
of the interaction with DNA. These results suggest that a nuclear protein 
regulates the DNA-binding activity of Fos and Jun indirectly; perhaps by post-
translational modification (Xanthoudakis and Curran, I992c). 
The activity of this nuclear factor, designated Ref-I (Redox Factor-I) can be 
increased in the presence of thioredoxin, thioredoxin reductase and NADPH, 
implying that it may participate in a redox cycle by acting as an electron donor 
for AP-l proteins (Xanthoudakis et aI, 1992a, b). It is possible that the AP-l 
redox signaling pathway comprises several components that are responsible for 
reducing Ref-I. Whether thioredoxin itself acts to regenerate active Ref-l in vivo 
is not known, but it is clear that thioredoxin alone, as well as glutathione and 
glutathione transferase, failed to substitute for Ref-l activity in vitro. This 
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protein, Ref-l (a 37kDa protein), is identical to the human apurinic-apyrimidinic 
endonuclease HAP 1 (Xanthoudakis et aI, 1992b). Ref-l is therefore a 
bifunctional protein possessmg AP-l redox and DNA reparr activities 
(Xanthoudakis et aI, 1994). Biochemical characterisation has revealed that only 
reduced Ref-l IS capable of stimulating Fos-Jun binding activity, whereas either 
reduced or oxidised Ref-l functions as a endonuclease. 
So to summanse, maintenance of the cysteinyl residue in a reduced and therefore 
DNA binding state is mediated by Ref-l which is elevated when hypoxia is 
induced (Ausserer et aI, 1994). The importance of Ref-l in control of AP-l 
binding is evident from hypoxia induced transcription of Ref-l mRNA and 
increased stability of Ref-l protein (Yao et aI, 1994). However other reducing 
agents including thioredoxin as well as small molecular weight thiols also 
promote AP-l binding of Fos/Jun (Abate et aI, 1990a; Xanthoudakis et aI, 
1992b). 
1.5 3D ModeJ(s) for DNA Binding bZIP Proteins. 
Binding sites on DNA impose several constraints on the proteins that must 
recognise them: a. The DNA contact surface of a protein must be capable of 
penetrating either the major or minor groove (Oakley et aI, 1992) of the DNA 
in order to interact with the functional groups that distinguish one binding site 
form another. b. Dyad-symmetric binding sites (Risse et aI, 1989) further demand 
that the two contact surfaces of the binding protein be assembled so that they 
can simultaneously interact with both halves of the recognition site. 
An evaluation of the properties of conserved ammo acids within the basic reg10n 
of these bZIP protein sequences, coupled with the observation that they are 
located at an invariant distance from the leucine zipper, has led to the 
formulation of the "scissors-grip" model for DNA binding (Vinson et aI, 1989). 
The architectural features of this model are well suited for interaction with 
directly abutted, dyad-symmetric DNA sequences. This model proposes that two 
polypeptide chains join to form a Y -shaped molecule. The stem of the Y 
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corresponds to a coiled pair of a -helices. Therefore its proposed that the cleft 
of the Y would be the point where the protein contact the DNA-binding site at 
the center of the dyad. The two arms of the Y, representing the two basic 
regions, are then proposed to wrap around the DNA so as to sit in the major 
groove and contact the two half sites of the dyad. To achieve this, it is thought 
that a sharp kink would be necessary in the basic region helix, probably at the 
conserved asparagine residue and this would facilitate protein contacts with the 
outer bases of the binding site. 
Although the scissors-grip model provides a plausible architectural scheme for 
stable interaction between protein and DNA (Neuberg et aI, 1991), it raises the 
question as to how bZIP proteins engage and disengage from their substrates. A 
variation on this model was proposed after further peptide studies ( circular 
dichroism and rum) revealed that in solution the GCN4 bZIP domain was only 
30-70% oc-helical (Gartenberg, 1990), but became almost completely oc-helical on 
binding to DNA (O'Neil et aI, 1991). Studies on fos/jun peptides also indicated 
a conformational change on binding to DNA (Patel et aI, 1990). Consequently, 
the Induced Helical Fork model was proposed whereby a partially helical 
conformation allows the protein to efficiently "search" the DNA before it 
interacts with the DNA-binding site producing a true a-helix stabilised by 
specific protein DNA contacts (O'Neil et aI, 1991). Thus preferential stabilisation 
of the DNA-binding conformation provides an attractive mechanism for the· 
regulation of DNA binding by bZIP proteins. It also appears that DNA 
recognition by bZIP proteins is a dynamic process that involves changes in both 
protein and DNA conformation (Suzuki et aI, 1996). Whether sequence 
recognition depends on the formation of specific hydrogen bonds with functional 
groups on the bases (direct read-out) or on a particular helix geometry induced 
primarily by contacts with the phosphodiester backbone (indirect read-out) 
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1.6 Summary of the bZIP Proteins. 
Cell growth and differentiation are controlled, to a large extent, through the 
selective regulation of gene expression by extracellular signals. In the past several 
years, a large number of sequence-specific DNA-binding proteins have been 
identified that function as regulators of gene transcription. 
The product of two cellular proto-oncogenes, Fos and Jun (Talanian et aI, 1990; 
1992) (figure 3) appear to play a central role in the regulation of cell growth. 
They are thought to function in coupling short-term signals, elicited at the cell 
surface, to long-term changes in cellular phenotype by regulating expression of 
specific target genes. These proteins belong to a growmg family of 
transcriptional regulators that include the cyclic AMP response element-binding 
protein (CREB) (Hoeffler et aI, 1988), the yeast GNC4 protein (Hope and 
Struhl, 1987), and CIEBP enhancer-binding protein (Land schulz et aI, 1988a). 
These transcriptional factors form dimeric complexes which recognise and bind to 
specific cognate DNA sequences. 
Figure 3: Schematic diagram and nomenclature of protein domains. 
I NH2-Tenninus H Basic-Region H Leucine-Zippe!H COOH-Terminusl 
Jun J 1-255 J 256 -282 J283-311 J312~33 333 aa 
Fos F 1-137 F138-164 F194~80 
F 194-380 380aa 
Two domains of these proteins are required for the combined functions of 
protein-protein and protein-DNA complex formation. The leucine zipper domain 
mediates protein dimerisation (Talanian et aI, 1990) through the formation of 
parallel a.-helical dimers as in the two-stranded coiled-coils of fibrous proteins 
(O'Shea et aI, 1989a). The dimerisation interface in proteins consists of a 4-3 
heptad repeat of hydrophobic amino acids that are almost exclusively leucines. 
Substitutions that change one or more of the residues in the leucine zipper can 
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abolish dimer formation and DNA binding; this demonstrates that dimerisation IS 
required for DNA binding. 
1.7. DNA Recognition by Hybrid Molecules-
Naturally Occuring Hybrid Molecules. 
Nature provides examples of drugs whose binding to DNA simultaneously 
implicates various processes. Such is the case for actinomycin D, a natural 
antitumour agent which consists of a phenoxazone disubstituted with a cyclic 
pentapeptide. Intercalation of actinomycin (Takusagawa et aI, 1982) occurs 
preferentially at some, but not at all, GpC sequences with the cyclic peptides 
fitting above and below the intercalating nng in the minor groove, each covenng 
















Other such bimodal binding process has been found III the intercalation with 
DNA of different natural antitumour anthracyclines, typified by daunorubicin 
(daunomycin) and doxorubicin (adriamycin). 
X-ray diffraction analysis (Quigley et aI, 1980; Frederick et aI, 1990) has 
definitely demonstrated that while the chromophore intercalates CpG steps, the 
glycan moiety lies in the minor groove. The sugar forms several bonds with 
DNA and so greatly contributes to the stability of the complex. 
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R 
Daunorubicin R = COCH3 
Doxorubicin R = COCH20H 
A considerable number of DNA-binding natural products contain carbohydrate 
residues that are likely to serve as DNA recognition elements. The molecular 
architecture is even more complicated with another natural anthracydine, 
nogalamycin, which differs from daunomycin and doxorubicin in that it contains 
two sugars moieties attached to the chromophore. The binding of nogalamycin to 
DNA consists of intercalation of the anthracycline ring and groove binding of 
the sugar moieties (Liaw et ai, 1989). The nogalose is lying III the minor 
groove, and the positively charged aminoglucose is lying in the major groove, 
with the two sugars pointing on the same side of the aglycon ring. 
OH 0 OH 0 
Nogalamycin 
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Other examples of natural drugs presenting these binding characteristics are the 
quinoxaline antibiotics. Quinoxaline antibiotics are a family of antitumour drugs, 
of which echinomycin is the best-known member, and in which two quinoxaline-
2-carboylic acid chromophores are attached to a cross-bridged cyclic octapeptide 
dilactone containing both L- and D-amino acids. This group of compounds 
include triostin (Wang et aI, 1984), which has the common properties with 
echinomycin (Ughetto et aI, 1985) to bisintercalate with DNA placing the 
peptide ring into the minor groove. 
L-Ala 
o 





Thus actinomycin, doxorubicin, daunomycin, nogalamycin, and the quinoxaline 
antibiotics are all examples of drugs whose binding to short DNA sequences 
implicates two processes, intercalation and groove-binding simultaneously and in 
close proximity. Both processes contribute to the affinity and sequence-specific 
recognition. All these natural compounds could provide models for the rational 
design of ligand exhibiting mixed modes of binding. 
29 
1.8 Aims 
The purpose of this study is to investigate a minimalist approach to inhibition of 
redox sensitive transcription factors involved in malignant transfonnation and 
growth of tumour cells. This should assist the development of agents that are 
active specifically under reducing conditions and with specificity for the DNA 
binding domain of redox sensitive transcription factors. 
The two mam objectives are (a) to synthesise novel intercalator-cysteinyl peptides 
designed to interact with the DNA recognition sequence of redox sensitive 
proteins that bind to the AP-I transcription site. It is anticipated that subsequent 
binding will inhibit binding of the relevant up regulating transcription factors and 
hence inhibit cell growth and promote cell death. (b) To correlate binding of the 
agents developed in (a) with the DNA binding domain of AP-l using cell free 
nuclear extracts and then with free DNA constructs in binding assays. 
In this work, the synthesis of Fos-Jun basic region-intercalator hybrid peptide 
(figure 4, see next page) will be described. This molecule has been designed to 
investigate the combination of minimum features of the peptide necessary for 
recognition of the consensus site with the known binding enhancement of an 
intercalating anthrapyrazole (APZ) moiety. In this way, it is hoped to achieve 
both tight binding and high degree of molecular recognition with a comparatively 
small peptide. 
Chapter 2 of this thesis will be devoted to the synthesis of the anthrapyrazole 
derivatives. Chapter 3 will then discuss the synthesis, characterisation and 
isolation of the peptides. Chapter 4 will then outline the coupling of the 
intercalator (APZ) to the peptide sequence to yield the target hybrid ligand. Cell 
free biological evaluation of these hybrid ligands will be investigated in chapter 
5. DNA binding assays will also be used in investigating the nature and the 
affinity of the binding. 
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Figure 4: Fos-Jun region-intercalator hybrid peptide construct. 
Intercalator: 
Anthrapyrawle 
Intercalator = Anthraprazole 
Linker 
Peptide 
= Alkylamines and alkylamides 








Synthesis of the 
Anthrapyrazo[e Derivatives 
The first part of this Chapter outlines the Lerman model 
of intercalation. The synthesis of the different anthrapyrazole 
(APZ) intercalator derivatives are discussed together with the 
mechanisms for each reaction. The experimental procedure for the 
synthesis of the APZ derivatives can be found in chapter 6. 
In this work a senes of intercalators based on the anthrapyrazole compounds 
have been synthesised. It is important to begin this chapter by briefly describing 
the mechanisms underlying intercalation, and also the structural requirements for 
intercalating agents. 
2.1 Lerman Model for Intercalation. 
Lerman (1961) proposed that the planar aromatic pro flavin molecule becomes 
inserted between adjacent base pairs of double helix of DNA (figure 5). The 
base pairs remain perpendicular to the helix axis, but they are moved apart, by 
3.4A, to accommodate the acridine molecule which lies in van der Waals contact 
between the base pairs. The intimate contact between the n-orbitals of the drug 
molecule and the base pairs would help to stabilise the complex via hydrophobic 
and charge-transfer forces. Local distortion of the helix occurs since it has to 
unwind in order to accommodate the drug molecule (Neidle et aI, 1987). 
Distortion of the helix due to local unwinding at intercalation sites would 
destroy the long-range regularity of the helix, as observed by X-ray diffraction 
studies. Lerman (1961) proposed an unwinding angle of 45° in his original 





Figure 5: The Lerman intercalation model, in schematic form. (a) illustrates the 
double-stranded DNA helix: (b) shows DNA with bound-drug molecules as 
shaded discs intercalated between base pairs, shown as unshaded discs. 
33 
2.1.1 Anthrapyrazoles as Intercalators. 
The binding of various anthrapyrazoles to double stranded oligonucleotides, usmg 
computer assisted modelling techniques, indicate an intercalative mode of binding 
(Chen et ai, 1987). This intercalative binding hypothesis has been verified by 
Hartley and colleagues who characterised the structural requirements for DNA 
binding using phage PM2 plasmid DNA (Hartley et ai, 1988) and various A-ring 
modified anthrapyrazoles (figure 6). The 7,10 unsubstituted APZ was found to be 
an efficient intercalator, similar in magnitude to ethidium, but that the hydroxyl 
groups on the A-ring of the chromophore, resulted in a decrease of the 
unwinding angle, indicative of a decrease in the intercalative ability (Hartley et 
ai, 1988). The trihydroxy anthrapyrazoles did not cause any significant unwinding 
of the DNA but were still strongly bound, presumably to the surface of the 
DNA helix. 
Figure 6: Structures of various A-ring modified anthrapyrazoles 
Compound A-ring substituent 
PD 110095 7,10-H 
CI-941 7-0H 
PD 114057 10-0H 
PD 111707 7,10-0H 
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2.2 Synthesis of the Anthrapyrazole derivatives. 
The rationale behind the synthesis of the anthrapyrazoles (Showalter et aI, 1986a; 
Showalter et aI, 1984), stems from the observation that the quinoneimine 
anthracyc1ine, 5-iminodaunorubicin, has proved less cardiotoxic than doxorubicin 
in experimental systems (Tong et aI, 1979). By analogy to 5-iminodaunorubicin, 
the anthrapyrazoles as modified quinoneimines are theoretically poor candidates 
for metabolic reduction and drug free radical formation. Electrochemical studies 
by Showalter et al (1986a) on the anthrapyrazoles have confirmed that these 
compounds are very difficult to reduce. 
The first report of anthrapyrazole synthesis materials was that of Mohlau in 
1912 in conjunction with the synthesis of the dyestuff pyrazoloanthrone yellow 
derived from 9,1 O-anthracenedione starting materials. Since then there have been 
numerous reports in both the patent and journal literature of the synthesis and 
chemistry of this commerically important class of compounds (Showalter et aI, 
1986b; Beylin et aI, 1989). 
2.3 Discussion and Mechanisms. 
In general the synthesis of N-substituted APZ has required separate synthesis of 
the substituted hydrazine side chain, which was then reacted with the 
chloroanthraquinone. Further side chain functionalities were introduced 
subsequently to form the pyrazole ring. The overall synthetic strategies utilised in 
the preparation of target APZ derivatives are outlined in figure 7-9. 
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Figure 7: General synthetic route to 2-substituted APZ derivative. 
NH2NH2·H20 + ~N~OH 
( 1 ) ( 2) 
1 STIP 1 
H 
0 CI N-~N~OH 
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Figure 9: General synthetic route to 2,5-disubstituted APZ derivative. 
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2.3.1. Synthesis of 2-[(2-Hydrazinoethyl)amino]ethanol (4) (Step 1). 
The initial synthetic procedure involving the fonnation of side chain (4) was 
readily achieved using a literature procedure (Showalter et aI, 1986b). This 
product was extremely hygroscopic and decomposed on prolonged heating, and 
was therefore stored under inert conditions at 5°C. Figure 10 shows a direct 
nucleophilic attack by the monohydrazine hydrate (1) on the strained 3-membered 
ring of l-aziridine ethanol (2), to afford an energetically more stable dipolar 
intennediate (4i). 
Bis-substituted hydrazine (4ii) produced as a by-product was separated from the 
desired monosubstitued hydrazine (4) by Kugelrohr distillation. The 
monosubstituted hydrazine of lower boiling point was collected in the first 
fraction. 
Figure 10: Synthesis of the side chain 2-[(2-hydrazinoethyl)amino] ethanol 









H HH H 
HO~N~NN~N~OH 
(4ii) 
2.3.2 Synthesis of 2-{2-[N-(-2-Hydroxyethyl)amino]ethyl}anthra[I,9-c,djpyrazol 
-6(2H)-one (5) (Step 2). 
Coupling of l-chloroanthraquinone (3) to side-chain (4) was carried out usmg a 
literature procedure (Showalter et aI, 1986c), however by reducing the amount 
of solvent (dimethylfonnamide:acetonitrile) used in the reaction mixture, the yield 
was increased by at least 10%. An outline mechanism for the coupling step is 
shown in figure 11. 
Figure II: Mechanism of reaction of l-chloroanthraquinone with side-chain 4. 
o 






Figure 12: Mechanism of imine formation by reaction of ketone with pnmary 
arrune. 
RHN-N ... 














Figure 11 shows that the initial nucleophilic attack by (4) occurs favourably at 
the more electrophilic carbonyl carbon (see also figure 12) and not at the chloro 
substituted carbon. Figure 12 illustrates the nucleophilic attack by the primary 
amine on the ketone functionality resulting in a polarised tetrahedral intermediate 
(Si), which then undergoes proton transfer to yield a neutral carbinolamine (Sii). 
A proton picked up by the hydroxyl oxygen generates water as the leaving 
group. lminium ion (Siii) was formed as a result of water lost to yield the 
product imine (Siv). The electron sink effect facilitated the second nucleophilic 
attack at the chlorinated substituted carbon giving rise to the loss of hydrogen 
chloride. Triethylamine, a lewis base, was added to the reaction mixture to 
increase the pH. 
After the reaction had completed, the product was isolated by cooling the 
reaction mixture to room temperature, and storing at 4°C overnight. The solid 
product was then filtered in vacuo with thorough cold methanol washes. The 
product was further purified by recrystalisation from hot methanol. The 6n 
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electron ring closure ensures that the reaction lies to the 'right hand side' of the 
equilibrium resulting in high yield. 
2.3.2.1 Synthesis of 2-{2- [N-(2-Hydroxyethyl)-N-methylamino] ethyl} anthra [1,9 
c,dJpyrazol-6(2H)-one (6) (Step 3). 
The APZ derivative (5) synthesised during the last step contained a secondary 
amine in the side arm. An alkylation step was carried out to prevent acylation 
of this 'active' nitrogen (figure 13). This reaction required the refluxing of 
formaldehyde solution with formic acid as shown in figure 13. 
The transfer of a proton from the formyl aruon to the cationic intermediate 
resulted in the concomitant liberation of gaseous carbon dioxide detected as 
bubbles. The product initially, in the protonated form, was solubilised in the 
aqueous phase. In isolating this product, the reaction mixture was taken up in 
chloroform and the aqueous phase extracted. The aqueous phase was then 
basified to ~pH12 to give a fine precipitate, which was extracted using ethyl 
acetate. The combined organic phase was dried in vacuo to afford a dark 
VISCOUS oil which on trituration with methanol and cooling overnight gave a lime 
green solid material (6). This was further recrystallised to yield a very pure final 
product. 
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2.3.2.2 Synthesis of 2-{2-[N-(2-ChloroethyI)-N-methylamino]ethyI}anthra[I,9-
c,d]pyrazol-6(2H)one (7) (Step 4). 
The next stage was to consider ways of coupling the monosubstituted methylated 
anthrapyrazole to the peptide sequence (see chapter 4 for coupling and table 7 
for the peptides used). One way of linking the two components was to convert 
the hydroxyl group to a chloride to afford an anthrapyrazole mustard 
hydrochloride derivative. In this reaction thionyl chloride reacted with the 
hydroxyl group making it readily expelled by SN2 nucleophilic attack by the 
chloride ion (see figure 14). 
On completion of the reaction, excess thionyl chloride was carefully removed in 
vacuo and the solid residue that remained was triturated with anhydrous ether. 
Crystallisation from methanol yielded a bright yellow product (7). Coupling of 
the mustard anthrapyrazole to the amino terminus of the peptide took place VIa 
formation of a highly reactive aziridium ion (see session 4.1.1 on coupling). 
o 
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2.3.3 Synthesis of 7-Chloro-2-{2-[N-(2-hydroxyethyl)amino]ethyl}anthra[l,9-c,dj 
pyrazol-6(2H)-one (9) (Step 5). 
The mechanism for coupling of the side chain (4) to 1,5-dichloroanthraquinone 
was exactly the same as that described in step 2 (Showalter et aI, 1986c). 
However because the starting material, 1,5-dichloroanthraquinone has two possible 
attack sites, 1- and 5-, a side product in which two side chains were substituted 
was also produced (figure 15). This by-product (9i) was removed by washing 
the yellow product mixture thoroughly with cold methanol during filtration under 
vacuo. The absence of the carbonyl carbon signal in the IR range 1650-1750 
cm-1 was indicative of the presence of this side-product in the mother liquor. 
Figure 15: Two possible products. 
H 
N-N ............... N""'OH 
H 
N-N ............... N~H 
H 
CI 0 HO~N ............... N-N 
(9) (9i) 
However, the second carbonyl is less susceptible to nucleophilic attack because 
of an increase in electron density in the aromatic chromophore following 
coupling of the first side-chain. As a result, the yield obtained for the desired 
mono-substituted product (9) was higher. 
2.3.3.1 Synthesis of 7 -Chloro-2-{2-[N-(2-hydroxyethyl)-N-methylamino] ethyl} 
anthra [1,9-c,djpyrazol-6(2H)-one (10) (Step 6). 
The procedure carried out for this reaction was as described for step 3. Except 
that In this case the final product (10) was a yellow rather than a lime green 
solid. 
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2.3.3.2 Synthesis of 7-(2-Aminoethyl)amino-2-{2-[N-(2-hydroxyethyl)-N_methyI 
amino]ethyl}anthra [1,9-c,djpyrazol-6(2H)-one (11) (Step 7). 
This next reaction involved making a substitution at the 7- position. To synthesise 
the title compound, excess ethylenediamine was refluxed for 4 hr or until all the 
APZ starting material had reacted. This was determined by t.I.c. The amine 
functionality in the new side arm helps to stabilise the binding of APZ to the 
DNA backbone by interacting with phosphate groups (patterson and Newell, 
1994). To avoid possible intramolecular nucleophilic attack by the primary amine 
on the ring to form a stabilised 6-membered ring (figure 16), the refluxing was 
kept to a minimum. 
(11) 








However, this type of closure involves loss of aromaticity and IS therefore 
unlikely to occur. Nevertheless, intramolecular attack of this nature could be 
possible at temperatures exceeding 250°C. The reaction mixture was then taken 
up in water and the crude product extracted with dichloromethane. The resulting 
red viscous oil formed upon evaporation of the solvent was triturated with 
hexane to remove any remaining ethylenediamine. The desired product (11) was 
isolated by column chromatography using dichloromethane: ethanol: ammonia 
(9:1:0.1) as the eluent. 
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2.3.3.4a Synthesis of 7 -{2-[( methoxycarbonylmethyl)amino] ethylamino }-2-{2- [N-
(2-hydroxyethyl)-N-methylamino] ethyl}anthra[I,9-c,d] pyr azol-6(2H)-one (13) 
(Step 9). 
To further extend the side arm, methyl chloroacetate was made to react with 
(11) to give the APZ ester derivative (13). This reaction was carried out under 
ambient conditions in the presence of dimethylformamide (DMF) for 24 hr. By 
usmg a one-to-one equivalent it was possible to avoid a second substitution at 
the same nitrogen. The product (13) was isolated by column chromatography 






The following section outlines the dealkylation of this APZ ester to form the 
APZ acid derivative. Activation of this resulting carboxylic acid using PyBOP 
(section 4.l.2) will allow the direct coupling of the APZ intercalator with the 
amino terminus of the peptide, hence forming the desired intercalator-peptide 
complex (see chapter 4 for coupling). 
2.3.3.5 Conversion of Ester to Acid. 
An initial attempt at dealkylation of the APZ ester was carried out according to 
the method of Node et al (1991). The mechanism for this reaction is based on 
the principle of hard and soft acids and bases as shown below. 
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R-C-Q-R' + AIX3 + R"-SH • 




I + R'-S-R" + HX 
Q-A1X2 
The following components, compound (13), aluminum chloride and 
tetrahydrothiophene were dissolved in dichloromethane and left to stir overnight. 
Unfortunately, no reaction took place. This reaction was therefore abandoned, in 
favour of another procedure. 
An alternative method involved refluxing (13) with lithium bromide and pyridine. 
After 9 hr the pyridine was evaporated under vacuum. Ethanol was added and 
heated and filtered while still hot to remove the remaining inorganic materials. 
The ethanol was removed and the final acid product (14) was obtained on 
acidification usmg hydrochloric acid. The yield was very low at this stage and 
therefore it could not be used in subsequent steps. The synthesis of (14) was 
again dismissed, and other acid containing APZ compounds were synthesised 





2.3.3.4b Synthesis of 7-(2-Succinamidoethyl)amino-2-{2-[N-(2-hydroxyethyl)-N-
methylamino]ethyl} anthra[I,9-c,d]pyrazol-6(2H)-one (12) (Step 8). 
Instead of methyl chloroacetate, succinic anhydride was used in extending the 
linker. The coupling onto the peptide could then occur via the resulting carboxyl 
group. Note however, this linker contained an amide functionality which is less 
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H H 0 
(12) 
For this reaction, 1.2eq of succinic anhydride and compound (11) were dissolved 
in DMF:methanol (1: 1) and left to react at 40°C for 1.5 hr. The solvent was 
removed in vacuo and the product 12 isolated using column chromatography. 
N eat methanol was used to elute the desired component. 
(12) was recrystallised usmg ethanol and dried over phosphorous pentoxide. A 
relatively good yield was obtained of the analytically pure acid APZ product. 
2.3.4a Synthesis of 1,4-dichloroanthraquinone (15) Via Friedel Craft's 
Acylation (Step 11). 
Two very different methods have been employed for the preparation of 1,4-
dichloroanthraquinone. The first of these involved the Friedel-Crafts acylation 
(Phillips, 1926). 
Laboratory preparation was carried out according to Philips 1926. In this 
reaction p-dichlorobenzene, pthalic anhydride and anhydrous aluminium chloride 
were heated together at 140-160°C for 5 hr (figure 17). 
The driving force in the first step of this reaction was nng operung of the 
anhydride by catalytic aluminium chloride. p-Dichlorobenzene was added in great 
excess effectively to compensate for the electron withdrawing effect of the two 
chloro-groups. These have the effect of reducing the nuc1eophilicity at the 0-
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carbon, the attacking site for the acylium ion. Formation of aluminium salts at 
this stage led to darkening of the reaction mixture. 
Sublimation of the p-dichlorobenzene during heating resulted ill blockage of the 
neck joint which was dislodged hourly using a strong metal rod. To obtain the 
product, benzophenone acid (lSi), water was added to the cooled black reaction 
mixture, followed by 50mL of concentrated hydrochloric acid. Excess p-
dichlorobenzene was then removed by steam distillation rather than by 
temperature distillation. A combination of steam and p-dichlorobenzene gave nse 
to an azeotropic vapour mixture. This vapour on cooling deposited solidified p-
dichlorobenzene on the inner surface of the cooling condenser. The solid starting 
material p-dichlorobenzene was then collected at the end of the condenser by 
continual and careful alteration of the rate at which water flowed through the 
condenser. 
Figure 17: Friedel-Crafts Acylation. 





The remaIrnng content of the reaction mixture was then basified and filtered 
under vacuo to remove any precipitated aluminium salt. Decolourising charcoal 
was added before further acidification to yield the intermediate product 
benzophenone acid (15i), as an off-white precipitate. This low yielding reaction 
was a direct result of the electron-induction effect mentioned above. 
The second step of the reaction (figure 18), cyclisation of the benzophenone acid 
to 1, 4-dichloroanthraquinone, takes place under extreme acidic conditions. 
Approximately 50 fold excess of concentrated sulphuric acid was added to the 
starting material, which was then heated for 5 hr at ISO-160°C. 




As shown in figure 18, formation of 1,4-dichloroanthraquinone takes place VIa a 
second acylium ion. After heating for -5 hr, the reaction mixture was poured 
into ice cold water upon which a fine precipitate formed, which was extracted 
using ethyl acetate. The orgarnc layer was then washed several times with 
aqueous sodium hydroxide and then with saturated brine. A brown-yellow 
precipitate was obtained on drying In vacuo. Purification by column 
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chromatography and further recrystallisation usmg methanol and chloroform gave 
a bright yellow solid material of melting point 128-129°C (cf lit. 129°C). 
2.3.4b Synthesis of 1,4-Dichloroanthraquinone (15) via leucoquinizarin (Step 
12). 
An alternative method for the preparation of 1, 4-dichloroanthracenedione-9, 10-
dione was carried out according to Krapcho and Gretahun (1985). This method 
makes use of the widely available leucoquinizarin (also called 1,4,9,10 
hydroxyanthracene). This method of preparing 1,4-dichloroanthraquinone was 
favoured over the above mentioned Friedal Crafts because of the higher yield. 
This reaction involved refluxing leucoquinizarin, phosphorous pentachloride and 
1,1,2,2-tetrachloroethane for 24 hr (figure 19). The mixture was then allowed to 
cool to room temperature before excess methanol was added. Hydrogen chloride 
gas was vigorously produced at this stage and the mixture was then left to stir 
overnight. Upon further cooling to -20°C a brown-yellow solid appeared which 
was filtered with cold methanol and air dried to give 15. 













The next reaction step involved oxidation of the hexachloro compound (15ii) by 
refluxing in I-pentanol for 18 hr. On completion, the reaction mixture was 
cooled to room temperature, then further cooled to -20°C before filtering to 
afford a yellow solid. T.L.C. showed a single UV spot and the analytical data 
was as expected. 
2.3.4.1 Synthesis of 5-Chloro-2-{2-[N-(2-hydroxyethyl)amino]ethyl}anthra[I,9-
c,dJpyrazol-6(2H)-one (16) (Step 13). 
The coupling of the side chain (4) onto 1,4-dichloroanthraquinone is very similar 
to that described for the 1,5-dichloroanthraquinone (section 2.3.3) (Showalter et 
aI, 1986b). However the yield obtained was different in each case, with the 
yield of the 1,5-dichloroanthraquinone being slightly lower. The reason being that 
the electron withdrawing effect of the chloride in the same ring destabilises the 
cationic intermediate and thus disfavours its formation. However, once formed, 
nucleophilic attack is rapid. 
2.3.4.2 Synthesis of 5-Chloro-2-{ 2-[N-(2-hydroxyethyl)-N-methylamino ] ethyl } 
anthra[I,9-c,dJpyrazol-6(2H)-one (17) (Step 14). 
The procedure carried out was again the same as that for the synthesis of the 
2,7 -substituted APZ (section 2.3.2.1). However, because of the lower melting 
point of 2,5-N-methylated APZ, it was an oil at room temperature. It was 
possible to form the solid hydrochloride of the title compound by adding an 
equivalent number of moles of acetyl chloride/methanol at O°C to a solution of 
the described compound. 
2.3.4.3 Synthesis of 5-(2-Aminoethyl)amino-2-{2-[N-(2-hydroxyethyl)-N-methyl 
amino]ethyl}anthra [1,9-c,dJpyrazol-6(2H)-one (18) (Step 15). 
Substitution at the 5-position was achieved by refluxing (17) with excess 
ethylenediamine for 4 hr. The reaction mixture was then taken up in water and 
the crude product extracted with dichloromethane and dried to give a viscous 
red oil. The product (18) was isolated by column chromatography using 
dichloromethane:ethanol:ammonia (9: 1 :0.1) as eluent. 
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Using similar synthetic routes, anthraquinone derivatives (refer to T. Ijaz (1998) 
for more experimental detail) were also synthesised (figure 20). 







~ (CsHsbPI I CC4) 
CH3 
I o HN ............... N ............... CI 
o 
Anthraquinones are also well known intercalators (Kapuscinski and Darzynkiewicz, 






x = OR mitoxantrone 
x = R ametantrone 
The synthesised anthraquinone chromophores were coupled to the peptide chain 
to give a series of peptide-hybrid ligands. The cell free biological evaluation of 
the synthesised anthrapyrazole compounds along with the anthraquinones, and 
their respective peptide hybrid complexes can be found in chapter 5. 
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Chapter 3 
The Synthesis, Isolation 
and Characterisation of 
Short Oligopeptides 
The DNA sequence specificity of the intercalator-peptide 
complex is almost entirely dependent on the attached peptide 
sequence. Solid phase peptide synthesis (SPPS) used in the 
synthesis of short polypeptides is discussed. The final part of this 
chapter looks at three different methods used in the isolation, 
purification and characterisation of the synthesised peptides. 
3.1 The Synthesis of the KCR containing Peptide using the Solid Phase 
Peptide Synthesizer. 
In this work, two short polypeptide sequences (figure 21) were synthesised on a 
semi-automated solid phase peptide synthesiser. Additional peptides (table 7) were 
purchased from N ovabiochem. 
3.1.1 Solid Phase Peptide Synthesis (SPPS). 
Solid Phase Peptide Synthesis (SPPS) is based on sequential addition of oc-amino 
and side chain protected amino acid residues to an insoluble polymeric support 
(Merrifield 1963; Atherton et aI, 1979). 
The general procedure was (see also figure 22): Following the removal of the 
base-labile Fmoc group using 20% piperidine:Dl\1F, the next protected amino 
acid was added usmg a pre-activated protected amino acid derivative. The 
resulting peptide attached to the resin, via a linker, through its C-terminus was 
cleaved to yield the peptide acid or amide, depending on the linking agent used. 
Cleavage of the side chain protecting groups and detachment of the peptide from 
the resin was simultaneously carried out in the presence of a strong acid, 
trifluoroacetic acid (TF A). Details of the practical approach can be found in 
"Solid Phase Peptide Synthesis" by Atherton and Sheppard (1989). 
Figure 21: Two peptides synthesised on the solid phase peptide synthesizer. 
Protecting Groups Pmc Trt Boc 
I I I 
Amino Acids H2N -ALA- ARG -CYS -LYS -ALA -OH---IResinl 
Pmc Trt Boc 
I I I 
H2N- ALA-ARG-CYS -LYS -ALA -NHr-~Resinl 
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Figure 22: The strategy of solid phase peptide synthesis (Novabiochem catalog 
and Peptide Synthesis Handbook). 
side~hain protecting group 
R1 0 
I II 
IN-protecting grouprNH-CH-C-OH + ~support! 
side-eh.in protecting group 1 Attach to linker 
R1 0 
I II 
! N-protecting groupr NH-C H-C-~support! 
side~hain protecting group 
R 0 
12 II 
IN-protecting groupr NH-C H-C-o--tactivating group! 
side~hain protecting group 
R 0 R 0 
I Deprotect amino 
• function 
Couple 
I 2 II I 1 II 
IN protecting groupr NH-CH-C- NH-C H-C-o~support! 
side~hain protecting group 
R 0 R 0 
I Repeat deprotection 
• and coupling 
12 II 11 II 
IN protecting groupr(NH-CH-C-)n NH-CH-C-O~support! 
1 ere.ve 
R 0 R 0 
I 2 II I 1 II 
(H2N-CH-C-)n NH- C H-C-OH + !support! 
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3.1.2 The Fmoc Strategy. 
The Fmoc stategy (Dryland and Sheppard, 1986) was chosen over the Boc 
strategy for the synthesis of the peptides since with the Boc-group, deprotection 
by repetitive TF A acidolysis could lead to alteration of sensitive peptide bonds 
as well as acid catalysed side-reactions. With the Fmoc strategy, the growing 
peptide was subjected to mild base treatment using piperidine during Fmoc-group 
deprotection, and TF A (Albericio and Barany, 1990) was used in the final stage 
of cleavage and deprotection of the peptide-resin. By contrast however, cleavage 
and deprotection in the Boc strategy would require the use of highly acidic 
conditions such as hydrogen fluoride. 
The cleavage of Fmoc was carried out with 20% (v/v) piperidine in D11F which 
allowed the dibenzofulvene olefin, produced by J3-elimination, to be trapped as its 
piperidine adduct (19), as shown in figure 23. Deprotection with piperidine took 
only a matter of seconds at room temperature. The mechanism of cleavage 
occurs via the stabilised dibenzocyclopentadienide anion; the dibenzofulvene 
produced reacted with piperidine, giving the adduct (19) as co-product. 
3.1.3 Coupling Reagent. 
In recent years, in situ activating reagents have become widely accepted because 
of their ease of use, fast reaction even between sterically hindered amino acids, 
and their general lack of side-reactions. Most coupling reagents are based on 
phosphonium or uranium salts which, in the presence of a tertiary base, can 
smoothly convert protected amino acids to a variety of activated species. The 
coupling reagent used as part of the Fmoc strategy, PyBOP allowed efficient, 
fast and racemisation-free coupling. The mechanism for this coupling can be 
found in section 4.1.2. 
PyBOP 
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3.1.4 Amino Acid derivatives: problem species. 
One of the residues that was considered a 'problem species' was the argmme 
residue. The tri-functional guanidino side chain group of Arg, being strongly 
nucleophilic, could become acylated during the peptide synthesis if not protected. 
Ideally all three side chain nitrogen atoms should be blocked, however, in 
practice, the majority of protecting groups only block the UJ-nitrogen. The 
2,2, 5,7, 8-pentamethylchroman-6-sulphonyl (pmc) group is the preferred protecting 
group for arginine, as this gives superior acid lability over the other available 
protecting groups (such as Mtr) (Ramage and Green, 1987). 
Pmc 
Cysteine residues are both nucleophilic and susceptible to oxidation under basic 
conditions to form disulphide bridges (White, 1967), it was therefore imperative 
that the sulfhydryl (mercapto ) moiety be protected. The triphenylmethyl (trt) 
(Atherton et aI, 1985) group being acid labile was used for this purpose. 
Trt 
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3.1.5 Spectrometric Monitoring in Continuous-Flow Synthesis. 
Spectrometric monitoring of both acylation and deprotection reactions was 
possible because of the UV -absorbing Fmoc protecting group (Dryland and 
Sheppard, 1986). In the peptide-bond-forming step, the activated Fmoc-amino 
acid was taken out of solution and transferred to the solid phase. The 
introduction of the deprotection reagent caused an initial rapid release of the 
amme carbamate salt and dibenzofulvene; the latter then reacts further with 
excess reagent to form the piperidine adduct (19). DMF was used at this stage 
to wash the resin of any remaining deprotection reagent. The corresponding 
changes in absorbance were taken as a direct measure of the efficiency of the 
two reactions (see figure 24). 
3.1.6 Qualitative Colour Tests usmg Ninhydrin 
The ninhydrin colour test for residual resin-bound ammo groups was used to 
determine completion of the acylation reaction (Kaiser et ai, 1970). It was easy 
and quick to carry out. Whilst some deprotected amino acids do not show the 
expected dark blue colour typical of free primary amino groups, it provided a 
seemingly reliable indication of the presence of free primary amino functions on 
the resin beads. A repeat acylation step was undertaken for any incomplete 
acylation. This proved necessary for the arginine and alanine residues in the 
target peptide. The test was only semiquantitative because the amount of amine 
present was estimated visually from the intensity of the blue colour found both 
in the solution and on the resin beads. Attempts made in the past (Sarin et ai, 
1981) to make this test quantitative have been generally unsatisfactory. 
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Figure 24: A complete cycle for the acylation of a single ammo acid residue_ 
3.1.7 TFA Cleavage and Deprotection. 
Optimum cleavage conditions were very much dependent on the individual ammo 
acid residues present, their number and sequence, the side-chain protecting 
groups, and the amino acid residue attached to the handle. Both 1,2-ethanedithiol 
(EDT) and TIS (triisopropylsilane) (pearson et aI, 1989) were used as 
scavengers to trap reactive TF A liberated carbonium ions (figure 25) and thereby 
prevent them from undergoing deleterious side-reactions with sensitive amino acid 
residues i.e. cysteine. 
Figure 25: Carbonium Ions 
o +OH 
II II 
Me3C-Q-C-NH..w - Me3C-Q-C-NH 
(BocNH ....... ) 
It was interesting to observed that with the thioanisole scavenger, the liberated 
carbonium ions reassociated with the ammo acid side chains. This was evident 
from the rp-HPLC chromatograph, in which the signal for the peptide appeared 
significantly further along the chromatograph (non-polar region) then would 
normally be expected. This aspect of the work is discussed further in section 
3.2. 
The isolation and characterisation of the peptides and of the peptide-linked 
intercalators were performed using the following techniques, rp HPLC, MALDI-
MS and 2D N1v1R. The results onbtained from applying these techniques are 
discussed below. 
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3.2 Isolation and Characterisation of the Synthesised Peptides. 
The inherent complexity of peptide drug substances demands suitable analytical 
methodology for determining their structure, stability, and purity (and for 
correlating this information with biological activity). Three methods were 
employed for the analysis of the synthesised peptides in this work. The first was 
reversed phase HPLC (rp-HPLC) where fragments differing by a single residue 
can be isolated as separate components. The second method was mass 
spectroscopy. In particular, matrix assisted laser desorption ionisation (MALDI) 
was used for the characterisation of isolated peptides. This technique relies on a 
special matrix to absorb excess kinetic energy upon firing of the pulse. This 
effectively leaves the peptide fragment of interest intact allowing its entire 
molecular structure to be analysed. The third method, 2D NMR (COSY and 
NOESY), yielded information about the peptide structure, along with information 
relating to the conformation adopted by the peptide. 
3.3 Isolation of the Synthesised Polypeptide usmg rp-HPLC. 
After strong acid deprotection from the resin, the peptides were isolated usmg 
HPLC at Amax 210nm (Rivier et ai, 1984). A gradient made up of an aqueous 
mobile phase containing TFA (0.1%) and acetonitrile as the organic modifier was 
used to elute the peptide components. TF A was used throughout this work 
because of its volatility which enabled easy removal from collected fractions. 
Additionally, it had little UV adsorption (Winkler, 1987) at the set wavelength 
which therefore enhanced the sensitivity of detection. Acetonitrile was used as 
the organic modifier because of its low viscosity and hence reduced back 
pressure, compared with methanol (Winkler, 1987). 
rp-HPLC can also be used to determine peptide homogeneity. In particular for 
peptides produced by synthetic methods (Rivier et ai, 1984), since various 
chemical reactions (e.g., racemisation) can alter the desired biological activity of 
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Figure 26: HPLC chromatograph of peptide acid after cleavage from resin using 
TF A. Reversed phase CIS column. Elution with linear gradient over 30 min of 
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Figure 27: HPLC chromatograph of peptide acid after storage at O°C in 
CH3NIH20 for three days. Reversed phase CIS column. Elution with linear 
gradient over 30 min of 0.1% TFA in CH3CN and 0.1% TFA in H20 from 
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Figure 28: HPLC chromatograph of peptide acid after cleavage from resin using 
TF A Reversed phase CI8 column. Elution with linear gradient over 30 min of 
0.1% TFA in CH3CN and 0.1% TFA in H20 from 0:100 to 100:0, flow rate 
1.0mL/min. 
In this work, the stability of the peptides were assessed by reinjecting the 
isolated peptide sample. Figures 26 and 27 clearly shows the appearance of 
additional peaks. There are several explanations for this occumng, (a) the 
peptide may undergo acid catalysed racemisation (b) thiol oxidation of the 
cysteine residue or (c) the peptide is unstable and undergoes gradual degradation 
above 4°C. It was found that when stored under nitrogen at -78°C the peptide 
remained intact hence this was the main method for storage of the synthesised 
peptides. 
Below is a table outlining the results obtained from the HPLC of the two 
synthesised pentapeptides (also shown below). Figure 28 shows a typical 
chromatograph of the peptide amide. 
H2N-Ala-Lys-Cys-Arg-Ala-CONH2 (amide) 
H2N-Ala-Lys-Cys-Arg-Ala-COOH (acid) 
Table 4: Retention times, eluent and purity for both peptide acid and amide. 
Peptide Retention time /min Eluent : Approximate % purity 
Acetonitrile/water (%) 
Amide 17 (total run time 30) 57/43 70 
Acid 15.5 (total run time 30) 52/48 70 
The retention times for both the acid and amide peptides were found to be very 
similar, the acid peptide being slightly more water soluble. 
3.4 Mass Analysis of the Peptides using MALDI-MS. 
The characterisation of the synthesised peptides were carried out usmg a matrix 
assisted laser desorption ionisation mass spectrometer (MALDI-MS) (Hillenkamp 
and Karas 1990; Karas et aI, 1990). The mass analyzer used in this work was a 
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Figure 29: Positive-ion MALDI mass spectrum of peptide acid (H2N-A-K-C-R-
A-C02H). Molecular ion is seen as mJz 550. 
Figure 29 shows a MALDI-MS spectrum of a peptide acid, following isolation 
by HPLC. Notice that signals below 442 MW correspond to those of the ACH 
matrix (Beavis et aI, 1992), so consequently any peptide fragments occurring in 
this region will be indistinguishable from those of the matrix. Figure 29 shows a 
signal at mJz = 558.48 which coincides with the peptide fragment of interest. The 
smaller of the two signals has a molecular weight of 621.51, a difference greater 
of 71 D. Essentially, the 71D coincides with an alanine residue. One obvious 
explanation for a repeat addition of an alanine residue stems from following the 
cleavage of the Fmoc protecting group from the initial resin-attached alanine. 
The subsequent concentration and base strength of the primary amine resulting 
from the first Fmoc cleavage was therefore a problem. This was resolved by 
allowing the resin to swell in DMF (pugh et aI, 1992) for at least 45 minutes 
before coupling the first residue. The swelling of the amino-component reduced 
the strength of the base per unit volume on the resin hence preventing any 
unwanted Fmoc deprotection. 
It was also noted that in the presence of low abundance of analyte and 
relatively high levels of contaminants, it was necessary to find "good spots" on 
the probe tip of the MALDI slide. In addition poor crystalline peptide samples 
could caused a combination of reduced signal intensity and peak broadening 
(Mock et aI, 1992). 
One disadvantage of usmg the dried-drop preparation method in prepanng the 
slides for MALDI was the nonhomogeneous surfaces which led to signal 
variations over the surface of the target. And because of the nonhomogeneous 
crystallisation process, there was little correlation of the signal intensity with the 
amount of sample analysed (Hillenkamp and Karas, 1990). Consequently, because 
of the intra- and intersample heterogeneity, a slightly different laser irradiance 
was required to reach the thresthold of ion production on different spots of the 













'" c 50 Q) -c - 45 Q) 
> 
















1600 1800 2000 2200 2400 2600 
Mass 1Tl/Z) 




Figure 30: Positive-ion MALDI mass spectrum of intercalator (D)-linked peptide 



























Figure 31: FAB mass spectrum of peptide amide (H2N- A-K-C-R-A-CONH2). 
Molecular ion seen as m/z 565. 
Nevertheless, despite the poor shot to shot as well as sample to sample signal 
reproducibility and an ion production process which was strongly dependent on 
laser fluence, MALDI was a powerful tool for the analysis of the synthetic 
peptides. 
Figure 30 shows a relatively 'clean' signal for one of the many synthesised 
intercalator-peptide molecules (intercalator D linked-peptide acid). It has been 
estimated from HPLC chromatographs and MALDI spectra that the purity of the 
hybrid ligands used in the biological evaluation (chapter 5) is within the 90-95% 
range (see also T. Ijaz, 1998). 
For companson, a FAB-MS of the same conjugate was also obtained (figure 
31). Notice that with this technique extensive fragmentation was observed. So by 
usmg the matrix assisted technique, minimal fragmentation was obtained and 
hence a very high success rate in the characterisation of peptides and 
intercalator-linked peptide ligands was achieved. 
3.5 2D NMR of the Peptide. 
In order to record NJ.\.1R spectra of sufficient quality for detailed NJ.\.1R structural 
studies, sample concentrations of at least ImM in 0.5ml solution were prepared 
(Wuthrich, 1990). The peptide was required to be stable for at least 24 hr at 
room temperature. 
Figure 32 shows a small regIOn of homonuclear 2D IH NJ.\.1R COSY spectrum 
of the peptide amide. The Nl\1R. peaks are spread out along the two frequency 
axes and they are therefore quite well separated, CaR protons typically resonate 
between 3 and 5ppm and methyl groups between 0 and 2ppm. Differences in 
chemical shifts between two amide protons, for example, are caused by structural 
differences in their vicinity. However, no clear correlation between local structure 
and chemical shift has yet been shown (pardi et aI, 1983; Gross et al 1988). 
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The table below shows typical chemical shifts (ppm) observed with each of the 
residue present in the synthesised pentapeptide. 
Table 5: Chemical shifts for the four amino acid residues. 
Amino HN /ppm W HI3 rr HO W 
acid 
Ala (A) 8.3 4.5 1.6 
Arg (R) 8.1 4.5 1.9 1.8 3.6 
Cys (C) 8.4 4.8 3.2 
Lys (K) 8.5 4.5 1.9 1.5 1.8 3.0 
3.5.1 Nuclear Overhauser Effect (NOE). 
A second even more important source of structural information stems from the 
fact that the protons continuously exchange their nuclear magnetisation with one 
another, at rates that depend on the sixth power of their interspatial distance, r6. 
This magnetisation exchanger is often refered to as the nuclear Overhauser effect 
(n.O.e) (Noggle and Schirmer, 1971) and the most convenient method for 
measuring it is called the NOESY (NOE spectroscopy) experiment (Jeener et ai, 
1979). In contrast to all other NMR parameters IH_IH distance measurements by 
NOE experiments can be directly related to the peptide conformation. Short 
distances «2.5 A) always yield substantial NOEs, medium-range distances (2.5-
3.5 A) yield weaker NOEs, whereas distances larger than 3.5A are often two 
weak to be observed in the short mixing time NOESY spectra. 
Figure 33 shows a NOESY spectrum of the hexapeptide amide. The presence of 
through space interactions were indicated by cross-peaks, a good indication of 
helicity formation. The amino acid residues that are considered to favour helical 
conformation are the alanine, lysine and cysteine all found in the peptide 
sequence, whereas arginine is indifferent. Tyrosine, threonine, glycine, serine and 
proline, absent from the hexapeptide amide sequence, all break up helical 
formation (Creighton, 1983). 
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Figure 33: Partial IH_IH NOESY spectrum of NHr A-R-C-K-A-NH2 in 
dimethylsulfoxide. 
Similar analysis for the other six peptides used in this work was observed (T. 
Ijaz, 1998). The remainder of this thesis focuses on the in vitro biological 






This chapter describes how the intercalator is coupled onto 
the amino terminus of the peptide to form the intercalator-linked 
peptide molecule. 
4.1 Synthesis of Intercalator-Iinked Peptide Ligands. 
The sequence-specific recognition of double-stranded DNA has been the subject 
of extensive studies. The design of ligands specific to a given DNA sequence is 
an important area of research, as such ligands have the potential to control 
transcription (Chuang et aI, 1984) and replication (Fox and Smith, 1990). 
Research to date has mainly focused on the recognition and modification of 
double-stranded DNA by oligonucleotides containing both natural and synthetic 
base pairs, these bind into the major groove of DNA by forming Hoogsteen 
hydrogen bonds, resulting in a triple helix structure (Mouscadet et aI, 1994). 
In this chapter, the synthesis of the AP-1 basic region-intercalator hybrid peptide 
is described. This molecule has been designed to combine the minimum features 
of the peptide necessary for recognition of the consensus site with the known 
binding enhancement of an interacting anthrapyrazole moiety. In this way it is 
hoped to achieve both tight binding and a high degree of molecular recognition 
with a comparatively small peptide. 
In the section below, two different methods for the synthesis of novel peptide 
intercalator ligand have been described. Each route involves several reaction steps 
and of high yielding, and can easily be adapted to incorporate other 
linker/intercalator combinations. 
4.1.1 Coupling via formation of a reactive Aziridinium Ion. 
A model system, glycine methyl ester hydrochloride (20) was employed m place 
of the actual peptide in the first instance (figure 34). This model system 
successfully demonstrated that the coupling via the aziridinium was viable in the 
presence of a base, N, N-diisopropylethylamine (DIEA). The high reactivity of the 
aziridinium ion made it susceptible to even very weak nucleophiles such as 
methanol (21). 
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The coupling between the resulting aziridinium ion and the ammo terminus of 
the peptide sequence was carried while the peptide was still attached to the 
resin (figure 35). Any excess drug and contaminants can then be filtered-off on 
washing the resin through a sintered glass funnel. Once formed the intercalator-
peptide was cleaved from the resin-support using TF A, dried and analysed. 
HPLC and MALDI-MS techniques were then used to characterise the hybrid 
(chapter 3). 
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4.1.2 Coupling using a PyBOP Reagent. 
The second method of peptide acylation makes use of benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate (PyBOP), the same coupling 
reagent used in solid phase peptide synthesis. The carboxylate group on the 
anthrapyrazole was pre-activated using PyBOP (figure 36) prior to contact with 
the amino functionality of the peptide sequence. This method proved to be 
highly successful, both in terms of yield and simplicity. As a result the majority 
of the intercalator-peptide complexes were synthesised using this latter method. 
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Figure 36: Mechanism for PyBOP coupling. 
H 
N-N~N~OH 
+ DIEA + 
o 
o 
II 8 R-HN'-""'N-C-OP (N ) + H 3 OBr 
R = Intercalater 
o 






NH2 -1 Peptide I 
-HOBt 
THF 
+ --DIEAH ,PF6 
As well as synthesising a senes of anthrapyrazole-linked peptide ligands, similar 
synthetic routes were used to produce a series of anthraquinone-peptide ligands 
(see figure 37 and T. Ijaz, 1998), these compounds were also tested for their 
biological activity. Both the anthrapyrazole and anthraquinone compounds together 
with their respective peptide complexes were tested in vitro for their inhibition 
of AP-1 transcription factor protein from binding to AP-1 DNA consensus 
sequence (chapter 5). 
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Figure 37: Shows two anthraquinone derivative-linked peptide complexes (see 











Cell free Biological 
Evaluation and DNA 
Binding Studies 
This chapter assesses the binding of the intercalator -peptide 
ligand to the AP-I DNA consensus oligonucleotide in vitro using 
an electrophoretic mobility shift assay (EMSA). For assessing the 
nature and the binding affinity of the intercalator -peptide complex, 
two separate methodologies using UV Ivis spectrophotometry and 
fluorimetry are used. 
5.1 Introduction. 
Recently many research efforts have been aimed at targeting specific sequences in 
DNA using synthetic ligands with the idea of designing both drugs and 
molecular probes for DNA polymorphism. The selective inhibition of transcription 
from particular sequences by the specific targeting of a ligand, in other words 
the control of gene expresslOn, has become a very attractive and productive 
research area (Neilsen, 1991) 
Many groups have described a strategy to reach this objective with the common 
and ultimate aim of designing agents which can effectively read DNA in a 
manner analogous to regulatory proteins. Among the various approaches, 
oligonucleotides capable of recognising DNA via the formation of triple helices 
are described (Mouscadet et ai, 1994). 
In this thesis, the synthesis of novel AP-1 base region-intercalator hybrid peptide 
molecules has been attempted. AP-1 was chosen in particular because of its very 
unique and specific mode of binding and because of the potential for redox 
control of its binding. The main features of this molecule combine the peptide 
necessary for the recognition of the AP-1 DNA consensus site with the DNA 
binding affinity of an intercalating moiety. In this work, the effect of the 
synthesised intercalator-peptide molecules on the binding of the AP-1 transcription 
factor protein to the AP-1 consensus was determined by an electrophoretic 
mobility shift assay. In support of this, the mode and binding affinity of the 
hybrid molecules for DNA was determined by spectrophotometry and fluorimetry. 
All three techniques are described below. 
5.2 Binding of the Intercalator-Peptide to the AP-1 DNA consensus 
sequence as determined by PAGE. 
The gel electrophoresis mobility shift assay (Fried, 1989; Revzin, 1989; 
Hendrickson, 1985) was chosen for the study of protein-DNA interactions. This 
assay provided electrophoretic resolution of protein-DNA complexes from each 
other and from free DNA. The advantages of the electrophoresis DNA-binding 
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assay include its speed, simplicity and flexibility. Binding of proteins that interact 
weakly with DNA, or of proteins that for other reasons fail to be detected in 
other assays (i.e. a filter-binding assay), can generally be detected by gel 
electrophoresis. One other major advantage is that highly purified protein or 
DNA samples are unnecessary (Strauss and Varshavsky, 1984; Varshavsky, 
1987). For example, in this work, sequence-specific DNA binding of recombinant 
transcription factors as well as cell lysates were shown. 
5.3 The affinity and mode of binding to DNA as determined by UV/vis 
Spectrophotometry and Fluorimetry. 
In order to evaluate DNA-binding of the compounds prepared, two methods 
were selected. Both methods allowed the nature of binding and affinity of the 
ligand for DNA to be determined. Changes in the UV visible and fluorescence 
absorbance properties of the ligand can occur upon its binding to DNA (Neidle, 
1978; Waring, 1981). Methods which monitor such changes were also used here. 
5.3.1 Effect of Intercalator-Peptide on the thermal denaturation properties of 
DNA. 
When double-stranded DNA molecules are subjected to an Increase m 
temperature or extremes of pH, the DNA denatures to give two single-stranded 
molecules as a result of the rupturing of the hydrogen bonds in the double 
helix. On denaturation there is. an increase in absorbance of the DNA solution, 
so the change in absorbance can be used to monitor denaturation (Marmur and 
Doty, 1962). The temperature at which half the total increase in absorbance has 
occurred is known as the melting (or transition) temperature (Tm). 
By measuring the change in absorbance with temperature of the DNA solution at 
the DNA Amax (260nm), in the presence and absence of the ligand, the L1 T m 
( difference in T m' s) can be determined. This IS a measure of the stability of the 
ligandlDNA complex. The increased stability imparted to the DNA helix by the 
ligand is a measure of the affinity of binding. Furthermore the stability of the 
DNA helix is also affected by changes in the base composition; DNAs with high 
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guanine-cytosine content have higher Tm's than DNAs with high adenine-thymine 
content (Marmur and Doty, 1962). 
5.3.2 Effect of Intercalator-Peptides on the binding of ethidium to DNA. 
By using a compound which is known to intercalate into DNA and which has a 
large change in quantum yield upon release from DNA (such as ethidium 
bromide), it was possible to examine the DNA binding of the compounds 
synthesised in this work using fluorescence spectroscopy by competition 
displacement of ethidium from DNA. This type of competitive study provides 
information on both the nature of interaction of ligands with DNA and the 
relative affinity of the drugs for DNA. 
The interaction of ethidium bromide with DNA has been extensively reviewed, 
(Waring, 1981; Yielding et aI., 1983). Ethidium bromide has been shown to bind 
to DNA by intercalation. When binding to DNA the quantum yield of the 
fluorescence of ethidium is enhanced (Le pecq and Paoletti, 1967). Hence if a 
compound binds to the same site in the DNA helix as ethidium the drug will 
compete with ethidium for that site. Provided the compound, in the absence of 
DNA, has no effect on the fluorescence of ethidium, it is possible to monitor 
the effect of that compound on fluorescence enhancement. 
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RESULTS 
5.4 Specificity and Redox Sensitivity of the c-Jun homodimer protein for 
AP-l DNA consensus sequence. 
Specificity of c-Jun homodimer protein for the AP-I DNA consensus sequence 
was demonstrated by competition experiments. Two such experiments were 
performed, one with unlabelled target (AP-I) DNA consensus sequence as 
competitor (figure 38) the other with unlabelled (SP-I) DNA consensus sequence 
as the competitor (figure 39). Figure 39 showed that with increasing 
concentration of unlabelled SP-I (0.11-0.86ng) the binding of the AP-I protein 
to the labelled AP-I DNA consensus sequence was unaffected. However, with 
increasing concentration of unlabelled AP-I DNA consensus sequence a reduction 
in band intensity was observed. 
Cell lines treated with phorbol diesters such as TPA (12-0-tetradecanoyl-phorbol-
13-acetate) can express elevated levels of Fos and Jun proteins. Treatment of 
cultured cells with TPA was shown to lead to a rapid 3- to 4-fold increase in 
TRE binding activity by the AP-I protein. This has been observed previously 
and it is suggested to be due to a post-translational modification (Angel et aI, 
1987). The exact mechanism responsible for the increase in TRE activity shortly 
after TP A treatment remains to be determined. Figure 40 shows that a TP A 
dissolved in DMSO as a vehicle, was responsible for elevating AP-1 binding, 
probably by an increase m both fos and jun expression as previously shown by 
Barber and Verma (1987). 
In figure 40 it can be seen that cell lysates 2 and 4 (which were TP A treated 
cell lines) displayed elevated concentrations of AP-I binding proteins compared 
with untreated equivalent cells not TRE treated. Both these cell lysates were 
used to investigate the specificity of the intercalator-peptide for the AP-I DNA 
consensus sequence (see section 5.13). 
Figure 41 shows that the binding of c-Jun homodimer recombinant protein was 
highly specific for AP-1 DNA wild type, and that no binding was observed with 
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mutant AP-1 DNA. The redox sensitivity of the AP-1 binding to its oligomer 
consensus sequence was subsequently demonstrated by direct oxidation of the 
protein. This was accomplished using oxygen which was allowed to pass through 
a sample containing the Fos/Jun proteins at 4°C. A similar set- up using 
nitrogen gas was investigated. It was clear from figure 43 that the oxygenated 
sample displayed a reduction in AP-1 protein-DNA complex formation. 
Figure 43 indicates that binding of c-Jun homodimer protein to AP-1 
oligonucleotide was very much enhanced by a reducing environment. This was 
consistent with the results described previously (Xanthoudakis and Curran, 1992). 
Dithiothreitol (DTT) was used as the reducing agent in this assay. It was 
observed that c-Jun protein was highly selective for the AP-1 DNA consensus 
sequence but not for the SP-l. The presence of a faint band corresponding to 
c-Jun-DNA complex even in the absence of DTT can be accounted for by the 
presence of some DTT in the storage buffer of the commercially available c-Jun 
protein. However, whether or not bands of DNA-protein complexes are observed 
can sometimes be dependent on many other factors including intrinsic stability of 
the complex itself, the salt concentration and temperature within the gel and the 
total time of electrophoresis. Any DNA from complexes which dissociate during 
analysis will trail behind the free DNA band, forming a 'smear' between the 
complex and the unbound DNA bands. For an example, see figure 40. 
Figure 44 demonstrates that even in a crude lysate extract, specific binding of 
AP-1 heterodimer protein did still occur as has also been observed previously 
(Strauss and Varshavsky, 1984; Varshavsky, 1987). This was shown by a 
supershift in which HeLa cell extract was incubated with 32P-Iabelled AP-1 DNA 
consensus sequence and AP-1 antibody. The presence of specific antibodies 
during binding reactions was used here as a form of identification of protein 
complexes (Kristie and Roizman, 1986). Notice that no supershift was observed 
with the 32P-Iabelled SP-1 DNA consensus sequence, an indication of the lack of 
binding of AP-1 antibody for the SP-1 protein-DNA complex. 
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5.5 The effect of Anthrapyrazole and Anthraquinone derivatives on the 
binding of AP-l protein to AP-l DNA consensus sequence. 
In this work 32P-Iabelled DNA fragment containing the putative target site AP-1 
DNA consensus sequence was incubated with a cell extract containing AP-1 
proteins and was then subjected to the electrophoretic mobility shift assay 
(EMSA). The transcription factors used in in vitro systems were derived from 
extracts of HeLa cell nuclei as previously described by Shapiro et ai, 1988; 
Dignam et ai, 1983. However, because nuclear factors are likely to contain both 
sequence-specific transcription factors and sequence-independent DNA binding 
proteins, upon gel electrophoresis, high molecular weight complexes formed 
between the AP-1 DNA consensus sequence and specific as well as nonspecific, 
binding proteins which were retained near the loading wells. This was 
subsequently resolved by preincubating the nuclear fractions with poly (dI-de) 
DNA prior to adding the AP-1 DNA consensus sequence, which effectively 
removed the non-specific high molecular weight proteins. The highest practical 
concentration of protein used in this work was dictated by a combination of the 
availability of specific reagents, the detection limits of the assay and to some 
extent by the solubility of the intercalator-peptide conjugates. 
For companson and as a control, ethidium was also tested for its effect on the 
binding of AP-1 protein to the AP-1 DNA consensus sequence. It was observed 
that at 20: 1 (ethidium:DNA) almost complete inhibition of AP-1 protein binding 
was accomplished, (see figure 45). In contrast, with some of the synthesised 
anthrapyrazole/anthraquinone intercalators, little or no inhibition of AP-1 protein 
from binding to AP-1 DNA was detected, even at concentration ratios of 800: 1 
(APZ:DNA). An example of such an intercalator is A (figure 46), see table 6 
for other intercalators investigated. Figure 47 shows an example of an 
intercalator (D) which clearly does display some inhibition of AP-1 protein from 
binding to AP-1 DNA but only at a high (800:1) APZ:DNA ratio. 
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5.5.1 The effect of Peptide units on the binding of AP-I protein to the AP-
I DNA consensus sequence. 
It was observed that peptide I (figure 48) had no effect on the binding of AP-I 
protein to AP-I DNA consensus sequence even at concentration ratio of 8000: 1 
(peptide:DNA) (see table 7 for results of other peptides). This can be seen as a 
direct measure of the binding affinity of AP-l protein for AP-1 DNA. However, 
inhibition was observed with peptides 4, 5, 6 and 7 all containing greater 
numbers of basic residues, such as Cys, Lys and Arg. For an example see figure 
49. 
5.5.2 The effect of Intercalator-Peptide conjugates on the binding of AP-l 
protein to AP-I DNA consensus sequence. 
Table 8 contains a list of all the intercalator-peptide molecules tested and figures 
50 and 51 show typical examples of results obtained. The extent of inhibition of 
AP-1 protein from binding to AP-1 DNA was found to be most significant with 
the intercalator-peptides and least with the peptide units alone (see also figures 
54, 55 and 56 for data obtained). This is discussed in section 5.9. 
5.6 The Specificity of Intercalator-Peptide for AP-I DNA consensus 
sequence. 
Specificity of the intercalator-peptide for AP-1 consensus oligonucleotide was 
investigated. This was achieved by measuring the extent of inhibition when 32p_ 
labelled AP-1 DNA consensus sequence was replaced by SP-I DN~ and AP-1 
protein replaced by SP-I protein. The results showed (figure 52 and 53) that 
the intercalator-peptide molecules displaced the SP-I protein from its consensus 
sequence. This is discussed further in section 5.13. 
DNA binding assays 
5.7 The effect of Intercalator-Peptide conj ugates on the thermal 
denaturation properties of DNA. 
The spectra of DNA plus drug were recorded against DNA alone at Amax 
260run· the concentrations of DNA in both reference and sample cuvette were , 
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identical and therefore only the affect of the DNA on the absorbance spectrum 
of drug was recorded. The Tm of calf thymus DNA in the absence of the drug 
was shown to be 7l.2 + 0.1 °C at pH7.4. The Tm values obtained for DNA, 
DNA and drug (10:1 DNA/drug ratio) are shown in table 9. It was observed 
that J conjugates, containing an extra lysine moiety had higher Ll Tm values than 
D containing conjugates. Higher L1 Tm values were also observed with conjugates 
containing the more basic peptides (i.e. 4, 5, 6 and 7). Typical melting curves 
for DNA and DNA in the presence of drug are shown in figure 57. 
5.7.1 The effect of Intercalator-Peptide conjugates on fluorescence 
enhancement of ethidium bromide due to binding to DNA. 
The ability of the intercalator linked peptide complexes to displace intercalated 
ethidium bromide was investigated. For each compound investigated fluorescence 
reading versus ethidium:DNA ratio was plotted (figures 58 and 59). These plots 
show the fluorescence enhancement, and hence DNA-binding, of ethidium is 
reduced when hybrid compounds are added to DNA. It is clear from the two 
plots that displacement of the ethidium does occur with the ligands and that 











32P .AP_1 DNA with increasing conc. 
of AP-1 DNA consensus sequence 
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32P .AP_1 DNA = 32P -labelled AP-1 DNA consensus sequence 
Figure 38: The effect of increasing concentration of unlabelled AP-1 DNA 
(lanes 2. to 2; 2.: 0 .011 ; 1: 0.022; 1:: 0 .032; 2: 0.043 ; 2: 0 .054; 1: 0.065 ; li: 0 .076 
and 2: O. 086 ngl~1) on the binding of c-Jun homodimer protein. Lanes 1 and lQ 
contain 32P-labelled AP-1 DNA. The concentration of labelled AP-1 DNA and c-
Jun protein used was 2.10nM and 0 . 055~g1~1, respectively. See section 6 .11.3 
for experimental detail. 
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32p .AP-1 DNA with increasing conc. r-;' 
of SP-1 DNA consensus sequence ~ 
~ I ~ 
~ r-------.l--------.., ~ 
1 2 3 4 5 6 7 8 9 10 
32P .AP_1 DNA = 32P-Iabelled AP-1 DNA consensus sequence 
Figure 39: The effect of increasing concentration of unlabelled SP-1 DNA 
(lanes 2 to 2; 2: 0.011 ; 1: 0.022; 1: 0.032; 2: 0.043 ; Q: 0.054; 1: 0.065 ; ~ : 0.076 
and 2: 0.086 ng/J. . tl) on the binding of c-Jun homodimer protein. Lanes 1 and lQ 
contain 32P-labelled AP-1 DNA. The concentration of labelled AP-1 DNA and c-
Jun protein used was 2 .10nM and 0.0551J.g/IJ.I, respectively. See section 6.11.3 


























TP A responsive element 
D imethylsulfoxide 
Figure 40: Effect of TPA treated MDA-468 breast carCInoma cell line lysates 
on AP-1 protein binding to AP- 1 consensus sequence. Lanes 3/4 and 7/8 are the 
TPA treated MDA-468 cell line variants whereas the remaining cell line variants 
were controlled experiments starved of TP A. The concentration of the 
radiolabelled AP-1 DNA and protein used was 2 .10nM and 0.0 18flg/fll , 
respectively. See section 6 .11 .1 for experimental detail. 
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mutant AP-1 + c-Jun 
wild-type AP-1 + c-Jun 
1 2 3 4 5 6 7 8 
~ c-Jun protein bound 
bound wild-type 
AP-I DNA complex 
~ Unbound 
radiolabelled wild-
type AP-l DNA 
Wild-type AP-1 DNA = 5' -CGCTTGATGAGTCAGCCGGAA-3 ' 
Mutant AP-1 DNA = 5 ' -CGCTTGATGAGTTGGCCGGAA-3 ' 
c-Jun = c-Jun homodimer protein 
Figure 41: Electrophoretic mobility shift assay of c-Jun homodimer with w ild-
type (lanes 1, 1, .2 & 1) and mutant (lanes 2, 1, Q & ~) AP-1 oligonucleotide. 
The amount of c-Jun protein and oligonucleotide used was O.055)J.g!)J.l and 
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32P .AP_1 DNA = 32P-Iabelled AP-1 DNA consensus sequence 
32P .SP_1 DNA = 32P-Iabelled SP-1 DNA consensus sequence 
c-Jun = c-Jun homodimer protein 
DTT = dithiothreitol 
Figure 42: Electrophoretic mobility shift assay of c-Jun homodimer protein in 
the presence and absence of dithiothreitol (DTT) . Lanes 1 & 1 are 32P-Iabelled 
AP-1 and SP-1 consensus oligonucleotide, respectively. Lanes 2. & 1 consist of 
c-Jun protein incubated with 32P-Iabelled AP-1 DNA in the presence and absence 
of dithiothreitol (DTT), respectively . Lanes .2 & Q consist of c-Jun protein 
incubated with 32P-Iabelled SP-1 DNA in the presence and absence of DTT, 
respectively. The amount of c-Jun protein, oligonucleotide and DTT used was 
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32P-labelled AP-l DNA consensus sequence 
AP-I (fos/jun) heterodimer protein (HeLa cell 
nuclear extract) 
Figure 43: The effect of oxygenation on the binding of AP-l heterodimer 
protein to AP-l DNA consensus sequence. Lanes 1 & .2 contain 32P-labelled AP-
I DNA. Lanes 2 & Q are the controls with no addition of either oxygen or 
nitrogen. Lanes 1 & .1 are results from oxygenation for 3 and 6 hr, respectively_ 
Lane 1 and ~ are AP-I protein samples under nitrogen gas for 3 and 6 hr, 
respectively_ The concentration of the AP-1 protein and labelled AP-l D A used 
was O.073nghd and 2 .10nM, respectively. See section 6.11.5 for experimental 
detail. 
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+- AP-l protein bound 
32P .AP_l DNA bound 
AP-I antibody complex 
+- AP-l protein bound 
32P-Iabelled AP-l 
DNA complex 
32P .AP_l DNA = 32P-labelled AP-l DNA consensus sequence 
32P .SP-1 DNA = 32P-labelled SP-l DNA consensus sequence 
HeLa = HeLa cell nuclear extract 
Figure 44: Electrophoretic mobility shift assay of AP-l (fos/jun) heterodimer 
protein binding to AP-l DNA consensus sequence in the presence of AP- l 
antibody. The HeLa cell nuclear extract was incubated with the 32P-labelled 
AP-l DNA, with (lane 1) and without (lane J:) AP-l antibody. As a control, 
HeLa nuclear extract was also incubated with 32P-labelled SP-l DNA, with 
(lane 1) and without (lane 1.) AP-1 antibody. The concentration of AP- l 
protein, AP-l antibody and oligonucleotide used was 1. 73 ng/~ . d, l. OOng/~.ll 
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32P .AP_1 DNA = 32P-labelled AP-1 DNA consensus sequence 
AP-1 protein = AP-1 (fos/jun) heterodimer protein (HeLa cell 
nuclear extract) 
Ethidium Bromide = 
Sr -
Figure 45: The effect on the binding of AP-1 protein to AP-1 DNA consensus 
sequence in the presence of a range of concentrations of ethidium (lanes ~ to 2; 
2/3: 21; 4/5: 42; 6/7 : 63 ; 8/9: 84 nM) and 2.10nM DNA. Lanes 1 & lQ contain 
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conc. of intercalator A 
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32p .AP-1 DNA = 32P-labelled AP-1 DNA consensus sequence 
AP-1 protein = AP-1 (fos/jun) heterodimer protein (HeLa cell 
nuclear extract) 





Figure 46: Electrophoretic mobility shift assay of AP-1 protein binding to 32p _ 
labelled AP-1 DNA consensus sequence in the presence of intercalator A. Lanes 
2 to 2 contain increasing concentration of intercalator A (2: 0.21 ; 1: 0.42; .1: 
0.63 ; 2: 0.84; Q: 1.05 ; 1: 1.26; li: 1.47; 2: 1.68 11M) and 2.10nM DNA. Lanes 1 
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32P .AP_1 DNA = 32P-labelled AP-1 DNA consensus sequence 
AP-1 protein = AP-1 (fos/jun) heterodimer protein (HeLa cell 
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Figure 47: Electrophoretic mobility shift assay of AP-1 protein binding to 32p _ 
labelled AP-1 DNA consensus sequence in the presence of intercalator D . Lanes 
2 to 2 contain increasing concentration of intercalator D (2: 0.2 1; 1: 0.42 ; 1: 
0.63 ; 2: 0.84; 2: 1.05 ; 1: 1. 26; ~ : 1.47; 2: 1.68 IJ-M) and 2.10nM DNA. Lanes 1 
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32P .AP_1 DNA = 32P-Iabelled AP-1 DNA consensus sequence 
AP-1 protein = AP-1 (fos/jun) heterodimer protein (BeLa cell 
nuclear extract) 
Peptide 1 = H2N-A-K-C-R-A-C02H 
Figure 48: Electrophoretic mobility shift assay of AP-1 protein binding to 32p _ 
labelled AP-1 DNA consensus sequence in the presence of peptide 1. Lanes 1 
and lQ contain no added peptide molecule. Lanes 2. to 2 consist of increasing 
concentration of peptide 1 (2.: 2.1; 1: 4.2; 1: 6.3; 2: 8.4; Q: 10.5; 1: 12.6; li: 14.7; 
2: 16.8 ~LM) and 2.10nM DNA. The concentration of the AP-1 protein and 
labelled AP-1 DNA was 1. 73 ng/~1 and 2.10nM, respectively. See section 6 12.1 
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32P.AP_1 DNA = 32P-Iabelled AP-1 DNA consensus sequence 
AP-1 protein = AP-1 (fos/jun) heterodimer protein (HeLa cell 
nuclear extract) 
Peptide 7 = H2N-A-K-C-R-K-R-A-CONH2 
Figure 49: Electrophoretic mobility shift assay of AP-1 protein binding to 32p_ 
labelled AP-1 DNA consensus sequence in the presence of peptide 7. Lanes 1 
and lQ contain no added peptide molecule. Lanes 2: to 2 consist of increas ing 
concentration of peptide 7 (2:: 2.1; 1: 4.2; ,1: 6.3 ; 2: 8.4; Q: 10.5; 1: 12.6; ~ : 14.7; 
2: 16.8 ~M) and 2.10nM DNA. The concentration of the AP-l protein and 
labelled AP-1 DNA was 1. 73ng/~1 and 2.10nM, respectively. See section 6 12 .1 
for experimental detail. 
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Figure 50: Electrophoretic mobility shift assay of AP-1 protein binding to 32p _ 
labelled AP-1 DNA consensus sequence in the presence of a range of 
concentrations of conjugate 4D. Lanes 1, 1, } , 1 and .2 contain increasing 
concentration of conjugate 4D (0 .2 1-1.68 /-lM : 2.1nM; 4D :DNA). The remalllmg 
lanes (2, 1, Q, ~ and lQ) contain no added conjugate . See secti on 6. 12.2 for 
experimental detail. 
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Figure 51: Electrophoretic mobility shift assay of AP-l protein binding to 32p_ 
labelled AP-l DNA consensus sequence in the presence of a range of 
concentrations of conjugate 7D . Lanes I , 1, 2, 1 and .2 contain increasing 
concentration of conjugate 7D (0 .21 -1.68 ~M : 2 .1nM; 7D :DNA). The remallllllg 
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Figure 52: Electrophoretic mobility shift assay to show the effect of conjugate 
7D on the binding of SP-1 protein to 32P-labelled SP-1 DNA consensus 
sequence. Lanes 1 & lQ contain no added 7D. Lanes 2: to 2 contain increasing 
concentration of 7D (2:: 0 .21 ; 1: 0.42; 1: 0 .63 ; 2: 0 .84; 2: 1.05 ; 1: 1. 26 ; ~ : 1.47; 2: 
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Figure 53: Electrophoretic mobility shift assay to show the effect of conjugate 
7D on the binding of AP-1 protein to 32P-labelled AP-1 DNA consensu 
sequence. Lanes 1 & lQ contain no added 7D . Lanes ~ to .2 contain increasing 
concentration of7D (~ : 0.21 ; 1: 0.42; 1: 0 .63 ; 2: 0 .84 ; Q: 105 ; 1: 126; ~ : 1 47; .2 
1.68 ).lM) and 2 .10nM DNA. See section 6 .13 for experimental detail. 
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Table 6: The effect of intercalators on the binding of AP-I protein to AP-I 




















:::v I :::v I 
::::,.. ::::,.. 























* These abbreviations are consistently used throughout this thesis. 
** The band intensity (i.e. the degree of inhibition of AP-I protein binding) was recorded 
using a densitometer (arbitrary units). The results are the mean value of two separate 
EMSA for each compound (see section 6.9 for experimental detail). For raw data 
obtained see figure 55. The concentrations used were as follows: [AP-I] = 1. 73 ngllll: 
[DNA] = 2.lOnM; [intercalator] = O.2I-1.68j.lM. 
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Table 7: The effect of peptide units on the binding of AP-l protein to AP-1 
DNA consensus sequence. 
Peptide Unit * Abbreviation * * Mean Band 
Intensity +10 %*** 
H2N-A-K-C-R-A-C02H 1 98 
H2N-A-K-C-R-A-CONH2 2 99 
H2N-A-K-S-R-A-CONH2 3 99 
H2N-A-K-C-R-N-A-CONH2 4 82 
H2N-A-K-C-R-K-A-CONH2 5 83 
H2N-A-K-C-R-N-R-A-CONH2 6 87 
H2N-A-K-C-R-K-R-A-CONH2 7 86 
H2N-A-A-K-C-R-A-A-CONH2 8 93 
* A, alanine~ K, Lysine~ C, cysteine~ R, arginine~ N, asparagine; S, serine. 
** These abbreviations are used consistently throughout this thesis. 
*** The band intensity (i.e. the degree of inhibition of AP-I protein binding) was 
recorded using a densitometer (arbitrary units). The results are the mean value 
of two separate EMSA for each compound (see section 6.9 for experimental detail). 
For raw data obtained see figure 54. The concentrations used were as follows: 
[AP-I] = 1.73ng!~1; [DNA] = 2.lOnM; [peptide] = 2.1-16.8~. 
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Table 8: The effect of intercalator-peptide conjugates on the binding of AP-1 
protein to AP-1 site. 
* 
Mean Band Intensity ± 10 % * 
Intercalator -peptide [Conjugate] [Conjugate] 
Conjugate* * 0.21-1.68fJ.M 2.1-16.8fJ.M 
ID 79 51 
2D 78 43 
3D 73 41 
4D 67 32 
5D 68 39 
6D 70 38 
7D 61 26 
8D 79 56 
5J** 70 35 
6J 69 34 
7J 64 23 
8J 78 53 
5K** 68 42 
6K 71 39 
The band intensity (i.e. the degree of inhibition of AP-I protein binding) was 
recorded using a densitometer (arbitrary units). The results are the mean value 
of two separate EMSA for each compound (see section 6.9 for experimental detail). 
For raw data obtained see figure 56. The concentrations used were as follows: 
[AP-I] = 1. 73ngl).ll; [DNA] = 2.lOnM. 
** These abbreviations are used consistently throughout this thesis. 
J = D-Lysine; K = D-(Lysineh (see table 6). 
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o 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 
Peptide conc. xl 0.5 M 
Peptide l = H2N-A-K-C-R-C-C02H ( • ) 
2 = H2N-A-K-C-R-C-CONH2 ( 0) 
4 = H2N-A-K-C-R-C-CONH2 (c) 
5 = H2N-A-K-C-R-C-CONH2 ( .. ) 
7 = H2N-A-K-C-R-C-CONH2 ( .) 
Figure 54: The effect of increasing concentration of peptides 1, 2, 4, 5 and i 
on the binding of A1'-l protein to .'-\1'-1 DNA consensus sequence as measured 
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Figure 55: The errect or mcreasing concentration of intercalators A~ D and E 
on the binding of A1'- I protein to AP- I DNA consensus sequence as me2.SUfed 
by densitometry. Note that the concentration ramze of erhidiurn and AQ4 is 10.
7 
:\1. See section 6.12 for experimental detail. 
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0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 
Conjugate conc. x ~ O·s M 
ConjUfrate ID - D-HN-A-K-C-R-C-C02H (c) 
7D - D-HN-A-K-C-R-C-CONH2 (0) 
7J - J-HN-A-K-C-R-C-CONH2 (A) 
8D - D-HN-A-A-K-C-R-A-A-CONH2 (.) 
Figure 56: The effect of increasing concentration of intercalator-peptide 
conjugates ID, 7D, 7J and 8D on the binding of AP-1 protein to AP-1 DNA 
consensus sequence as measured by densitometry. See section 6.12.2 for 
experimental detail. 
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Table 9: ~ Tm values for calf thymus DNA incubated with intercalator-peptide 
conjugates. 
Intercalator - TmoC* ~TmoC* 
peptide (DNA+ligand) 
Conjugate 
AQ4** 87.5 16.6 
ID 73.5 2.6 
2D 74.6 3.7 
3D 70.9 0 
4D 77.4 6.5 
5D 76.0 5.1 
6D 80.2 8.3 
7D 79.4 8.5 
8D 73.0 2.1 
4J*** 76.8 6.9 
5J 75.1 5.8 
6J 77.2 8.7 
7J 79.5 9.6 
8J 74.1 3.2 
4G 76.2 4.6 
7G 77.3 5.4 
4L*** 73.1 2.2 
7L 74.0 3.1 
* Mean Tm values ±D.loC and are the mean of three replicates. 
Tm of DNA = 70.9 ± O.loC; pH7.2, 0.05M NaCI, 0.008M tris buffer. 
** See table 6 for structure. 
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Conjugate 5J - D-KAKCRKA-CONH2 
Figure 57: Melting curve of DNA (0), DNA + 5J (D) and DNA + 7D (0), in 
the temperature range 58-94°C. The concentration of DNA and conjugate used 
was 2.5xIO-3 M and 2.5xI0-4 M, respectively. See section 6.14 for experimental 
detail. 
>. ..... . -tI) 
:: 
































20 30 40 50 60 
Ethidium conc. xl 0-7 M 
= 








Figure 58: The effect of 4D, 4G, 4J and 4L on the fluorescence enhancement 
of ethidium binding to DNA. The concentration of conjugate and DNA used was 
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Conjugate 7G - G- NH-AKCRKRACONH2 
Conjugate 7 J - D-KAKCRKRACONH2 
Conjugate 7L - D-NH(CH2)2NHC0 (CH2)2CONH-
AKCRKRACONH2 
Figure 59: The effect of 7D, 7G, 7J and 7L on the fluorescence enhancement 
of ethidium binding to DNA The concentration of conjugate and DNA used was 
2.0x10-6 M and 2.0x10-5 M, respectively. See section 6.14.2 for experimental 
detail. 
70 
5.8 Discussion: DNA Binding Studies. 
The aim of this section was to assess the relative affinity of the drugs for DNA 
and to investigate the nature of the drug-DNA interactions. 
5.8.1 Effect of Intercalator-Peptide conjugates on thermal denaturation of 
DNA. 
The intercalation of a drug molecule into the DNA helix stabilises the 
macromolecule such that more energy IS required to separate the two strands. 
Thus the T rn of the DNA is increased due to a change in enthalpy (Zunino et 
aI, 1972). However if the drug binds externally to the helix then there IS 
generally no significant change in the T rn. The L1 T rn values obtained in this work 
gives some indication of binding ability of ligand to DNA. From these data it 
was observed that all the conjugates tested (table 9) were able to stabilise the 
DNA to thennal denaturation, though to varying degrees. It was however 
evident that the higher L1 T rn were observed with conjugates containing the more 
basic peptides (i.e. peptides 4, 5, 6 and 7). This was consistent with the results 
obtained in the electrophoretic mobility shift assay and with the molecular 
modelling calculated for these peptides (section 5.14). EMSA and Trn data also 
showed that conjugates containing the J intercalator were slightly better than D 
containing conjugates. It was also interesting to observe that in general, 
conjugates which possessed the higher T rn values were most effective at 
displacing ethidium. The rank order of the T rn values relating to the conjugates 
was found to be J> D>G> L, where J conjugates were found to have the largest 
,1 T rn values. The conjugates which were most effective at displacing ethidium 
were J>D>L>G. Therefore, it seemed that the conjugates most able to stabilise 
the DNA duplex to thennal denaturation were also most effective at displacing 
ethidium and hence at intercalating. Thus mono-substituted anthraquinone 
chromophores such as J and D intercalators did display intercalation, especially 
in the case of J, where an extra lysine residue further enhanced binding. 
However, the di-substituted anthrapyrazole derivative G was shown to be less 
effective at displacing ethidium and also has a lower L1 T rn value when compared 
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with J and D. The unexpected weaker binding of G could be as a result of the 
amide moiety and the carboxyl functionality at the 7 -substituted position. 
5.8.2 Effect of Intercalator-Peptide conjugates on fluorescence enhancement 
of ethidium bromide due to binding to DNA. 
The ability of the intercalator-peptides to displace ethidium bromide was 
investigated. The results showed that fluorescence enhancement, and hence DNA-
binding, of ethidium was reduced when compounds 4/7(D, G, J and L) were 
added to DNA. It was noted that of the two main peptides studied, 4 and 7, 
peptide 7 was observed to be the better of the two at displacing ethidium. The 
same conclusion was derived from T rn and EMSA assays. Molecular modelling 
also indicated that the binding energies upon interaction of peptides 4 and 7 
were -499.27 and -495.12 kcal mor l , respectively (refer to section 5.14.1). Its 
believed that binding by peptide 7 was favoured because of the presence of an 
extra basic amino acid residue. Also, as mentioned above, the conjugates which 
had the most effect on ethidium displacement also displayed higher ~ T rn values. 
The results therefore showed that chromophores of the APZs and AQ conjugates 
intercalate with DNA as judged by displacement of ethidium from its binding 
site. Nevertheless, it must be highlighted that minor groove binders such as 
netropsin have been known to increase the melting temperature of DNA. Some 
intercalators (i.e. amsacrine see Baguley and LeBret, 1984) are also able to 
quench DNA-ethidium fluorescence without actually intercalating. 
5.9 Biological Evaluation: Establishing the Specificity and Redox Sensitivity 
of c-Jun homodimer protein for AP-l DNA consensus sequence. 
Before any in vitro assays were carried out with the synthesised intercalator-
peptide compounds, assays were performed to assess the specificity of the 
transcription factor protein used in this work and to optimise conditions for 
studying their binding to DNA. The specificity of the c-Jun homodimer protein 
was ascertained usmg wild-type and mutant AP-1 oligonucleotides, which 






The results showed that purified c-Jun homodimer protein was highly specific 
and can readily distinguish the mutant (has one inverted base pair) from the 
wild-type AP-1 oligomer (figure 41) 
Subsequently it was demonstrated that binding of the c-Jun homodimer protein is 
required to be in the reduced state. Figure 42 clearly indicated that only when 
the reducing agent dithiothreitol, (DTT) was present did the c-Jun homodimer 
bind to the AP-1 consensus oligomer. This is consistent with reduction of the 
cysteine residue in the c-Jun homodimer being a prerequisite for binding to AP-1 
site to occur (Abate et aI, 1990a). 
It was also observed that binding of the c-Jun homodimer protein does not 
occur with the SP-1 consensus oligomer. The SP-1 protein like the AP-1 binds 
to DNA via a redox regulated mechanism but interacts with the DNA structure 
via a zinc finger rather then via an oc-helical conformation (Briggs et aI, 1986). 
Both SP-1 and AP-1 proteins and their respective oligomers were used in later 
experiments to investigate the specificities of the synthesised interCalator-peptide 
conjugates (see figures 52 and 53). 
SP-1 5' -ATTCGATCGGGGCGGGGCGAGC-3' 
3' -T AAGCTAGCCCCGCCCCGCTCG-5' 
AP-1 5' -CGCTTGATGAGTCAGCCGGAA-3' 
3' -GCGAACTACTCAGTCGGCCTT -5' 
Competition assays were also performed to detect the specificity of purified c-
Jun protein. Competition assays can be seen as a way of assessing the stability 
of the interaction between the protein and its consensus oligonucleotide. The 
competing DNA acts as a catalyst causing the dissociation of preformed 
complexes in a DNA concentration-dependent and sequence-specific manner. The 
magnitude of the effect also depends on the particular protein under study. The 
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displacement of protein in direct transfer from one DNA site to another could 
be important in the search process for specific binding sites. 
Two competition experiments were carried out. The first of these showed how 
the band intensity becomes diluted out with increasing concentration of unlabelled 
AP-l oligomer. However the same effect was not observed with increasing 
concentration of unlabelled SP-l oligomer. The unlabelled SP-l oligomer in this 
case was unable to compete with the labelled AP-1 oligomer for the c-Jun 
protein. Essentially, the binding of the c-Jun homodimer protein to the labelled 
AP-l DNA was not displaced in the presence of SP-1 DNA. This demonstrates 
the high specificity of the c-Jun homodimer protein for the AP-l consensus 
oligomer. 
In this work, the effect of the intercalator-peptide on the binding of the AP-1 
protein to AP-1 site was investigated using HeLa nuclear extract. The extract is 
relevant to the complex cellular systems in which drug/DNA interactions would 
take place. It was important initially to show that the AP-1 heterodimer protein 
present in the HeLa extract was indeed responsible for binding to the AP-1 
DNA consensus oligonucleotide and not by nonspecific proteins. One way in 
which this was achieved was by using AP-1 antibody. AP-l antibody was 
incubated with the HeLa extract and AP-l DNA consensus oligomer. The 
resulting ternary complex (antibody-protein-DNA) caused a 'supershift' to occur, 
this was seen as a second band above the existing protein-DNA band. This 
supershift was caused by an increased in molecular weight upon binding of the 
AP-l antibody to AP-l protein, and of the latter to DNA. It is therefore highly 
likely that the protein-DNA complex found in the existing HeLa extract 
corresponds to that of the AP-l protein-AP-l oligomer complex (see figure 44). 
It was also successfully demonstrated that direct oxygenation of the AP-l protein 
caused a reduction in binding to AP-1 DNA consensus sequence. The reversible 
oxidation product is thought to either be in the fonn of sulphenic (RSOH) or 
sulphonic (RS02H) acid (Abate et aI, 1990a). 
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5.10 Effect of Anthrapyrazole and Anthraquinone derivatives on AP-l 
protein binding to AP-l DNA consensus sequence. 
A ligand is accepted as an intercalator for several reasons including (a) it 
produces a helix extension corresponding to 3.4A per drug chromophore, as 
measured by, say, viscosity changes (Wilson and Jones, 1981); (b) the 
chromophore is aligned parallel to these patrs, as indicated by electric dichroism 
or X-ray fibre diffraction (Neidle and Berman, 1983); or (c) DNA unwinding is 
produced (Wang, 1974). It is clear that planar drug molecules inserted between 
DNA base pairs can cause the DNA to unwind and hence show a somewhat 
smaller value of propeller twist. Propeller twist is defined as the angle (-12°) 
between two base planes when viewed along the axis joining them (Neidle and 
Berman, 1983). 
Ethidium bromide (figure 45) is perhaps the best studied of the intercalators 
which along with 1,4-bis{[2-(dimethylamino-ethyl]amino }5,8-di-hydroxyanthracene-
9,l0-dione (AQ4) an analogue of mitoxantrone, both display good inhibition of 
AP-l protein binding to AP-l consensus sequence. Inhibition was observed with 
ethidium at ratio of 10: 1 (ethidium:DNA), compared with some of the APZ and 
AQ derivatives synthesised in this thesis which showed inhibition at higher ratios 
(200:1). 
Its been shown by preVIOUS workers that as a general principle following 
intercalation the base pairs remain perpendicular to the helix axis, but they are 
moved apart (by up to -3.4A) to accommodate the intercalator molecule. Van 
der Waals contact between the 1t-orbitals of the drug molecule and the base 
pairs would help to stabilise the complex via hydrophobic and charge-transfer 
forces. Local distortion of the helix occurs since it has to unwind in order to 
accommodate the drug molecule. Distortion of the helix due to local unwinding 
at intercalation sites would destroy the long-range regularity of the helix, as 
observed by X-ray diffraction studies. In principle, saturation of the DNA by 
intercalators causes the recognition site to become distorted (Chen et ai, 1985). 
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This could explain the displacement of AP-1 and SP-1 transcription factors from 
binding to DNA.· 
A senes of compounds (table 6) were tested for their intercalative activity, and 
compound B was found to display little or no inhibition of AP-1 protein binding 
to AP-1 DNA, even at concentrations of 800: 1 (B:DNA). The lack of 
intercalation by B can be explained by considering its structure (see table 6), a 
very short side arm with no basic ammo group and of mono-substituted 
configuration. Other mono-substituted intercalators that caused a slight inhibition 
of AP -1 binding were A, C and D. These structures differ from B in that they 
have a tertiary amine separated from N2 by two methylene groups (in the cases 
of A and C intercalators). Nevertheless, it has also been shown (see review by 
Patterson and Newell, 1994) that the amine can either be primary or secondary 
to be active. The effect of extending beyond three methylene groups has not 
been reported. It has been suggested (Showalter et aI, 1987) that for related 
anthraquinones there is a more rigid requirement for only two methylene groups 
separating the two nitro gens. Basic side chains will allow electrostatic attraction 
of the positively charged amino functionalities to the phosphate residues on the 
outside of the DNA duplex. An amide containing side chain as in the case of 
intercalator D, was also seen to cause some inhibition of the binding of AP-1 
protein to AP-1 DNA consensus sequence. 
The compounds that proved most effective at displacing AP-1 were the di-
substituted intercalators, E, F and G. Intercalator E (2,5-disubstitution APZ) 
binds directly to the DNA by inserting between the base pairs in a conventional 
manner (Fry, 1991), however with intercalators F and G (2,7 -disubstitution APZ) 
the intercalation process is more complex. Its been demonstrated on similar 
compounds that, in order for F and G to bind, DNA-breathing (transient base 
pair unstacking) (Tanious et aI, 1992; Fry, 1991) has to occur to allow the 
docking of the drug molecule into the intercalation site. Once the intercalator 
has 'straddled' the DNA, DNA-breathing is required before dissociation can take 
place. The latter method of intercalation by F could explain why inhibition of 
123 
AP-1 protein from binding to AP-1 DNA was more significant than either E or 
G. The order of decreasing inhibition AP -1 protein binding to AP -1 site was 
found overall to be F>E>G>D>A>C>B. 
The dissociation rate constant for DNA complexes with disubstituted 
anthraquinones was investigated by Gandecha (1985). He found that the order of 
dissociation was 1,4-bis-substituted anthraquinones followed by 1,5-bis-substituted 
anthraquinones, with the latter possessing the lower dissociation rate constant 
(Le. 3.82 and 0.91 S-I). Nevertheless both types of compounds were found to 
have similar DNA affinity constants. 
It was highly likely that the binding of F VIa straddling the F:DNA complex, 
could account for the higher activity. Disturbance of the DNA structure would 
be required in order to affect straddling/threading of a bulky polar side chain 
from one side of the DNA to the other. Two key features can therefore be 
summarised for such a mechanism: (i) both the association and dissociation rate 
constants should be decreased relative to classical intercalative DNA binding and 
(ii) threading of cationic side chains through the DNA duplex would require 
sequential formation and breakage of electrostatic interactions in the threading 
complex. In support of this Tanious et al (1992) shown that the binding modes 
for the anthracene-9, 10-diones involved threading-type intercalation for the 1,5-
or 2,6-disubstituted compounds and classical DNA intercalation for the 1,4- and 
1,8-difunctionalised derivatives, where both side chains occupy the same groove. 
In considering the ratio of intercalator used in this work to cause an inhibition 
(as high as 800: 1), it was possible that the intercalator interacted directly with 
the transcription factor protein AP-1 rather then with the DNA. However 
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because very similar intercalators had very different degrees of inhibition, it can 
be concluded that interaction of the intercalator was predominately with DNA. 
However, it must be highlighted that in the presence of large excesses of 
intercalator material a different and unique mode of binding might arise. For 
example, ligands that are known to intercalate can also display self association. 
This 'stacking' process involve ligand molecules binding to the exterior of the 
DNA helix and stacking upon each other (Blake and Peacock 1968). This 
stacking is due to electrostatic interactions of the positive charges of drug with 
negatively charged phosphate groups. However, this interaction is unlikely to be 
of significance in vivo, where relatively low ligand concentrations, are found. It 
must be emphasised, however, that stacking, unlike intercalation, is a non-specific 
event and often occurs when the ratio of ligand to DNA is greater than one; 
and often with extended side chains on the chromophore, where incorporation of 
all parts of the molecule is precluded. This can effectively lead to different 
modes of binding (Foye et ai, 1982) including exterior electrostatic binding as 
well as intercalation and stacking. The stronger binding is most likely associated 
with intercalation of the chromophore. 
This work suggested that there was no clear preference/selectivity of any 
intercalator synthesised for the AP-l site compared to the SP-l site. This was 
not surprising since only a few of the intercalators are known to display any 
preferences for either GC or AT base pair sequences and these often have very 
well defined functional moieties that would enable them to behave as such. For 
example, actinomycin (Muller and Crothers, 1968) and mitoxantrone (Lown et aI, 
1985) are G-C specific, tilorone (Strum et aI, 1981) and the neocarzinostatin 
chromophore (Dasgupta and Goldberg 1986) is A-T specific. Threading 
intercalators tend to be AT specific since the breathing of A-T rich DNA is 
facilitated by presence of two hydrogen bond per base pair compared to three 
hydrogen bonds in G-C rich regions. A more involved situation can occur as in 
the case of daunomycin and adriamycin (Chen et ai, 1985) for which the actual 
sequence selectivity must be expressed at the level of a triplet of mixed base 
paIrs. 
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5.11 Effect of Oligo peptide functionality on AP-1 protein binding to AP-l 
DNA consensus sequence. 
In this work eight short peptides (table 7) ranging from 5 to 7 amino acid 
residues in length, all containing the KCR motif were tested for their effect on 
binding to the AP-1 DNA consensus oligonucleotide. KCR is the centre for 
recognition of the AP-1 site and it is responsible for redox sensitive DNA 
binding of the AP-1 heterodimer (O'Neil et ai, 1990). The mode of binding is 
very well documented and involves the formation of an a-helix upon binding to 
the DNA recognition site (see chapter 1). Note, however, that this design is not 
limited to AP-l. Any protein or other molecule that recognizes a specific DNA 
sequence by binding along the major groove could be a candidate. 
The results from these assays showed that even when the peptide concentration 
used was 10-fold greater than that for the intercalator, only four of the eight 
peptides displayed any effect on the binding of AP-l protein to the AP-I DNA 
binding site. However, it was interesting to note that of the eight peptides, the 
four that did display inhibition of AP-1 binding were those considered to be 
most basic (i.e. peptides 4, 5, 6 and 7). It was also observed that conjugates 
containing these peptides (4, 5, 6 and 7) displayed higher .1Tm (table 9) than for 
conjugates coupled to the other four peptides (1, 2, 3 and 8). Peptide-dependent 
conjugates were seen for both D and J intercalators (see table 9). This 
observation highlights the significance and the influence that the peptide has on 
the binding nature of the intercalator. In addition the binding energies upon 
interaction of peptides 1 to 8 with the AP-1 DNA binding site were considered 
most favourable for peptides 4, 5, 6 and 7 (see table 10). Furthermore, the 
peptide sequences that most resembled the AP-l basic binding domain were 4, 
5, 6 and 7. The high concentration of peptide required to inhibit the binding of 
AP-l protein (ranging from 2000 to 8000: 1, peptide:DNA), effectively means 
that the affinity constant between the peptide unit and DNA AP-1 oligomer IS 
relatively low. However, despite the low affinity of the peptide for DNA, it IS 
considered to be the more selective half of the peptide-intercalator molecule. In 
principle, it was antipicated that by linking the peptide unit to an intercalator it 
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is possible to facilitate binding of the oligopeptide to DNA in a selective manner 
governed predominantly by the peptide unit used. 
As mentioned before, it is possible that inhibition of AP-l binding to the AP-l 
site can be caused by fonnation of ligand-AP-l protein complexes rather then 
drug-DNA. Nevertheless, this was unlikely since all eight peptides despite their 
similarity have very differing degrees of inhibition. It was therefore likely that 
the peptide units were bound to the DNA and not to the AP-l protein. It 
appears that the interaction between the DNA and KCR containing peptide unit 
was selective and influenced by the sequence and nature of the peptide used. 
Tal ani an et al (1992) have addressed this area of peptide sequence-specific DNA 
binding. They showed from DNAase I footprinting experiments that dimers of 
peptides containing 20 residues of GCN4 (see chapter 1) bind DNA with a 
sequence specificity similar to that of the intact protein. Also circular dichroism 
experiments suggest that specific binding involves only 15 residues (corresponding 
to residues 231-245 of GCN4), in an oc-helical confonnation. Thus, the essential 
contribution of the leucine zipper to DNA binding appears to be dimerisation, 
and the basic domain of the peptide contains sufficient information for specific 
DNA binding (Talanian et aI, 1990). 
5.12 Effect of Intercalator-Peptide conjugates on AP-l protein binding to 
AP-l DNA consensus sequence. 
The approach of ligands having mixed binding functions is complicated by drug-
induced DNA confonnational changes. Indeed, theoretical and experimental studies 
have both clearly shown that binding to DNA, whatever the nature of the 
implied process, results in an adoptation of the DNA conformation to that of 
the ligand rather than vice versa (Gilbert and Feigon, 1991). 
In this work a senes of intercalator-linked peptide compounds were synthesised, 
see table 8. Such hybrid ligands were designed with the rationale that an 
intercalating chromophore would provide DNA affinity whilst the appended 
peptide may encourage -DNA sequence selectivity. 
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The intercalator D was selected as one of the mam intercalators to be used in 
this work for several reasons. Firstly, D showed an appreciable degree of 
inhibition of AP-l binding to AP-l site. Secondly it was readily coupled onto 
the peptide using PyBOP. The relatively low affinity of intercalator D for DNA 
(deduced from EMSA data) was also considered advantageous in that the search 
for the AP-l recognition site by the attached peptide unit would be facilitated. 
In contrast, intercalators with high DNA affinity constants would tend to inhibit 
sliding of the peptide along the DNA (see introduction). The role of the 
chromophore was seen therefore to anchor the peptide to DNA which has 
practically no affinity for DNA but nevertheless possesses higher specificity. Thus 
by conjugating the intercalator and peptide, the resulting molecule will be directly 
delivered to the DNA target. 
A total of seventeen intercalator-peptide compounds were tested for their effect 
on the AP-l binding to AP-l DNA consensus sequence. The results obtained in 
this work clearly indicated that inhibition of protein-DNA complex formation was 
most significant with the intercalator-peptide. The relative activity was therefore 
in order of intercalator-peptide > intercalator »peptide. From this it can be 
postulated that, in order for the intercalator-peptide to possess a greater 
inhibition/activity than the intercalator or peptide, both the intercalator unit and 
peptide unit must be bound simultaneously to the DNA (see Waring and Bailly, 
1994; Bailly and Henichart, 1991) i. e. intercalation of the flat aromatic 
chromophore and major groove binding of the peptide part. It was observed that 
the most potent conjugates were those containing peptides 4, 5, 6 and 7, which 
was consistent with the fact that these peptides were most potent when tested 
as peptide units. This outcome further supports the concept of bimodal binding 
by the intercalator-peptide, in which conjugates containing peptides 4, 5, 6 and 7 
have superior activity. Conjugates containing the more basic peptides also gave 
the largest L1 Tm values. Furthermore, EMSA and T m assays showed that 
conjugates containing J intercalator (with one extra lysine residue) were more 
active than the D intercalator containing conjugates. In addition, EMSA showed 
that peptide 7 containing conjugates were favoured over 4, this was consistent 
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with the data obtained from molecular modelling (see section 5.14), Tm and 
ethidium displacement assays. 
The choice of the linker connecting the recognition elements may also be a 
critical design feature with regard to simultaneous binding of all moieties 
(Dervan, 1986). The most suitable linkers are considered to be the alkyl amino or 
aminoalkylamino, as these generally show greater activity. Conjugates 4J to 8J 
and 5K and 6K all contained one (J) and two (K) lysine residues in their 
linker group, respectively. It was anticipated that distortion of the double helical 
structure upon intercalation could alter the AP-1 recognition site thus preventing 
the peptide unit from binding. Therefore it seemed beneficial to increase the 
length of the linker between the two DNA-binding units in order to permit 
bimodal binding of the hybrid to DNA. The extended linker might allow proper 
placement of the peptide in the groove and the chromophore in between base 
paIrs. 
The results III table 8 indicated that conjugates with a lysine extended linker 
(conjugates J and K) were more effective at inhibiting AP-1 protein from 
binding to AP-1 DNA consensus sequence. However the enhanced activity may 
be as a result of the basicity of the lysine residue contributing to the DNA 
binding. In fact, the presence of basic peptides bearing as many as seven free 
amino groups supports the view that binding of the peptide moiety will be 
external as opposed to intercalative. Furthermore, electrostatic interactions may 
come to predominate over the expected specific hydrogen-bond formation in the 
major groove of DNA, just as observed with polyamines such as spermine and 
spermidine (Tabor and Tabor, 1984). 
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5.13 Specificity of Intercalator-Peptide conJ·ugates ~or AP 1 DNA 
II - consensus 
sequence. 
In this work the relative concentrations of oligomer transcription factor protein 
and drug was kept constant for both AP-1 and SP-I. In assessing the 
specificity, intercalator-peptide compound 7D (and 4D) was incubated with both 
AP-1 and SP-1 DNA oligomer along with their respective AP-1 and SP-I 
proteins. 
AP-1 5'-CGe TTG ATG AGT CAG CCG GAA-3' 
3'-GCG AAC TAC TCA GTC GGC CTT-5' 
SP-1 5'-ATT CGA TCG GGG CGG GGC GAG C-3' 
3'-TAA GeT AGe CCC GeC CCG CTC G-5' 
SP-1 is a sequence-specific transcription factor that recognises GGGGCGGGGC 
and closely related sequences, which are often referred to as GC boxes (Briggs 
et aI, 1986; Kadonaga et aI, 1987). The sequence specificity of SP-I protein 
binding to DNA is conferred by Zn (II) fingers, whereas a different region of 
SP-1 appears to regulate the affinity of DNA binding. 
Binding of AP-1 to AP-1 DNA binding site was inhibited by conjugates 7D and 
4D. However, a similar extent of inhibition was observed for the SP-I oligomer. 
It would therefore seem that the compounds lacked selectivity. However on 
evaluation, several contributory factors to the selectivity or specificity of the 
intercalator-peptide ligand should be considered. The concentration of intercalator-
peptide used (200 to 800: 1; hybrid:DNA) in order for an effect to be observed 
was very high. At this concentration it was possible that any specificity displayed 
by the conjugate was lost. However, one solution to this problem would be to 
use more sensitive detection methods. One approach that could be considered is 
DNA foot printing. However, this method requires the drug in question' to have 
a high affinity for DNA. It is also now thought that although the leucine zipper 
region is not directly involved in DNA binding, results by Park et al (1992) 
indicate that its position relative to the basic regIon may play a role in 
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determining which target sequence of DNA the protein recognizes. Therefore it 
is possible that by replacing the leucine zipper with an intercalator the molecule 
has been "disabled". 
It is also possible that because both the binding mechanism of AP-1 and SP-l 
protein involves a redox mechanism, better comparisons would have been made 
using non-redox regulated transcription factors. Other widely commercially 
available transcription factors that could have been used include, TFIIB 
(Maldonado et aI, 1990) and TFIID (patterson et aI, 1990). Furthermore, the 
GC boxes found in SP-I DNA consensus sequence could invariably favour 
binding of both AQ and APZ intercalators (see section 5.10) whilst binding of 
the peptide moiety to AP-I is preferred. Despite the lack in selectivity 
demonstrated by these intercalator-peptides, a novel approach in using EMSA to 
explore drug mediated displacement of transcription factors has been established. 
Moreover, future peptides can potentially be modelled around this concept of 
hybrid ligands and bimodel binding. 
Recently Tabor (l996) described the synthesis of a peptide-intercalator hybrid 
based on the bZIP motif from GCN4. Like the target hybrid molecule presented 
in this thesis, the design of the hybrid ligand described by Tabor combined a 
peptide necessary for recognition of the consensus site with the known binding 
enhancement of an intercalating moiety specifically acridine. 
/(C H2)1 oC ONH-GGDP AALKRARNTEAARRSRARKLQRMKQGGC 
HN 
2 
No biological evaluation was carried out on this hybrid ligand, although even if 
this hybrid had been selective for AP-I, the enormous length of the peptide 
moiety makes it an unlikely candidate for drug development. The in vivo 
situation is considerably more complicated due to problems of permeability 
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(particularly hybrids with longer ligands), solubility, competitive binding to 
proteins and/or lipids and metabolic breakdown of the conjugates. It is therefore 
important when designing future drugs that a balance is struck between activity 
and pharmacokinetics. 
5.14 Molecular Modelling of the AP-l Leucine Zipper-
Oligopeptide-DNA Interaction. 
As mentioned before in chapter 1, how much DNA sequence-information is 
available in the phosphate backbone in terms of interphosphate distances (groove 
widths), deoxyribose conformation, and electronegative potential and to what 
extent this is exploited by nature is still not clear. Nevertheless, most sequence 
information is considered to be on the 'floor' of the major groove. 
Four recognition sites are present in the major groove of AT base paIrs (figure 
61). These are the adenine-N7 (hydrogen acceptor), the adenine amino group 
(N6) (hydrogen donor), the thymine-04 (hydrogen acceptor), and the thymine 
methyl group (van der Waal interaction). Similarly, the recognition sites available 
at GC base pairs are two hydrogen acceptors (guanine-N7 and guanine-06) and 
one hydrogen donor (the cytosine amino group at C4). Thus the DNA sequence 
can be unambiguously read from the major groove as a 'two-dimensional grid' 
of hydrogen-donor and -acceptor and van der Waals contact sites. In this respect 
ApT versus TpA (and GpC versus CpG) base pairs are readily distinguishable. 
Since the floor of the groove is not planar, the corresponding sites of the DNA 
binding ligand furthermore have to be positioned correctly in space in much the 
same way as the key-lock principle of the substrate-enzyme recognition. 
5.14.1 Molecular Modelling of Peptides containing the AP-l Leucine Zipper. 
A series of binding energies (Horton and Lewis, 1992) were obtained for each 
of the eight peptides (table 10) using the molecular modelling software Insight 
II. Previously Niles and Brunger (1991) developed a largely automatic GCN4 
leucine zipper. They first constructed an idealised Ca: model, corresponding to 
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Figure 60: Donor and acceptor groups in the grooves of A·T and GC base 
paIrs. 
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from the Ccx: coordinates. The model is refined with minimisation and molecular 
dynamics, with a final stage of unrestrained molecular dynamics simulation with 
explicit solvent. It is assumed the model is some kind of parallel coiled-coil, but 
the detailed parameters of the coiled-coil can vary. 
Table 10: Binding energies upon interaction of peptides 1 to 8 with the AP-1 
DNA binding site. 
Peptide Unit Binding Energies 










From the data obtained In table 10 it was observed that binding to the major 
groove was favoured by peptides that were longer and more basic in nature i.e. 
peptides 4, 5, 6 and 7. This was consistent with the results obtained in EMSA 
in which peptides 4, 5, 6 and 7 were found to show the greatest degree of 
inhibition. Furthermore, conjugates containing these particular peptides were also 
most effective at inhibiting AP-1 protein from binding to AP-1 DNA consensus 
sequence. The same conjugates containing these four peptides were shown also 
to have higher .1 T rn values. Of the two peptides mainly investigated, peptide 7 
was shown to have the greater binding constant compared to 4. This was 
consistent with the EMSA data in which peptide 7 showed better inhibition of 
AP-1 protein binding than peptide 4. Peptide 7-containing conjugates were also 
demonstrated to be both better inhibitors of AP-I binding and have greater ~ T m 
values than peptide 4-containing conjugates. 
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Figure 61: Peptide 6 (H2N-A-K-C-R-N-R-A-CONH2) bound to AP- l D A 
consensus sequence. 
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The aim of this investigation was to design and synthesise hybrid (intercalator-
linked peptide) ligands combining a peptide necessary for recognition of the 
consensus site with the known binding enhancement of an intercalating moiety. 
Such a molecule was anticipated to inhibit transcription by preventing the binding 
of transcription factors such as AP-1 protein from binding to its consensus 
sequence. In this thesis, a series of intercalator-peptide conjugates were 
successfully synthesised, isolated and characterised using modem analytical 
techniques. It was also characterised using 2D nmr techniques such as NOESY 
to show that peptides prepared in this work exist in an oc-helical conformation. 
These intercalator-peptide compounds were then shown to bind to DNA VIa 
intercalation as demonstrated by their effect on the thermal denaturation of DNA 
and on their ability to displace ethidium. In addition, an electrophoretic mobility 
shift assay showed that binding of AP-1 protein to the AP-1 DNA consensus 
sequence was inhibited by these compounds, though not selectively. It is 
therefore worth while investigating how, by extending the peptide unit better 
selectivity could be achieved. Finally, the redox sensitivity of these peptide 
hybrids should be explored. The KCR motif central to all the compounds 
prepared is, in principle, hugely sensitive to oxidation. An oxidised cysteine 
residue should, by analogy with AP-1 proteins, prevent binding of the hybrid to 
DNA. In this way, redox control of binding could be achieved. This may have 
utility as a design feature in transcription factor inhibitors since it would ensure 
that the peptide hybrid is only active in cells under oxidative stress. This 
condition is often associated with cancer cells, and hence tumour selective 
therapy is possible by this approach. 
So for future work, it would be worthwhile to synthesise longer peptide 
sequences and to vary the binding constant by using other intercalators. It is 
also possible to enhance bimodal binding by looking at different linker groups. 
Cleavage based assays such as affinity cleavage, strand cleavage and footprinting 




(C=O), 1250 (C-N); OR (DMSO): 8.10 (7H, m, ArH), 4.65 (2H, t, NNCH
2
) , 4.40 
(IH, bt, OH), 4.00 (lH, s, NH), 3.40 (2H, q, CH20H) , 3.15 (2H, t, CH2NH) , 2.65 
(2H, t, HNCH2); Oc (DMSO): 182.6, 139.6, l37.5, 136.0, 133.8, l32.6, l31.4, 128.7, 
128.5, 128.5, 125.3, 122.5, 120.5, 117.1, 60.2, 51.2, 49.7, 49.0; mJz (F AB) 308 
(M+H)+; (Found: C, 70.71, H, 5.76; N, 13.92. CIsH17N302 requires C, 70.34; H, 
5.57; N, 13.67%). 
6.3.1 Synthesis of 2- {2-[N-(2-Hydroxyethyl)-N-methylamino] ethyl} anthra[I,9-
c,d]pyrazol-6(2H)-one (6). 
2-{2- [N-( -2-Hydroxyethylamino ) ethyl } anthra[ 1, 9-cdJpyrazol-6( 2H)-one (5) (1.23 g, 
4.02mmol) was dissolved completely in formic acid (2. 74mL, 72mmol) before 
addition of aqueous formaldehyde solution (37%, 0.71mL, llmmol). The mixture 
was heated to 95-100°C on an oil-bath for 5 hr. The reaction mixture was 
cooled to room temperature before being taken up in chloroform (5mL), giving 
rise to an immisible solution. The isolated water phase was then basified to 
pH12 with (2% w/v) NaOH (40mL) to afford a fine green precipitate. This was 
extracted with chloroform (4x30mL) and the solvent removed in vacuo to obtain 
a dark viscous oil, then triturated with methanol (2mL) and left overnight at ~5 
0c. Lime green solid material was obtained by filtration and further recrystallised 
from methanol to obtain the analytically pure 2-{2-[N-(2-hydroxyethyl)-N-
methylamino]ethyl}anthra[I,9-cdJpyrazol-6(2H)-one (6) (0.981g, 76.3%) m.p. 78-
80°C, t.1.c Rf 0.5 (CH2ChlMeOH 1/1), Vrnax (KEr) em-I: 3400 (OH), 1670 (C=O); 
OR (DMSO): 8.00 (7H, m, ArH), 4.70 (2H, t, NNCH2), 4.25 (IH, bt, OH), 3.40 (2H, 
q, CH20H) , 3.00 (2H, t, CH2NMe) , 2.50 (2H, t, MeNCH2) , 2.25 (3H, S, Me); oc 
(DMSO): 182.9, 139.7, 137.5, 136.2, 134.1, l32.9, 131.7, 129.0, 128.8, 127.5, 125.6, 
122.8, 120.8, 117.4, 59.6, 59.3, 57.4, 48.2, 42.9; m1z (FAB) 322 (M+Hf; (Found: C, 
71.32; H, 5.83; N, 13.25. CI9HI9N302 requires C,71.01; H,5.96; N,13.07%). 
6.3.2 Synthesis of 2-{ 2-[N-(2-Chloroethyl)-N-methylamino] ethyl} anthra[I,9-c,d] 
pyrazol-6(2H)-one (7). 
Thionyl chloride (4mL) was added dropwise to a cooled (O°C) and stirred 
sample of (6) (l.42g, 4.43mmol) with no other solvent present. The reaction 
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mixture was then removed from the ice-bath and allowed to come to room 
temperature over the course of 15 hr with minimal stirring under anhydrous 
conditions. Excess thionyl chloride was then carefully removed in vacuo to 
afford a dark tar-like material which on trituration with dry ether (3x5mL) gave 
a browny yellow solid. Bright yellow crystals were obtained on crystallisation 
with hot methanol (-lmL) to yield the product (0.86g, 51.7%) m.p. 108-1100 C, 
Vrnax (KBr) cm-
I
: 1670 (C=O), 1250 (C-N), 700 (C-CI); DR (DMSO): 8.00 (7H, 111, 
ArH), 5.05 (2H, t, NNCH2), 4.00 (2H, t, CH2CI), 3.85 (2H, t, CH2NMe) , 3.65 (2H, 
t, MeNCH2), 2.20 (3H, s, Me); Dc (DMSO): 182.2, 139.9, 137.5, 136.7, 133.9, 132.8, 
131.5, 129.2, 129.0, 128.8, 125.5, 122.8, 121.0, 116.8, 56.6, 54.7, 53.5, 44.1, 37.9; 
m1z (FAB) 341 (M+Hf; (Found: C, 67.33; H, 5.28; CI, 10.62; N, 12.65. 
CI9HISCIN30 requires C, 67.16; H,5.34; CI, 10.43; N,12.36%). 
6.4 Synthesis of 7-Chloro-2-{ 2-[N-(2-hydroxyethyl)amino ] ethyl } anthra[1,9-c,d] 
pyrazol-6(2H)-one (9). 
1,5-Dichloroanthraquinone (5. 54g, 20mmol) and 2-[ (2-(hydrazinoethyl)amino ] ethanol 
(4) (5.14g, 38mmol) were suspended III acetonitrile:Drv1F (50:25mL). 
Triethylamine (3. OmL, 27mmol) was added and the stirred mixture heated to 
reflux for -20 hr under positive nitrogen pressure. The mixture was then allowed 
to come to room temperature before further storage at ::;;5°C overnight. A deep 
red solution was obtained in which a yellow precipitate was suspended. This was 
filtered under pressure using a generous volumn of cold methanol followed by 
recrystallisation with methanol to yield the product as a yellow crystalline solid 
(4.03g, 58.9%) m.p. 140-142°C, t.I.c Rf 0.2 (CH2CliMeOH 111), Vmax (KBr) cm-
1
: 
3400 (OH), 1670 (C=O), 1250 (C-N); DR (DMSO): 8.00 (6H, 111, ArR), 4.65 (2H, t, 
NNCH2) , 4.45 (lR, bt, OH), 4.00 (lH, s, NH), 3.40 (2H, q, CH20H) , 3.15 (2H, t, 
CH2NH), 2.65 (2H, t, HNCH2); Dc (DMSO): 181.7, 139.5, 137.0, 136.0, 134.6, 134.0, 
132.5, 128.8, 128.4, 126.0, 122.0, 121.9, 120.7, 116.8, 60.7, 51.7, 50.2, 49.5; m1z 
(FAB) 342 (M+H)+; (Found: C, 63.26; H,4.68; CI, 10.07; N, 12.62. ClsH16CIN302 
requires C,63.25; R,4.72; CI, 10.37; N, 12.30%). 
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6.4.1 Synthesis of 7-Chloro-2-{2-[N-(2-hydroxyethyl)-N-methylamino] ethyl} 
anthra[I,9-c,d]pyrazol-6(2H)-one (10). 
(9) (0.17g, 0.50mmol) readily dissolved in formic acid (0.38mL, 10mmol) and 
formaldehyde solution (37%, 0.11mL, 1.50mmol). The mixture was heated at 95-
100°C on an oil bath for 4 hr. The reaction was then cooled to room 
temperature and dissolved in chloroform. The aqueous layer was separated and 
basified to pH12 with NaOH (2% w/v). The N-methylated product was extracted 
with chloroform (4x5mL). The chlorofonn was removed under vacuum to leave 
a viscous oil which on cooling formed a crystalline solid. This residue was 
redissolved in hot methanol and on cooling refonned as the pure product 
(0.085g, 48.0%) m.p. 119-121°C, t.l.c Rf 0.6 (CH2CliMeOH 111), Vrnax (KBr) cm-
1: 3400 (OR), 1670 (C=O), 1030 (C-N); OR (DMSO): 7.80 (6H, rn, ArH), 4.65 (2H, 
t, NNCH2), 4.20 (lH, bt, OH), 3.25 (2H, q, CH20H), 2.95 (2H, t, CH2NMe), 2.40 
(2H, t, MeNCH2), 2.25 (3H, s, Me); oc (DMSO): 181.5, 139.2, 136.9, 136.0, 134.4, 
133.8, 132.3, 128.7, 128.3, 126.0, 121.9, 121.8, 120.6, 116.6, 59.6, 59.3, 57.3, 48.1, 
42.9; m/z (FAB) 356 (M+Hf; (Found: C, 64.30; H, 4.95; CI, 10.08; N, 12.01. 
C19HlSCIN302 requires C, 64.14; H, 5.10; CI,9.96; N,l1.81%). 
6.4.2 Synthesis of 7-(2-Aminoethyl)amino-2-{2-[N-(2-hydroxyethyl)-N-methyI 
amino] ethyl}anthra[I,9-c,d]pyrazol-6(2H)-one (11). 
(10) (0.322g, 0.90mmol) was suspended in ethylenediamine (5mL, excess) and 
refluxed with stirring for 4 hr at -118°C. The reaction mixture was cooled to 
room temperature to which water (20mL) was added. The product was then 
extracted using dichloromethane (3x50mL) and concentrated under high vacuum. 
Trituration with hexane (2x 1 OmL) removed any remammg ethylenediamine, the 
sample was agam dried. The product was then isolated by column 
chromatography with dichloromethane: ethanol: ammonia (9: 1:0.1) eluent. The 
product was redissolved in dichloromethane (5mL) and pet. ether (40:60) added 
dropwise until the product precipitated ( -1 0 drops). This was left to stand at 
4°C overnight and filtered with cold pet. ether (40:60) and dried to afford (11) 
(0.12g, 34.9%) m.p. 125-126°C, t.l.c Rf 0.2 (CH2CblMeOH 4/1), Vrnax (KBr) cm 
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1: 3400 (OH), 1670 (C=O), 1230 (C-N); DH (CDCh): 10.3 (1ll, bt, NHAr), 8.00 (6ll, 
m, ArR), 4.60 (2H, t, NNCH2), 4.30 (1H, bs, OH), 3.45 (2ll, q, CH20R) , 3.40 (2H, 
q, CH2NH), 3.10 (2H, t, CH2NMe) , 3.10 (2H, q, HNCH2) , 2.60 (2ll, t, MeNCH2), 
2.25 (3H, s, Me); Dc (CDCh): 187.1, 157.7, 140.0, 138.9, 135.0, 133.1, 128.4, 127.9, 
122.9, 119.5, 114.6, 113.6, 11l.9, 109.8, 59.1, 58.9, 57.3, 48.0, 45.9, 42.3, 41.3; mlz 
(FAB) 380 (M+H)\ (Found: C, 66.87; H, 6.87; N, 18.18. C21H2SNs02 requires C, 
66.48; H,6.64; N, 18.46%). 
6.4.3a Synthesis of 7-{2-[(methoxycarbonylmethyl)amino]ethylamino}-2-{2-[N_ 
(2-hydroxyethyl)-N-methylamino]ethyl}anthra[I,9-c,d]pyrazol-6(2H)-one (13). 
(11) (0.42g, 1.11mmol) and methyl chloroacetate (0. 14g, 1.33mmol) was 
dissolved in DJvIF (1. OmL) and stirred at room temperature for 24 hr under 
nitrogen. After which DMF was removed in vacuo. Column chromatography was 
carried out using dicWoromethane:methanol (9.5:0.5 ~ 8:2) to elute the purified 
product derivative (13) (0.15g, 28.6%) m.p. 80-81°C, t.1.c Rf 0.3 
(CH2ChlMeOHINH3 9/1/2drops), Vrnax (KBr) cm-
1: 3400 (OR), 1670 (C=O), 1230 
(C-N), 1050 (C-O); DH (DMSO): 10.2 (1H, bt, HNAr), 8.00 (6H, m, ArH), 4.55 (2H, 
t, NNCH2) , 4.30 (lH, bs, OR), 4.10(2H, s, COCH2NH), 3.60 (3H, s, OCH3), 3.40 
(2H, q, CH20H), 3.35 (2H, q, CH2NH) , 3.10 (2H, t, CH2NMe) , 3.15 (2H, q, 
HNCH2) , 2.60 (2H, t, MeNCH2), 2.30 (3H, s, Me); Dc (DMSO): 186.2, 166.9, 152.4, 
139.6, 138.7, 135.6, 132.1, 129.4, 126.4, 121.9, 120.2, 115.6, 114.1, 112.4, 110.5, 
65.3, 57.3, 54.7, 54.4, 54.3, 52.9,46.9,45.4,43.6; m/z (FAB) 452 (M+R)+; (Found: 
C,63.56; H, 6.51; N, 15.90. C2JI29Ns04 requires C,63.84; H, 6.47; N, 15.51%). 
6.4.4 Synthesis of 7 -{2-( carboxymethylamino )ethylamino }-2-{2-[N-(2-hydroxy 
ethyl)-N-methylamino] ethyl}anthra[I,9-c,djpyrazol-6(2H)-one (14). 
For the dealkylation of ester, (13) (0.02g, O.044mmol), lithium bromide (0.012g, 
0.13mmol) and sodium iodide (6. 64mg, 0.044mmol) were dissolved in pyridine 
(1 OmL) and refluxed for 9 hr. The pyridine was evaporated and ethanol was 
added and heated and filtered to remove remaining inorganic material. The 
residue was further dried leaving behind a crude sample of the title compound. 
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6.4.3b Synthesis of 7-(2-Succinamidoethyl)amino-2-{2-[N_(2_hYdroxyethyl)_.;\~_ 
methylamino]ethyl} anthra[I,9-c,djpyrazol-6(2H)_one (12). 
(11) (0.20g, 0.53mmol) and succinic anhydride (0.063g, 0.63mmol) were 
suspended in Dl\1F (1 OmL) and heated to 80°C with stirring for 3 hr. On 
completion of the reaction D:rvtF was evaporated under vacuum. The solid residue 
was then taken up in methanol (ImL) and chromatographed with neat methanol 
(0. 12g, 47.5%); m.p. 101-102°C, t.1.c Rf 0.6 (CH2CliMeOHINH3 9/l/2drops), 
Vrnax (KBr) em-I: 3400 (OH), 1670 (C=O), 1230 (C-N); bH (DMSO): 8.50 (lH, bt, 
HNAr), 7.50 (6H, m, ArH), 4.60 (2H, t, NNCH2) , 4.40 (lH, bs, OH), 3.60 (2H, q, 
CH20H) , 3.30 (2H, t, CH2NHAr), 3.20 (2H, t, CH2CO), 3.0 (2H, t, CH2C02H), 2.90 
(2H, t, CH2NMe), 2.45 (2H, t, HNCH2), 2.40 (2H, t, MeNCH2), 2.30 (3H, s, Me); be 
(DMSO): 186.1, 176.5, 173.8, 153.1, 138.9, 138.5, 135.2, 132.6, 128.4, 126.6, 121.9, 
119.4, 115.7, 113.6, 111.9, 109.1, 59.1, 58.8, 57.0, 47.7, 42.5, 41.4, 37.9, 33.8, 33.1; 
mlz (FAB) 480 (M+H)+; (Found: C, 63.00; H,5.90; N, 14.58. C2sH29NsOs requires 
C,62.62; H, 6.10, N, 14.60%). 
6.5a 1,4-Dichloroanthraquinone (15) via Friedel Craft's Acylation - Synthesis 
of 2,5- Dichloro-2-benzoylbenzoic Acid. 
Phthalic anhydride (7.4g 50mmol), p-dichlorobenzene (36.7g, 250mmol) and 
anhydrous aluminum chloride (20g, 75mmol) were placed in a flask provided 
with an air condenser at the end of which was attached a calcium chloride tube. 
It was heated in an oil-bath maintained at 110-120°C until there was no further 
evolution of hydrogen chloride (4 hr). The black, viscous reaction product, after 
being cooled to room temperature, was poured into ice water. Concentrated 
hydrochloric acid (50mL) was added and the mixture was steam distilled to 
remove excess p-dichlorobenzene. The residue in the flask was washed with hot 
water and digested on the steam-bath with sodium hydroxide 15% (v/w). The 
digestion mixture was then boiled with charcoal and filtered. The filtrate was 
made acid with dilute hydrochloric acid. The dichlorobenzoylbenozoic acid was 
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extracted with ethyl acetate (4x30mL) and dried to afford (3.82g,27.2%) m.p. 
157-159°C, Vrnax (KBr) em-I: 3100 (C02H), 1670 (C=O), 1500 (Ar), 1230 (C-N); OH 
(DMSO): 7.2-7.8 (7H, m, ArH); Dc (DMSO): 181.2, 169.0, 155.6, 150.2, 147.9, 147.5, 
130.2, 129.8, 128.7, 127.4, 127.0, 125.8, 124.3, 123.7; m1z (FAB) 295 (M+Hf; 
(Found: C, 56.92; H, 2.35; CI, 24.46. CIJiSC120 3 requires C, 57.17; H, 2.40; CI, 
24.11%). 
6.5b 1,4-Dichloroanthraquinone (15). 
2',5'-Dichloro-2-benzylbenoic acid (0.70g, 2.5mmol) and concentrated sulphuric 
acid (8mL, in excess) were heated together in an oil-bath at 150°C for 4 hr. The 
reaction mixture, after cooling to room temperature was poured into ice water 
(200mL) and washed with sodium hydroxide (lM, 600mL) and saturated brine 
(600mL). It was recrystallised from methanol to give orange-coloured needles 
(0.51g, 78.5%) m.p. 187-189°C, Vrnax (KBr) em-I: 1670 (C=O), 1600 (Ar); OH 
(DMSO): 8.28-8.20 (2H, m, ArH), 7.87-7.80 (2H, m, ArH), 7.53-7.45 (2H, m, ArH); 
Dc (DMSO): 159.0, 154.3, 150.9, 148.4, 147.5, 128.9, 127.6; m1z (FAB) 277 (M+Ht; 
(Found: C, 60.29; H, 2.19; CI, 25.95. CIJi6Ch02 requires C, 60.68; H, 2.18; CI, 
25.59%). 
6.6 Synthesis of 1,4-Dichloroanthraquinone (15) from Leucoquinizarin. 
To phosphorous pentachloride (100g, 0.48mol) suspended III 1,1,2,2-
tetrachloroethane (65ml) was added leucoquinizarin (20g, 0.083mol). The mixture 
was heated to reflux with stirring for 27 hr. The mixture was cooled to room 
temperature using a water-bath. Methanol (50mL) was added slowly in 1-2mL 
aliquots. Further methanol (25mL) was added in 5mL aliquots. The mixture was 
allowed to stir overnight and then cooled to -20°C. The yellow solid was 
filtered, washed with cold methanol, and dried under vacuum to give the 
hexachloro intermediate product (19.75g, 61.3%). This (9.25g, 0.024mol) was 
refluxed in I-pentanol (lOOml) for 18 hr with stirring and the solid which 
separated upon cooling (-20°C) was filtered and washed with ethanol. The 
ethanol was dried to afford a yellow solid (5.39g, 81.4%). (Found: C, 60.71; H, 
2.22; Cl, 25.87. C1Jl6Ch02 requires C,60.68; H, 2.18; CI,25.59%). 
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6.6.1 Synthesis of 5-Chloro-2-{ 2- [N -(2-hydroxyethyl)amin 0] ethyl} anthra [1,9-
c,dJpyrazol-6(2H)-one (16). 
A mixture of 1,4-dichloroanthraquinone (0.55mg, 2.0mmol), 2-
[(2(hydrazino ethyl) amino ] ethanol (300mg, 2.5mmol) and triethylamine (0.3mL, 
2. 67mmol) in acetonitrile-DNlF (10mL, 0.6mL) were heated to reflux under 
positive nitrogen pressure for IS hr. The reaction mixture was initially cooled to 
room temperature then stored at ~5°C overnight. The solid precipitate was 
collected by filtration with thorough cold methanol washes. Recrystallisation with 
methanol was carried out to afford analytically pure bright yellow crystals 
(0.37mg, 55.3%) m.p. 129-130°C, t.1.c Rr 0.2 (CH2CliMeOH 111), Vrnax (KBr) cm-
1: 3400 (OH), 1670 (C=O), 1250 (C-N); OR (DMSO): 8.00 (6H, m, ArH), 4.70 (2H, 
t, NNCH2), 4.40 (lH, bt, OH), 4.00 (lH, s, NH), 3.35 (2H, q, CH20H), 3.10 (2H, t, 
CH2NH) , 2.60 (2H, t, HNCH2); oe (DMSO): 180.8, 137.8, 137.7, 133.7, 132.5, 131.3, 
130.1, 128.9, 128.6, 127.7, 123.4, 122.3, 120.6, 117.8, 57.3, 55.2, 53.9, 44.1; m1z 
(FAB) 342 (M+Hf; (Found: C, 63.01; H,4.71; CI, 10.70; N, 11.98. C18H16CIN302 
requires C,63.2S; H,4.72; CI, 10.37; N, 12.29%). 
6.6.2 Synthesis of 5-Chloro-2-{ 2-[N-(2-hydroxyethyl)-N-methylamino] ethyl} 
anthra[I,9-c,dJpyrazol-6(2H)-one (17). 
(16) (0.78g, 2.28mmol) was dissolved III formic acid (2.5mL, excess) and 
aqueous formaldehyde solution (37%, 1.1 mL) and the mixture heated to 100°C 
for 3.5 hr. The reaction was cooled to room temperature and extracted with 
chloroform (6mL). The organic layer was discarded. The aqueous phase was 
basified to pH 12 with NaOH (2% w/v), then extracted with chloroform 
(4x25mL). The combined chloroform extracts were washed with brine (300mL) 
and dried to afford an orange oil (0.75g, 92.4%). To obtain the solid 
hydrochloride form, acetyl chloride (0.2mL, 2.8mmol) was added dropwise to 
methanol (2.SmL) at O°e. The resulting solution was added to a solution of the 
N-methylated APZ derivative (0.7Sg, 2.11mmol) dissolved in methanol (15mL). A 
bright yellow precipitate was formed after a few minutes of stirring. Filtration of 
the reaction afforded bright yellow crystals which were dried under vacuum 
(0.64g, 77.2%), m.p. 263-265°C, t.1.c Rr 0.6 (CH2CbIMeOH 111), Vrnax (KEr) em-I: 
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3400 (OH), 1670 (C=O), 1030 (C-N); OH (DMSO): 8.00 (6H, m, .AsH), 4.60 (2H, t, 
NNCH2), 3.35 (2H, t, CH20H), 2.90 (2R, t, CH2NMe), 2.40 (2H, t, MeNCH
2
) , 2.20 
(3R, s, Me); oe (DMSO): 180.4, 138.0, 136.8, 133.6., 132.5, 130.8, 130.5, 128.6, 
128.5, 127.4, 123.1, 122.1, 120.5, 117.9, 59.4, 59.1, 57.1, 48.1, 42.7; mJz (F AB) 356 
(M+Ht; (Found: C, 64.50; H, 5.18; Cl, 10.21; N, 11.52. C19H18CIN302 requires C, 
64.14; H, 5.10; CI, 9.96; N, 11.81%). 
6.6.3 Synthesis of 5-(2-Aminoethyl)amino-2-{2-[N-(2-hydroxyethyl)-N-methyI 
amino]ethyl}anthra[I,9-c,djpyrazol-6(2H)-one (18). 
The yellow oily product was isolated by column chromatography using 
dichloromethane:methanol:ammonia (9:1:2 drops). Yield 0.098g, (28%), t.1.c Rf 0.2 
(CH2ChlMeOH 4/1), Vrnax (KBr) em-I: 3400 (OH), 1670 (C=O), 1220 (C-N); OH 
(CDCb): 9.80 (IH, bt, NHAr), 8.00 (6H, m, ArH), 4.50 (2H, t, NNCH2), 4.10 (lR, bs, 
OH), 3.45 (2H, q, CH20R), 3.35 (2R, q, CH2NH), 3.15 (2H, t, CH2NMe), 3.00 (2H, 
q, HNCH2), 2.55 (2R, t, MeNCH2), 2.30 (3R, s, Me); oe (CDCh): 183.3, 161.6, 
151.0,138.4,133.4,132.1,130.2,128.0,127.5,123.6, 122.5, 122.7, 118.1, 115.1, 
60.2, 58.0, 56.8, 47.5, 45.7, 43.9, 42.5; mJz (FAB) 380 (M+H)\ (Found: C, 66.82; H, 
6.50; N, 18.63. C21H2SNs02 requires C, 66.48; H,6.64; N, 18.46%). 
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6.7 Solid Phase Peptide Synthesis. 
All the protected amino acid derivative, PyBOP and the resm used were 
purchased from Novabiochem. Solvents used were of HPLC grade. 




O-CH2-CO-Nle-NH-(CH2b-NH-lPolyhipe P500 I 
(I) 
HO-CH2-\ }-O-CHrCO-NH-C~~-ipolystyrene Matrix I 










Peptide synthesis was carried out on a Pharmacia-LKB Model 4175. 
Ninhydrin (Kaiser) colour Test: 
Reagents: ninhydrin (lg) dissolved in ethanol (lOmL) 
phenol (5g) dissolved in ethanol (1.25mL) 
KeN 2mL of a stock O.OOlM solution diluted to 100mL , 
with pyridine 
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6.8 Preparing the Resin. 
The dried resin (1g) was weighed and placed in a column along with enough 
DI\1F to swell the resin, this took 30 min. Mixing of the DMF with the resin 
was carried out using a pipette and any 'fines' was allowed to come to the 
surface and removed using a pipette. 
6.8.1 Assembling the Peptide. 
The resin (loading potential of 0.14mmol/g) was made ready for acylation by 
cleaving the initial Fmoc by introducing the resin to 20% (v/v) piperidine:DW'. 
Each ammo acid derivative (4 molar eqv.) was weighed and placed in separate 
glass vial along with the PyBOP (4 molar eqv.) dissolved in 3 mL DMF and 
N,N-diisopropylethylamine (8 molar eqv.) added to this mixture. This cocktail 
was then immediately loaded onto the waiting column containing the free primary 
amine. The acylation reaction was left for between 2 to 5 hr (see table 11) 
depending on the amino acid residue. Complete acylation was determined by 
carrying out the Kaiser test. 
Table 11: Reactants and times for peptide assembly. 
Acyl Amino acid Amount (mg) PyBOC (mg) N, N-DIPA (~) Acylation (hr 
Fmoc-Lys(Boc)-OH 262.4 291.4 195 2 
Fmoc-Cys(Trt)-OH 328.0 291.4 195 2 
Fmoc-Arg(pmc )-08 340.9 291.4 195 3 
Fmoc-Ala-OH 174.4 291.4 195 4 
6.8.2 Ninhydrin (Kaiser) Colour Test. 
A sample (5-10 mg) was removed at the end of the wash period following 
deprotection, and transferred to a small sintered glass funnel. The resin was then 
washed with D:MF, ethanol, acetic acid, ethanol, DW' and ether, the resin being 
agitated throughout with a spatula. Some resin beads (10-20) from the funnel 
was transferred to a test tube and 2-3 drops of the above reagents (section 7.7) 
were added. The tube was then heated to 120°C for 5 min. Complete acylation 
was indicated by the test solution remaining a straw-yellow colour with no 
colouration of the beads. 
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F or the second pentapeptide the reSIn used was of polyhipe with an amme 
instead of an acid tenninus. Table 12 shows the quantity used for each acyl 
ammo acid residue. The ratio of the co t mponen s present was 1 : 4: 4: 8 
(resin:amino acid residue:PyBOP:base). The loading potential of the resin being 
0.36mmol/g. 
Table 12: Reactants and times of peptide assembly. 
Acyl Amino acid Amount (mg) PyBOP (mg) N, N-DIPA (!Jl,' Acylation (hr) 
Fmoc-Lys(Boc )-OH 674.6 749.2 501.7 2 
Fmoc-Cys(Trt)-OH 843.4 749.2 501.7 2 
Fmoc-Arg(pmc)-OE 876.5 749.2 501.7 3 
Fmoc-Ala-OH 448.3 749.2 501.7 4 
The peptide resin was stored at -80°C ready for coupling onto the intercalator. 
6.8.3 Coupling of the Peptide to the Intercalator-
Removal of N-terminal Fmoc-group. 
The peptide resin was placed in a round-bortom-flask with sufficient 20% (v/v) 
piperidine in DW' to cover the resin. This was stirred at room temperature for 
30 min. The peptide resin was then placed in a sintered glass funnel in vacuo 
and washed with DW', dichloromethane and ether. The resin was removed and 
dry under high vacuum for 4 hr. 
6.8.4 Attaching the Intercalator to the Peptide. 
The resin was placed in a r.b.f with Dl\1F along with the drug mixture (the 
ratio of each component being resin:intercalator:PyBOP:base; 1 :4:4:8). This was 
stirred under nitrogen for 3-4 hr. On completion, the resin was transferred to a 
glass sintered funnel under reduced pressure and washed as before, and then 
dried under vacuo. 
6.8.5 Cleavage from the Resin. 
An appropriate cleavage cocktail was prepared as listed below. 
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92.5 % Trifluoroacetic acid (TF A) 
2.5% 1,2-Ethanediothiol (EDT) 
2.5%, Triisopropylsylane (TrS) 
2.5% Water 
The amount added to the reSIn was 10-25 mL/g and allowed to stand at room 
temperature with occasional stirring for 2-4 hr. The peptide-intercalator complex 
was then filtered through a sintered funnel under reduced pressure, and washing 
twice with small volumes of TF A. Dropwise addition of 8-10 fold volume of 
cold ether caused precipitation to occur overnight at 4°C. The precipitated 
peptide/intercalator was filtered using a fine sintered glass funnel under low 
vacuum. The intercalator-peptide compound was further washed with cold ether 
and dried in vacuo. 
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6.9 Biological Evaluation. 
Materials and Methods 
Preparation of (mini) polyacrylamide gels 
A 40% stock solution of acrylamide was made up as follows: 
acrylamide 38g 
N,N' -methylenebisacylamide 2g 
Water 100mI 
TBE buffer (see below) was made up and stored as a lOx stock solution. The 
pH of the buffer was approximately 8.3. 
lOx TBE: 
890mM Tris-borate 
890mM boric acid 
20mM EDTA (pH8.0) 
10% Ammonium persulphate was also prepared 
ammonium persulphate 1 g 
H20 to 10mI 
The solution was stored at 4°C for no more than a week. 
The glass plates, inner (11cmx7cm) and outer (11cmx9cm) were prepared by 
washing with water then ethanol and allowed to air dry. The two spacers 
(0.5mm) were held in place by plastic holders and held in the vertical position 
by aid of a gel caster. 
In all cases tnlll1 gels were prepared usmg the following components indicated 
below; 
lOx TBE 2ml 
40% (19: 1) acylamide mix 3 ml 
TEMED 8J.lI 
ammonium persulphate (10%) 200J.lI 
water to 20ml 
TEMED (N,N,N',N'-tetramethylethylenediamine) acts as a catalyst for 
the polymerisation of polyacrylamide gels. 
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The gel constituents were mixed gently and poured between the glass plates. An 
appropriate comb was quickly inserted, being careful not to allow air bubbles to 
become trapped under the teeth. The acrylamide was then allowed to polymerise 
for 60 minutes at room temperature, after which a schlieren pattern was visible 
just beneath the teeth of the comb. The comb was carefully removed and the 
wells immediately rinsed out with the 0.5 x TBE buffer already present in the 
reservOIrs of the electrophoretic tank. This prevented small amounts of 
acrylamide solution trapped by the comb from polymerising in the wells, 
producing irregularly shaped surfaces that would give rise to distorted bands of 
DNA. 
The gel was pre-electrophoresed (30 minutes) in order to remove any poorly 
polymerised acrylamide monomer and avoid the formation of a "salt-front". For 
the mini gels a constant voltage of 100V was supplied giving a current of 
25mA. 
6.10 DNA "end-labelling" using y_[32p]ATP_ 
Phosphorylation Reaction. 
The following reaction mixture was assembled In a sterile micro centrifuge tube: 
consensus oligonucleotide 
T4 Polynucleotide Kinase lOx buffer 1 JlI 
[y_32p]ATP (3000Cilmmol at 10mCilml) I III 
Nuclease-free water 5 III 
T 4 Polynucleotide Kinase (5-1 Ou/J.lI) llli 
total volume IOJ.lI 
The combined mixture was then incubated at 37°C for 10 minutes, and 1 J.ll of 
0.5M EDTA was added to stop the reaction. 
b . "spin"-columns. 6.10.1 Removal of Unincorporated label fragments y usmg 
The labelling reaction from above was added to the top of a G50-Sephadex-
packed 1 ml syringe 'spin - column' along with lOOJ.lI of 1 xTE. The tip of spin-
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· column was then placed within a micro centrifuge tube. Both the column and 
micro centrifuge tube were placed in a Red-cap and centrifuged at 400xg for 2 
minutes. Depending on the amount of incorporated DNA eluted, a further 100111 
1 xTE was added to the top of the spin-column and repeat centrifugation as ill 





6.10.2 Determination of Percentage Incorporation. 
1111 of the labelled primer was spotted onto each of four Whatmann DE812.3cm 
circular filter. Two filters were dried under a heat lamp. The other two were 
used for the direct determination of total cpm in the sample. The first of the 
dried set of two was then washed in SOmI of O.SM Na2HP04, pH6.8, twice for 
S minutes each, to remove the unincorporated label. These were dried under a 
heat lamp. All four filters were placed into individual vials, followed by the 
addition of scintillation fluid (SmI). These were then counted in a scintillation 
counter. 
The average cpm for the total and incorporated filters was calculated as follows 
Percentage incorporation = cpm incorporated x 100 
cpm total 
Typically, 30-50% or more of the radioactivity was incorporated III the S' end-
labelling reaction. 
6.10.3 Ethanol precipitation. 
DNA precipitation was carried out by the addition of one-quarter volume 
ammonium acetate (5M, pHS. 6) and two volumes of 100% ethanol. The mixture 
was stored at -20oe overnight. After centrifugation at 12 000 xg for 20 minutes, 
the supernatant was discarded and the pellet washed with 70% ethanol and then 
dried in vacuo for 2-3 hr. The DNA pellet was then resuspended in 100111 of 
IS3 
water. A repeat scintillation count on 11 11 of th li l' . 
,.... e 0 gonuc eotIde solutIOn was 
undertaken (counts of 50 000-200 OOOcpm/1i1 . all . 
,.... were typIC y obtamed). Labelled 
oligonucleotide probes were stored at -200C. 
Gel Shift Retardation Assays-
6.11 Effect of Dithiothreitol (DTT). 
The following reaction components were assembled ill a sterile microcentrifuge 
tube: 
Nuclease-Free Water 5111 
Gel Shift Binding (x5) Buffer" 2111 
C-Jun Homodimer (0.551lg/1l1) 1111 
DTT (0.5mM) 1111 
32P-labelled 
DNA (SP-II AP-I 
consensus oligo) 1ill 
(typically 0.00Il]\1Bq/0.03IlCif 
total volume 10111 
.. GSB contained the following; glycerol 20%, MgC12 5mM, EDTA 2.5mM, 
NaCI 250mM, Tris-HCI, pH 7.5, 0.05mM, poly(dI-dC}poly(dI-dC) 
0.05mg/ml . 
.. this represents 50 000 - 200 OOOcpm/1l1 
Each reaction was incubated at room temperature for 10 minutes before adding 
1 III of 32P-Iabelled DNA probe followed by a further incubation at room 
temperature for 20 minutes. Loading-dye (x5) 2111 (two parts 50% glycerol: one 
part 0.1 % bromophenol blue) was added to the binding assay. Loaded on to 
designated wells on gel. Electrophoresed (lOOV, 25mA), typically until lower-
band of loading-dye reached the bottom of the gel. 
On completion (60-90 minutes) the gel-kit was dis-assembled, and the glass plates 
sandwiching the gel carefully separated, leaving the gel on a single glass plate. 
The exposed gel was then overlaid with Whatmann JMM paper tailored to fit 
the gel, ensuring an even contact between gel and paper. The paper was then 
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peeled off to which the gel adhered. Saranwrap was then overlaid on the 
exposed side of the gel. The paper/geVsaranwrap sandwich was transfered to the 
gel-dryer with the saranwrap side up and vacuum dried at 80°C for upto 2 hr. 
The dried gel was then subjected to autoradiography at -70°C with an 
intensifying screen. 
6.11.1 Effect of TPA on AP-l Protein. 
The following reaction components were assembled ill a sterile microcentrifuge 
tube: 
Nuclease-Free Water 5~1 
Gel Shift Binding (x5) Buffer 2~1 
Protein Cell Extract'" (O.18~g/~lf 1~1 
DTT (O.5mM) 1~1 
32P-Iabelled AP-1 Consensus 
Oligo .M 
total volume 1 O~l 
'" five :MDA 468 breast cancer cell lines prepared as described by Dignam 
et aI, 1983 at Nottingham University by Dr. S. Wrigley. 
'" total protein concentration was estimated by the Bradford assay to be 
O.18J,.lg/".d. The actual Fos and Jun protein present was estimated to be 
O.204mg/ml using SDS-page. 
The procedure for running this gel was similar to that described above. 
6.11.2 Determination of AP-l binding to wild-type and mutant AP-l DNA 
consensus sequence. 
The following reaction components were assembled ill a sterile micro centrifuge 
tube: 
Nuclease-Free Water 5~1 
Gel Shift Binding (x5) Buffer 2~1 




(wild type/mutant AP-I 
consensus oligo) 
total volume 
The remaining procedure was as described in section 6. 11. 
6.11.3 Specificity of c-Jun homodimer protein for AP-l DNA consensus 
sequence as demonstrated by Competition assay. 
The following reaction components were assembled III sterile micro centrifuge 
tubes as outlined in the table below: 
Lane on el 1 2 3 4 5 6 7 8 9 10 
8 7 6 5 4 3 2 1 o 8 Nuclease-
Free Water 
··········G~l"Shlft············ ··········2······~··········2·····~·········i··t·········i··t·······i··j··········2:···j··········2:···1"""·······2···(·······2···(·······2········ 
Binding 1 1 1 1 1 1 1 ~ ! 
Buffer (x5) j j 1 1 1 1 1 1 ~ 
··········c:i~~··················· ··········i·····r········i····l·········i··t······i··r·········"!···1··········i··"1"·········T··t········i···l··········1····:··········1········ 
Homodimer 1 1 1 1 1 1 1 1 1 
(0 5 5 ~g(~l) ~ ~ ~ ~ ~ ~ ~ ~ ~ 
··········DTI··c6j··········· ·········"!····t·········i····-[·········"1""·-[·········i··t·········T·j··········i···j··········i···j··········i··t·········i····~··········i······· 
.. :·:::::~t~:~f!~~:: ···.·.~::[::.~:I::·:~].·~I:····~[·~I.:.~I··i···llrl 
unlabelled 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7: 8: 0 
AP-l or SP-l 1 ~ . l ~ ~ : : ~ 
oli o' j l l l::: 
total volume 13 13 
.. depending on which competition assay (either with increasing concentration 
of unlabelled AP-I or SP-I), the unlabelled oligomer was added and then 
incubated for 20 min before subsequent addition of the 32P-Iabelled AP-1 
DNA. 
The gel was dried and developed as described in section 6.11. 
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6.11.4 Supershift assay for AP-l in BeLa nuclear extract. 
The following reaction components were assembled in a sterile microcentrifuge 
tube: 
Nuclease-Free Water 4~1 
Gel Shift Binding (x5) Buffer 2~1 
Nuclear HeLa Extract (1.67~g1~l) 1~1 
DTT (0.5mM) 1~1 
API Antibody/IGg (lOOngl~l) 1~1 
32P-Iabelled 
DNA (AP-l oligo) l!!l 
total volume 1 O~l 
AP-l antibody (1 ~l) was added subsequent to the addition of 32P-Iaballed AP-I 
DNA. The incubation was for 40 minutes at room temperature. The running of 
the gel was also extended to 3 hr. The procedure for developing the gel was as 
described in section 6.11. 
6.11.5 Effect of Oxygenation on the binding of AP-l Protein to AP-l DNA 
consensus sequence. 
AP-l (Fos/Jun) heterodimer protein (100/J.I) was placed in two separate sterile 
micro centrifuge tubes in which two fine glass capillaries were submerged into the 
liquid. Oxygen or nitrogen gas was then passed through the glass capillary to 
gas the respective samples while keeping the temperature at 4°C. 3/J.l of each 
sample was removed after 3 or 6 hr. 
The following was then assembled In sterile micro centrifuge tubes; 
Nuclease-Free Water 6/J.I 
Gel Shift Binding (x5) Buffer 2/J.I 
AP-l (Fos/Jun) heterodimer I/J.I 
32P-Iabelled 
DNA (AP-l oligo) .l!!l 
total volume 10/J.I 
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The protein samples were then loaded onto the gel and electrophoresed. The gel 
was dried and exposed to film. 
6.12 The Effect of Intercalators on the binding of AP-l protein to AP-l 
DNA consensus sequence. 
For each intercalator tested (see table 6) a stock solution was made up usmg 
nuclease-free water or in some cases with 5-10% methanol to aid solubility, in a 
volumetric flask. The final methanol concentration in the reaction was between 
0.5-1%. 
The following reaction components were assembled m sterile micro centrifuge 
tubes as outlined in the table below: 
Lane on el 1 2 3 4 5 6 7 8 9 10 
Nuclease- 6.0 I 4.7~ 4.5 4.251 4.0 3.751 3.5Q 3.251 3.0 1 6.0 
.......... !E~.~.Y!..~!~!. ...... .................. ~ .................. ~ .................... ~ ................... ~ ................... -:-................... ~ .................. : .................... : .................. : ................. . 
Gel Shift 2.0! 2.0 ! 2.0! 2.0! 2.0! 2.0! 2.0 i 2.0 i 2.0 : 2.0 
Binding iii iii i I : 
Buffer (x5) ! ! ! ! ! 1 : : : 
··········N~~i~M············· ·········io··r .. ·····"i:O··j .. ·······i·o····j··········i· .. O···j········ .. i:·o···j'··· .. ···io··j······· .. ·i:·o··f··········i· .. o···j"·· .. ····i:·o··j··········i:o· 
Extract 
········ .. i~t~~~~~t~?"············o·····T·······O:2$········ .. o.S .. ! 0.75! l.0! l.25! 1.5 j 1.75j 2.0 j 0 
........... !~.!~.Y.~.~~~ ... ........ }9.:9.L. ........ !9.:g ........ ..!.Q:QL ...... }Q:Q,L ......... !Q:QL ....... J9:.2,L ......... !9.:g ........ }9.:9.L ........ !Q:9L ...... }g:.~ 
>I< a stock solution was made up for each intercalator at 8Ax 10-6 M so that 
by adding the amount shown in the table, a ratio ranging from 100: 1 
through to 800: 1 (increasing by 100-fold intercalator:DNA) was achieved. 
6.12.1 The Effect of Peptides on the binding AP-l protein to AP-l DNA 
consensus sequence. 
The procedure carried out here was exactly the same as that with the 
intercalator. 
The following reaction components were assembled In sterile micro centrifuge 
tubes as outlined in the table below: 
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Lane on el 1 2 3 4 5 6 7 8 9 
~~i~!:::.T .. :~~;... .. ::~ .. !42"~'~0~;.~2~'~0 .. i ......... 37~j .......... ~ ... ~~ •....... ~~5 •........ ~ .• O ... : ......... . 
': ': ': ': .: 2.0 ~ 2.0: 20: 2.0 i 
~=~g(X5) I I I : I I ;': 
1. 0 ····i:o····t········i:O"···i··········i:o"···~·········· 
Extract 
Peptide 0 \ 0.25~ 0.5 1 0.75\ 1.0 r" . ·i:BT········"j3··T········i:7ST········io··T········( 
Fra ent : : : : : :: : 
.......... ~~~~ . .Y.~~.~~ ......... }Q:~ ......... }9.:9L ...... }Q:Q.L ...... }Q:QL ...... }Q:QJ. ...... JQ:.Q.l. .......... ~.Q:QJ .......... ~Q:.Q.L ........ ~Q:Q.L ....... . 
.. 
methanol was also used to aid in the solubility of the peptide. Stock 
solution of concentration 8.4 xl 0-5 M was prepared and so by adding the 
amount shown in the table of the peptide solution a ratio of peptide:DNA 
ranging from 1000: 1 - 8000: 1 (increasing by IOOO-fold) was achieved. 
6.12.2 The Effect of Intercaiator-peptide Conjugates on the binding of AP-l 
protein to AP-l DNA consensus sequence. 
Again a similar procedure to the two described above for the intercalator and 
peptide was carried out. However with the hybrid compounds, two separate 
stocks were prepared for each hybrid molecule giving a lower and an upper 
range of drug concentration, i.e. 8.4xI0-6 M and 8.4xIO-
5 
M respectively. (see 
table below and figure 50 and 51). 
Nuc1ease-
1 2 3 4 5 6 7 
8 9 
Lane on el 
4.0 4.5 ~ 5.0 1 5.0 3.5 5.0 3.0 5.0 
2.51 




··········"i~t~~~~t~·~· ·········O:·s"T········O·····T········i.o r 0 ~ 1.5: 0 : 2.0 ~ 0 : 2.) : 0 
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u.~~~mml··rmmm]mTITmmfmT·Tu.m 
........... ~.~~.~ .. y.~~~~ .......... ~9.:9.L ....... ..!9.:9L ......... ~.9.:9 .. t .......... ~9.:9.L ......... ~9.:9..l ........ }9.:Q.i .......... ~.~:Q.;m ....... ~.~:.~L.m .... !.~S... 10 
... 
two separate stocks were prepared one at the lower drug concentration 
range of 200-800:1 (conjugate:DNA) increasing by 200-fold. And at an 
upper concentration range of 2000-8000: 1 (conjugate:DNA) increasing by 
2000-fold. 
The gels were developed as described before. 
6.13 Specificity of Intercalator-Peptide Conjugates for the AP-l DNA 
consensus sequence. 
Reaction components were assembled In sterile micro centrifuge tubes as outlined 
in the table below: 
Lane on el 1 2 3 4 5 6 7 8 9 
Nuclease- 6.0 ~ 4.75 ~ 4.5 4.25 : 4.0 3.75: 3.50 ~ 3.25: 3.0 i 
........... £!.~~ .. ~.~~~.~ .......................... .;. ................... <. .........•..••• ·····;·· .......••..•...... i ..........•.••.••... .i. •...............•..• ; ......•.....•....... ! .................... .i. .......•.••.•.•.. , ......•• 
Gel Shift 2.0 ~ 2.0 1 2.0 1 2.0 ~ 2.0 1 2.0 j 2.0 ~ 2.0 j 2.0 j 
Binding ~ ~ ~ 1 1 . 1 1 i 
Buffer (x5) : 1 1 1 1 . 1 j ! 
···········p~~t~i~r············· ··········i:oT·······i"o··T·······io····[·········i·o···T········i:o··--r········i·o····[·········i·o···r········i:o··T·······i"oT"······ 
···········DTI···CO..-s·········· ··········ioT········i"o··r·······io··-r········i·o···r········i:o···r·······io···r·······i.·o···r········i:o···r·······io"j""······ 
···········3Tp~i~b~il~d······· ··········i:oT········i·o···r·········i:o····r·········i"o···T········"i:o····r·········i:o···r········i :·o····r-········i.·o··T·········i:o·r······· 
AP-1 or SP-1 : :: ::: : 
DNA l l ~ . . l l l : 
........•..• --_ ................................................ - .......... ~ ........................ ?.- .............. ··· .. ··t········· .. ··· .. ······i·· .. · .. -···· .. · .. ···-···~·· .. ·· .. ·· .. · .. ···· .. ····•········· .... ···"·····1· .. ··············· .. · .. ~·················t········ 
Con·u ate 4a* 0 1 0.251 0.5 ~ 0.751 1.0 1 1.251 1.5 1 1.75 ~ 2.01 
total volume 10.0 10.01 10.01 lO.O [ 10.0 ~ lO.O [ 10.0 l 10.0: lO.G ..................................................................................................... .' ................................ :. .................................................................................................................................................................... . 
... The relative molecular weights of AP-l (94 kDa, 0.204mg/ml) and SP-1 
(201 kDa, 0.035mg/ml) and c-Jun homodimer (78 kDa, 0.155mg/ml) were 
used to calculate the concentrations of proteins added. The AP-l 
heterodimer protein was diluted 12.5 fold using a lysis buffer provided. c-
Jun homodimer protein was diluted by -11 fold . 
... a stock solution of each conjugate at 8Ax 1 0-6 M was prepared. 
The reaction mixtures were then loaded onto the gel and electrophoresed. 
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6.13.1 Protein estimation using the Bradford Method. 
Bradford reagent: Coomassie Brillant Blue G-2S0 (10mg) dissolved in Sml of 
95% ethanoL Add 10ml of 8S% (w/v) phosphoric acid. Dilute to 500ml \\ith 
water. Bovine serum albumin (BSA) was used as the protein standard. A stock 
solution of the BSA was prepared using the same storage buffer as the protein 
sample being tested. The concentration of the B SA protein was so that it o. 1-
Img/ml (total volume 201l1). The protein samples being analysed were then 
added to separate wells to which 180111 of the Bradford reagent was then 
added. The absorbance was measured at 630nm using a spectrophotometer. The 
concentration of the protein sample was determined from the plot of [BSA] 
against the absorbance. 
6.13.2 Quantitating the [Fos] and [Jun] proteins m cell lysates usmg SDS-
Page - Preparing the gel. 
The gel used for this particular purpose was a discontinuous gel. The bottom 
half of the gel, the resolving gel (12%) was prepared as follows: 
acrylamide:bis (30:0.8) 





To which the following was then added 1 00 III of 10% SDS, IOOlll of fresh 
10% ammonium persulphate and Sill of TE1v1ED. The gel was then gently mixed 
and poured between to glass plates and overlayed with propanol/water. The gel 
was allowed to polymerise for 20 minutes. 
The stacking gel (the top half of the gel) was prepared as follows: 
acrylamide:bis (30:0.8) 0.40mI 
Tris-HCI pH6.8 0.5M 0.7SmI 
Water 1.80mI 
To which, 3 o III of 10% SDS, 30111 of fresh 10% ammoruum persulphate and 
3 III of TEJ\.1ED was then added. The propanol/water layer was removed and the 
gel rinsed 2-3 times with water. The stacking gel was then poured on top to 
which a comb was then fixed. The gel was then allowed to set (1 hr). 
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6.13.3 Preparing the protein molecular weight markers. 
The following components were found in each vial of protein standard. 
Jlg/vial Subunit MW 
Phosphorylase b 64 94000 
Bovine Serum Albumin 83 67000 
Ovalbumin 147 43000 
Carbonic Anhydrase 83 30000 
Soybean Trypsin Inhibitor 88 20000 
a-Lactalbumin 121 14400 
Sucrose 27mg 
The protein standards were then dissolved m 100JlI water: 100JlI sample buffer 
(2x) and boiled for 2 minutes. 




5 JlI of the above protein solution was then further diluted by ten fold usmg 
sample buffer (1 x). This was then pipetted into four micro centrifuge tube to give 
2, 5, 10 and 15 JlI all of which were then diluted to 15 JlI, again with the 
sample buffer (Ix). Next 5JlI of each of the five different cell extracts 
(containing the Fos and Jun proteins) were placed in five micro centrifuge tubes 
to which 5 JlI of the sample buffer (2x) was added. All ten tubes were then 
placed in boiling water for 5 minutes. 
6.13.4 Running the SDS gel. 
Loading buffer (2x) was added to each of the ten samples before loading onto 
the gel. The gel was allow to run in Tris, glycine and SDS for -1 hr at 150V. 
The run was stopped when the blue band (loading dye) reached the bottom of 
the gel. The apparatus was then disassembled and the isolated gel was 
submerged in coomassie blue for 5 minutes on a shaker. The excess dye was 
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then removed by placing the gel in a destain (10% methanol: 10% acetic acid) for 
1-2 hr on a shaker. Clearer bands were obtained on leaving it overnight. 
The intensity of the Fos and Jun bands were then compared with the that of 
the protein standard. An estimate of the concentration of Fos and Jun protein 
was calculated. 
6.14 DNA Binding Assays. 
Materials 
Calf thymus DNA was obtained from Sigma Chemical Company, London. All 
glass apparatus used in this work was silanised with Repelcote (Hopkins and 
Williams), washed twice with methanol (Fisons, HPLC grade) and dried overnight 
at room temperature before use. All volumetric glassware was of grade A 
specification. V olumes between ::;; 1 ml were measured using Hamilton precIsIOn 
glass syringes. All drugs solutions were protected from light and stored at 4°C 
pnor to use. Unless otherwise stated Tris buffer (pH 7.40, Tris CI 0.008M, 
NaCI, 0.05M) was used throughout this next part of the work. 
Methods 
6.14.1 Effect of Intercalator-Peptide Conjugates on Thermal Denaturation 
properties of DNA. 
A solution of an appropriate concentration of drug in buffer, and water (6.0mL) 
were added to a 10mL volumetric flask and the solution sonicated for 15mins to 
remove dissolved rur. 
DNA solution (Calf thymus), approximately 2.5x 10-3 M in buffer, (precisely 
o .2mL), was added to the contents of the flask, the solution made to volume 
with water, and mixed gently (final DNA:drug ratio of exactly 10: 1). The 
solution (2. OmL) was placed III a quartz cuvette with a ground glass stopper. 
The cuvette was placed in an Peltier cell holder of a Perkin Elmer 552S 
Spectrophotometer fitted with a temperature programmer. The absorbance of the 
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solution at 260nm was recorded as the temperature was raised from 55 to 
10SoC (0. SOC/min). This was duplicated and the mean Tm calculated. 
The mean Tm of DNA in the absence of drug m the same buffer was 
subtracted to give the ~ Tm value. 
6.14.2 Effect of Intercalator-Peptide Conjugates on the Fluorescence 
Enhancement of ethidium bromide bound to DNA. 
A solution of drug (2.0x10-6 M) in tris buffer was prepared, two further 
solutions containing DNA (2. Ox 10-5M) and DNA and drug (2. Ox 10-5 M and 
2.0x10-6 M respectively) were prepared. Buffer (precisely 3ml) was places in one 
cuvette and the same volume of each of the above solutions were placed in 
three separate cuvettes; buffer and drug solutions acting as controls. The 
cuvettes were placed m a thermostatted cell holder of a Perkin Elmer LSS 
spectrofluorimeter and fluorescence intensities, (A excitation, 47 6nm, A emission, 
S96nm), of solutions were determined at 2S0C. Aliquots, (6x10~1, Sx20~1, 
6x40~1, and 6x100~1), of ethidium solution (2.0xlO-5 M) were sequentially added 
to each of the four cuvettes and readings taken after mixing and allowing to 
stand for 1 min. Fluorescence intensities were corrected for changes in volume. 
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